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Wilms tumor protein 1 (WT1) is a suitable target to develop an 
immunotherapeutic approach against high risk acute myeloid leukemia (AML), 
particularly their relapse after allogeneic hematopoietic stem cell transplantation 
(HSCT). As an intracellular protein traversing between nucleus and cytoplasm, 
recombinant expression of WT1 is difficult. Therefore, an induction of WT1-specific T-
cell responses is mostly based on peptide vaccination as well as dendritic cell (DC) 
electroporation with mRNA encoding full-length protein to mount WT1-derived peptide 
variations presented to T cells. Alternatively, the WT1 peptide presentation could be 
broadened by forcing receptor-mediated endocytosis of DCs.  
In this study, antibody fusion proteins consisting of an antibody specific to the 
human DEC205 endocytic receptor and various fragments of WT1 (anti-hDEC205-WT1) 
were generated for a potential DC-targeted recombinant WT1 vaccine. Anti-hDEC205-
WT1 antibody fusion proteins containing full-length or major parts of WT1 were not 
efficiently expressed and secreted due to their poor solubility and secretory capacity. 
However, small fragment-containing variants: anti-hDEC205-WT110-35, anti-hDEC205-
WT191-138, anti-hDEC205-WT1223-273, and anti-hDEC205-WT1324-371 were obtained in 
good yields.  
Since three of these fusion proteins contain the most of the known immunogenic 
epitopes in their sequences, the anti-hDEC205-WT191-138, anti-hDEC205-WT1223-273, and 
anti-hDEC205-WT1324-371 were tested for their T-cell stimulatory capacities. Mature 
monocyte-derived DCs loaded with anti-hDEC205-WT191-138 could induce ex vivo T-cell 
responses in 12 of 16 blood samples collected from either healthy or HSC transplanted 
individuals compared to included controls (P < 0.01). Furthermore, these T cells could 
kill WT1-overexpressing THP-1 leukemia cells in vitro after expansion.  
In conclusion, alongside proving the difficulty in expression and purification of 
intracellular WT1 as a vaccine protein, our results from this work introduce an 
alternative therapeutic vaccine approach to improve an anti-leukemia immune response 
in the context of allogeneic HSCT and potentially beyond.  
 







Für die Entwicklung eines immuntherapeutischen Ansatzes zur Behandlung von 
hoch Risikopatienten mit akuter myeloischer Leukämie (AML) und insbesondere zur 
Vorbeugung von Rezidiven nach allogener Stammzelltransplantation (SZT) stellt das 
Wilms-Tumor-Protein 1 (WT1) ein geeignetes Angriffsziel dar. Die rekombinante 
Expression von WT1, welches als Transkriptionsfaktor vom Zytosol in den Zellkern 
transloziert, gestaltet sich äußerst schwierig. WT1-spezifische T-Zellantworten werden 
daher hauptsächlich mittels Peptidvakzinierung oder Transfektion dendritischer Zellen 
(DC) mit mRNA, welche das vollständige WT1-Protein kodiert, herbeigeführt. Letzterer 
Ansatz bietet den Vorteil, dass passierenden T-Zellen eine größere Vielfalt an WT1-
Peptidvarianten präsentiert werden kann. Eine verbesserte Peptidpräsentation kann 
außerdem über eine Optimierung der Rezeptor-vermittelten Endozytose der DCs erzielt 
werden. 
Ziel der folgenden Arbeit war es, ein rekombinantes DC-gerichtetes WT1-Vakzin 
zu entwickeln. Dazu wurden anti-hDEC205-WT1-Fusionsproteine,  bestehend aus einem 
Antikörper gegen den humanen DEC205-Endozytoserezeptor und verschiedenen WT1-
Fragmenten, konstruiert. Während sich Fusionsproteine, die das vollständige WT1-
Protein oder große Teile dessen beinhalteten, aufgrund ihrer schlechten Löslichkeit und 
schwachen Sekretion kaum exprimieren und aufreinigen ließen, lieferte die Produktion 
der Fusionsproteine mit kürzeren WT1-Fragmenten,  anti-hDEC205-WT110-35, anti-
hDEC205-WT191-138, anti-hDEC205-WT1223-273 und anti-hDEC205-WT1324-371, sehr gute 
Ausbeuten. Da letztere drei Proteine die meisten bislang bekannten immunogenen WT1-
Peptide in ihrer Sequenz enthalten, wurde anschließend ihre Fähigkeit zur T-
Zellstimulation untersucht. Dabei konnte in 12 von 16 Blutproben, die entweder von 
gesunden Spendern oder SZT-Patienten stammten, gezeigt werden, dass mit anti-
hDEC205-WT191-138 beladene, reife, aus Monozyten generierte DCs ex vivo signifikant 
stärkere T-Zellantworten auslösen als die jeweils mitgeführten Kontrollen (P < 0.01).  
Nach Expansion waren die so aktivierten WT1-spezifischen T-Zellen sogar in der 
Lage, die WT1-überexprimierende AML-Zelllinie THP-1 in vitro zu lysieren. 
In der vorliegenden Arbeit konnten daher nicht nur die bereits bekannten 
Schwierigkeiten der WT1-Expression und Aufreinigung bestätigt werden, sondern 




darüber hinaus konnte eine alternative therapeutische Vakzinierungsmethode zur 
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Haematological malignant diseases are often difficult to be cured due to their 
heterogeneous and complex pathophysiology as well as progressive characters and 
systemic manifestation. On account of advanced treatment options including intensive 
chemotherapy, allogeneic haematopoietic stem cell transplantation (allo-HSCT) and 
molecular targeted therapy, the disease-free (DFS) and overall survival (OS) rates of 
patients suffering from these diseases have been remarkably ameliorated. For instance, 
acute myeloid leukemia (AML), one of the poor prognostic malignancies, is treated now 
with 60-80% of complete remission (CR) and 30-60% of long-term survival rates, not at 
least due to establishing allo-HSCT as a treatment option. However, 20-70% of the allo-
HSC transplanted patients are affected by relapse and only 2-20% of them have a 
possibility to receive second transplantation (Savani et al. 2009). AML patients who are 
not candidate for allo-HSCT because of their age or comorbidities have even poorer 
prognosis. Thus, there is an urgent clinical need to improve the current treatment 
modalities by combining HSCT with other immunotherapy strategies (Barrett and Le 
Blanc 2010).  
The most promising immunotherapeutic strategies for haematological malignant 
disorders are drug-conjugated monoclonal antibodies, T-cell engaging antibody 
constructs, adoptive transfer with chimeric antigen receptor (CAR) T cells, and dendritic 
cell (DC) vaccination (Lichtenegger et al. 2015). Plantinga et al. have recently reviewed 
that the latter strategy is an attractive and effective treatment modality to prime and/or 
stimulate tumor-specific cytotoxic T cells (CTLs) in early phase after allo-HSCT, in a 
setting of a better-predicted immune reconstitution. The selection of specific tumor-





priming capacity of the DC (Plantinga et al. 2014). With this work, we contributed to the 
DC vaccination strategy to AML treatment in the context of allo-HSCT using Wilms tumor 
protein 1 (WT1). 
 
 
1.2. State of current knowledge and contribution 
 
 
AML is a heterogeneous clonal disorder of haematopoietic progenitor cells. 
Approximately, four new cases of AML per 100 000 people are diagnosed each year.  
Various genetic alterations have been detected in patients with AML which result in a loss 
of normal regulation of growth, differentiation, and apoptosis of haematopoietic cells.  
This leads to an accumulation of cells (blasts) with uncontrolled proliferative capacity 
and ineffective function in peripheral blood and bone marrow. Consequently, normal 
haematopoiesis is displaced by the abnormal cell expansion. The survival rate is strongly 
dependent on age, comorbidities, disease type and advancement, and response to 
chemotherapy. Other adverse prognostic factors include central nervous system 
involvement with leukemia, systemic infection at diagnosis, elevated white blood cell 
count, therapy-induced AML, and history of MDS or other antecedent haematological 
disorders. The long-term survival rates in adult AML are inversely related to age (Table 1, 
Cancer research UK, statistics based on the data 2008-2012).  
Table 1. The long-term survival rate in patients with AML. 
Age <14 15-24 25-64 65< 
5-year survival 66% 60% 40% 20% 
 
Cytogenetic analysis at the time of diagnosis provides the most important 
prognostic information, predicting outcome after induction chemotherapy, relapse rate, 
and OS (Estey and Dohner 2006). In 2010, recommendations from an international 
expert panel on the diagnosis and management of AML in adults were updated and 
proposed four different genetic groups (Table 2) to standardize reporting system of 





clinical outcomes. Between 10% and 40% of the newly diagnosed patients do not achieve 
an complete remission with intensive induction therapy and are therefore categorized as 
primary refractory or resistant (Thol et al. 2015).  
Table 2. Prognosis for AML patients on the basis of their genetic abnormalities (Dohner et al. 
2010).  
Genetic group Subsets 
Favorable 
t(8;21)(q22;q22); RUNX1-RUNX1T1 
inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 
inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 
Mutated NPM1 without FLT3-ITD (normal karyotype) 
Mutated CEBPA (normal karyotype) 
Intermediate-I 
Mutated NPM1 and FLT3-ITD (normal karyotype) 
Wild-type NPM1 and FLT3-ITD (normal karyotype) 
Wild-type NPM1 without FLT3-ITD (normal karyotype) 
Intermediate-II t(9;11)(p22;q23); MLLT3-MLL 
Cytogenetic abnormalities not classified as favorable or adverse 
Adverse 
inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 
t(6;9)(p23;q34); DEK-NUP214 
t(v;11)(v;q23); MLL rearranged 
−5 or del(5q); −7; abnl(17p); complex karyotype 
 
Depending on age and  other prognostic values, patients with AML are treated with 
standard chemotherapy regimens and HSCT as well as salvage therapies. The standard 
chemotherapy treatment is divided into two phases: a remission induction and a post 
remission. To achieve the complete remission, induction of a profound bone marrow 
aplasia is usually necessary with currently used combination chemotherapy regimens. 
The two most effective drugs used to induce remission in patients with AML are 
cytarabine and an anthracycline (mostly daunorubicin). Salvage chemotherapy regimens 
have been tested for different subtypes of the disease. Since the myelosuppression is an 
anticipated consequence of both leukemia and its treatment with chemotherapy, patients 
must be closely monitored during therapy. Antibacterial, antifungal prophylaxis or 
treatment, as well as  haematopoietic growth factors, blood cell fractions (red blood cell 





The postremission therapy is to prolong the duration of the initial remission with 
induction chemotherapy or HSCT. In practice, most patients are treated with an intensive 
chemotherapy after remission is achieved, as only a small subset of the patients have a 
matched-family donor. The most commonly used regimen for postremission 
consolidation is high-dose cytarabine and it improves clinical outcome. Patients of the 
intermediate and adverse genetic groups are candidates for HSCT to benefit from the GvL 
effect and potential cure after significant reduction of leukemia burden as a result of prior 
induction/reinduction therapy. However, even with such advanced treatment options, 
the long-term survival rates of patients are still not satisfactory.  
Thereupon huge research efforts and clinical trials have been carried out for 
refractory/relapsed AML patients since highly effective and standardized treatments for 
this situation are still not available. In this regard, immunotherapy is auspicious, indeed, 
various efforts to achieving to a good clinical outcome have been explored.  
 
 
The most prominent immunotherapy to fight AML is the HSCT. In addition, various 
immunotherapeutic approaches including cytokine therapy, monoclonal antibodies, 
therapeutic vaccines,  chimeric antigen receptors and bispecific antibodies have been 
developed for AML treatment (Figure 1) (Grosso et al. 2015). IL-2 or IFN-monotherapy 
was tested for stimulation of the immune system during the first remission period after 
induction chemotherapy. However, a significant impact of the cytokine therapy on OS and 
DFS was not reached, meaning that cytokine therapy alone is insufficient to the disease 
with complex mechanism of pathogenesis. Various types of monoclonal antibodies 
(mAbs) with or without conjugation of cytotoxic drugs and radioisotopes have been 
evaluated for AML treatment. Among them, Gemtuzumab ozogamicin (GO), a 
recombinant, humanized CD33 mAb has been reported to prolong survival of AML 
patients with favorable cytogenetics. The CD19-targeting bispecific T cell engaging 
(BiTE) antibody, Blinatumomab, was successful to initiate cytotoxic T cell response to 
acute lymphoblastic leukemia. Initial tests with the CD33 targeted BiTE AMG330 
revealed furthermore that AMG330 is able to lyse primary leukemia cells (Krupka et al. 
2014). Chimeric antigen receptor (CAR) T cells are thought to be promising to eliminate 





constructed on the intracellular signaling domain of the T cell receptor (TCR). T cells 
expressing IL-3 receptor  chain (CD123)-specific CARs have been appreciated by 








Figure 1. Current immunotherapeutic approaches to AML.  
mAbs, monoclonal antibodies; 131I-HuM195, iodine-131 labeled humanized monoclonal antibody 
195; CAR, chimeric antigen receptor; LEY, Lewis antigen;  BiTE, bispecific T-cell engager; scFv, 
single chain variable fragment; IFN, interferon; IL-2, interleukin-2; NK, natural killer; WT1, 
Wilms tumor 1; PR3, proteinase 3; CTL, cytotoxic lymphocytes; GM-CSF-granulocyte-
macrophage-colony-stimulating factor; HLA, human leucocyte antigen; miHC, minor 






1.2.2.1. Haematopoietic stem cell transplantation (HSCT) and Graft-versus-
Leukemia (GvL) effect  
 
It is exactly 60 years after the first human bone marrow grafting programme was 
began by E. Donnal Thomas and his colleagues. As long as it aged, HSCT, the most 
successful of the immune-based therapies, has developed to a standard therapy for AML 
and other haematological malignancies. HSCT is the transplantation of multipotent 
haematopoietic stem cells (HSCs), usually derived from bone marrow, peripheral blood, 
or umbilical cord blood. Depending on the source of HSCs, there are three types of the 
transplantation: autologous, allogeneic, and cord blood. Stem cells are defined as 
undifferentiated cells capable to divide for indefinite periods, to self-renew and to 
generate functional progeny of highly specialized cells. HSCs are the prototype of 
multipotent adult tissue stem cells. In a step-wise differentiation process, HSCs give rise 
to the committed oligopotent progeny of the lymphoid and myeloid lineages and, further 
downstream, to the lineage-restricted unipotent precursors of mature blood cells. It is 
thought that normal stem cells transform to malignant stem cells keeping the mechanism 
for self-renewal. Most leukemic cells have a limited capacity for proliferation and are 
continuously replenished by leukemic stem cells. Normal and malignant stem cells are 
quiescent, therefore insensitive to the chemotherapy which acts mostly on proliferating 
cells. Both normal and malignant stem cells repair DNA efficiently, resist apoptosis, and 
excrete toxic drugs with the help of ATP-binding transporters. Thus, although 
chemotherapy can destroy a tumor almost completely, the stem cells are remained, 
allowing the cancer to recur. Such cells can be eliminated by immunologically active 
donor cells in allogeneic grafts (Copelan 2006). In allo-HSCT, if recipient T cells recognize 
foreign donor antigens, graft rejection may occur, whereas donor T cells recognizing 
recipient antigens may induce graft-versus-host-disease (GvHD) and graft-versus-
leukemia (GvL) effects.  
The GvL effects are mediated by donor derived CD8+ and CD4+ T cells as well as by 
NK cells and macrophages. An important mechanism of the GvL effect is that donor 
immune cells are reactive to recipient major (MHC) and minor (miHC) histocompatibility 
antigens. MHC class I and II molecules on the recipient APCs can be directly recognized 
by allo-T cells. Alternatively, allo-T cells indirectly recognize recipient MHC class II-





effect are strongly associated with each other, major histocompatibility molecules 
targeted by allo-T cells are able to induce both of them. Minor histocompatibility antigens 
are polymorphic and diversify recipient peptide-HLA complex presented to allo-T cells 
(Figure 2). HA-1, HA-2, HA-8, UGT2B17, HB-1, ACC-1, ACC-2, B8/H-Y, and LRH-1 miHC 
antigens are haematopoietic tissue-restricted, therefore, they are thought to be crucial to 
induce GvL effect against certain type of leukemia (Sprangers et al. 2007). If allo-T cells 
respond to miHC antigens expressed on haematopoietic and epithelial cells, rather a 
development of GvHD occurs. The allo-reactive cells to miHC antigens inhibit the growth 
of leukemic colonies, thus, leukemic stem cells can be eliminated by means of this 
mechanism. The third mechanism of allo-T cell mediated GvL effect is implemented by 
targeting of  tumor associated antigens (TAAs).  
 
 
TAAs are non-polymorphic and aberrantly expressed by tumor cells. WT1, 
proteinase 3, and survivin are known to eliciting anti-leukemia immune responses and T 
cells specific to those TAAs can inhibit leukemic, but not normal colony formation (Gao 
et al. 2000). Therefore, GvL effect can be strengthened by improving the TAA-specific T 
cell response.  
Figure 2. Generation of miHC antigens.  
Minor histocompatibility antigens are generated by gene nucleotide polymorphisms that lead to 
differences in the amino-acid sequences of homologous proteins between donor and recipient 
cells. Polymorphic proteins are degraded within the proteasome. Peptides derived from the 
degraded protein are then transported to the endoplasmic reticulum, where they bind HLA 
glycoproteins. The peptide-HLA complexes travel through the Golgi apparatus to the cell surface, 







1.2.2.2. AML vaccines  
 
In 1977, a cancer vaccine trial with bacilli Calmette-Guerin (BCG) and  irradiated 
autologous leukemia cells reported prolonged remission and survival in the vaccinated 
group (Powles et al. 1977). In 1990, the first donor lymphocyte infusion was performed 
for treatment of leukemic relapse after HSCT (Kolb et al. 1990). These important 
demonstrations of  leukemia-specific T cell responses led to the development of an array 
of AML vaccines in order to support GvL effect in the setting of HSCT and control minimal 
residual disease (MRD) by stimulating anti-leukemic immune responses in high-risk 
patients after HSCT as well as non-HSCT candidates after cytotoxic therapy. There are 
two main directions in the development of AML vaccines: peptide vaccines derived from 
TAAs and DC vaccines.  
1.2.2.2.1. Peptide vaccines:  
Wilms tumor protein 1 (WT1), proteinase 3, mucin 1 (MUC-1) (Kuball et al. 2011) 
and receptor for hyaluranon-mediated motility (RHAMM) (Schmitt et al. 2008) have been 
evaluated as peptide vaccines in AML vaccine strategies. For various TAAs, WT1 was 
prioritized as a vaccine candidate due to its therapeutic impact, immunogenicity, tissue 
restricted expression, and leukemogenic characteristics (Cheever et al. 2009). WT1126-134 
(Keilholz et al. 2009), WT1122-140, WT1331-352, WT1427-445  (Maslak et al. 2010), WT1235-243 
(Tsuboi et al. 2012) peptides were tested for their immunogenic capacities in vitro and in 
vivo. The WT1126-134 peptide vaccine trial by Keilholz et al. showed that at week 18 after 
vaccination, the median frequency of WT1 tetramer positive T cells in the bone marrow 
and peripheral blood of patients increased from baseline frequencies of 0.18 % and 0.12 
% to frequencies of 0.41 % and 0.28 %. Importantly, the increased frequency of WT1-
specific T cells were functional and remained at stable levels for follow up period.  
Rezvani et al. reported that the median value of the absolute number of WT1-specific 
CD3+CD8+ T cells after vaccination were 4-fold higher than that before vaccination (328 
vs 95 cells per mL). Entirely, WT1 peptide vaccine studies demonstrated immunologically 
as well as clinically positive and safe results.  
Common limitations for peptide vaccines are the human leukocyte antigen (HLA) 
restriction and need for prior identification of immunogenic epitopes (Benteyn et al. 
2013). To overcome these limitations, several approaches including transfection of 





Driessche et al. 2009) as well as treatment with long and polyvalent WT1 peptide (Maslak 
et al. 2010), (Weber et al. 2013), (Brayer et al. 2015) vaccines have been tested. Chaise et 
al. immunized HHD transgenic mice (HLA-A0201* expressing) with three different WT1 
DNA vaccines each encoding one of the HLA-A0201* restricted WT1-derived peptides: 
WT1.37 (VLDFAPPGA), WT1.126 (RMFPNAPYL) and, WT1.235 (CMTWNQMNL). The 
mice received 50 g of DNA by intramuscular injection for CD8+ T cell priming at day 0, 
while at day 28, the same amount of DNA was applied by in vivo electroporation for 
boosting. The DNA vaccination induced functional T cells to the three clinically relevant 
HLA-A0201*-restricted epitopes, in vivo. By injection of the DNA encoding the three 
promising epitopes at different sites, tumor immune escape mechanism could be 
overcome, however, only HLA-A0201*-positive patients could benefit from this 
approach.  
Modifying native peptides to more antigenic peptides by amino acid substitution 
in their sequences (heteroclitic peptides) is considered to be beneficial to improve 
immunity to self-proteins. Maslak et al. reported results of a pilot clinical study using 
polyvalent vaccine consisting of four heteroclitic WT1 peptides (one peptide for CD8+, 
two long peptides for CD4+, and one for both subsets) in nine AML patients at CR status. 
They showed that immune responses of both CD4+ and CD8+ T cell subsets to the peptides 
in seven patients, however, median DFS had not been reached. Notably, median OS of the 
patients were longer than estimated average (35+ months vs 9 months). Similarly, Brayer 
et al. assessed the safety, tolerability, and immunogenicity of vaccination with 
combination of WT1 peptides restricted to different HLA molecules. Three of the 14 
vaccinated patients with AML or MDS showed prolonged relapse-free survival. Weber et 
al. generated multi-TAA-specific T cells from peripheral blood of healthy donors using 
peptide mix covering whole WT1 and other four TAAs. The generated pool of CTLs 
included different specificities and WT1-specific T cells were found within the pool. 
Overall, it is accepted that vaccination strategies using WT1 are safe and have a potential 
to improve immune responses against leukemia. Therefore, in WT1-based vaccination, 
alternatives have been searched to improve the feasibility and effectiveness of this 
approach.    
 
1.2.2.2.2. DC vaccines:  
DC vaccination is another icon to induce strong and sustained CD4+ and CD8+ T-





first to test DC vaccination. Four patients achieved tumor antigen-specific immunological 
response as a result of tumor cell pulsed HLA-matched allogeneic donor derived DC 
vaccination (Fujii et al. 2001). Subsequently, in this field, DCs  loaded with tumor cell 
lysates or TAA-derived peptides, DCs electroporated with mRNA encoding full-length 
protein antigens, as well as tumor peptide pulsed DC-derived exosomes have been tested. 
DCs can be generated from AML patients in remission and be rendered more antigenic by 
exposure to AML lysates (Galea-Lauri et al. 2002) or fusion with AML blasts (Banat et al. 
2004). Autologous moDCs transfected with mRNA encoding WT1 protein were able to 
induce a broad presentation on HLA class I and II molecules by DCs (Van Tendeloo et al. 
2010). In detail, monocyte-derived DCs were electroporated with the mRNA encoding 
full-length WT1, then injected intradermally at biweekly intervals four times. As a result, 
an immunological response comprising NK and CD8+ T cell activation were induced. 
Moreover, five of ten vaccinated patients with AML achieved molecular remission and in 
the two of those five, incomplete remission converted to complete remission. The fact 
that the achieved effects were transient was probably explained by the lack of CD4+ T cell 
stimulation which is otherwise considered to be necessary for the maintenance of long-
term CD8+ T cell memory. This approach is promising, but it seems to be laborious and 
the transfection efficiency of DCs is variable, thereby, the following effect could be varied.  
Classical prophylactic vaccines are mostly injected intramuscularly or 
subcutaneously where they are captured by various types of APCs. Upon activation, these 
APCs migrate to the lymph nodes to activate T cells. Whereas the concept of direct 
targeting of DC subsets in situ (resident) may overcome the need for cell migration and 
facilitate the instant delivery of antigen to resident DC subsets in the spleen and the 
lymph nodes. To this end, intra- and extracellular receptors expressed by DCs have been 
extensively targeted (Kreutz et al. 2013). Importantly, targeting of antigen directly to DCs 
reduces the required dose of antigen remarkably.  
The most common type of DCs used in DC vaccine studies are autologous moDCs, 
although isolation of mDCs or pDCs from peripheral blood as well as the use of the MUTZ-
3 cell line has been reported. Recently, de Haar et al. reported that cord blood derived 
CD34+ DCs are capable of inducing a WT1-specific T cell response after their 
differentiation, maturation and electroporation with WT1 mRNA (de Haar et al. 2015). 
Important parameters to optimize DC vaccines after HSCT were listed in Table 3. In 
addition, intrinsic characteristics of DCs such as intracellular signaling, antigen 





switch on their immunity-inducing capacity. Finally, interaction of DCs with other cellular 
and soluble factors may have an impact on induction of immune responses to leukemia 
cells, too. Nevertheless, DC vaccination is a virtue of  immunotherapy against various 
tumors including AML. 
 
Table 3. Parameters for optimization of DC vaccines (Plantinga et al. 2014). 
Cell sources Type of DCs Maturation Loading 





Cord blood Adherent 
monocytes 
TLR agonists Protein 
Mobilized HSCs in 
peripheral blood 
CD34-derived Interferons Cell lysate 
 Primary DCs CD40L Fusion 
  TNF- RNA/DNA 
electroporation 






Therapeutic antibodies inhibit a target that plays a major role in disease 
progression or cause the cytotoxic death of target cells. Alternatively, antibodies are used 
as carriers to target cytotoxic and imaging agents, such as radioisotopes, toxins, and 
drugs, to the site of a disease. The various clinical applications of antibodies lead to their 
modifications in terms of size, pharmacokinetics, immunogenicity, specificity, valency 
and effector functions. Antibodies have also been expressed as fusion proteins for the 
targeting of diverse cytokines, protein antigens, toxins, and enzymes for therapeutic 
applications (Jain et al. 2007). The first example of antibody engineering was the 
development of the single chain variable fragment (scFv) format of antibody, consisting 
of the variable heavy and light chains linked by a short peptide (Figure 3). The scFv format 
offers several advantages including better tissue penetrance, no binding to Fc receptors, 
avoidance of host antibody response, short serum half-life, and low cost. Another 
example of antibody engineering is the nanobody format, which is derived from the 





Multimerization of antibody fragments (miniabody, diabody, triabody) and 
incorporation of two specificities into a single antibody (bispecific antibody) have also 
been developed.  
 
 
Engineered antibodies have  been used for cytokine carriers to tumor tissues 
(Kontermann 2012). For instance, IL-15, IL-2, GM-CSF, IFN-, and death ligands (TNF, 
TRAIL, FasL) have been fused to antibodies with different specificities for various 
therapeutic applications. One of the latest developments in antibody engineering has 
been used for delivery of tumor antigen to APCs in order to facilitate accessibility of the 
antigen by the APCs (Idoyaga et al. 2011).           
 
 
WT1 gene is located at chromosome 11q13 and encodes a Krüppel type zinc finger 
transcription factor that plays an essential role in cell growth and differentiation (Call et 
al. 1990), (Gessler et al. 1990). A continuous shuttling of WT1 protein between nucleus 
and cytoplasm (Niksic et al. 2004) may reflect its complex roles in different cell function 
during both embryogenesis and ontogenesis. In embryonic development, WT1 is mostly 
expressed in the endoderm and mesoderm originated organs: the highest in kidneys and 
gonads as well as heart, lungs, intestines, spleen, peritoneum, pleura, and pericardium. 
Figure 3. Structural scheme of therapeutic antibody (IgG1) and single chain variable fragment 
(scFv) constructs.  
Fab, antigen binding fragment; Fv, variable fragment, Fc, constant fragment; VH, variable 






Its expression is also detected in distinct regions of the brain, spinal cord, and eyes which 
are developed from ectoderm (Armstrong et al. 1993). Thus, the broad expression profile 
of WT1 indicates its essential and universal role in tissue generation and intrauterine 
development of human. Postnatally, the expression of WT1 is strongly restricted to a 
limited set of tissues, including the gonads, uterus, kidneys and mesothelium, and to 
progenitor cells in various types of tissues including haematopoietic stem cells (Park et 
al. 1993, Buckler et al. 1991).  
 
The WT1 gene consists of ten exons flanking huge introns and there are two 
different alternative splices of WT1; exon 5 encoding 17 amino acids and 9 nucleotides 
encoding terminal three amino acids (KTS) of exon 9 (Figure 4) (Haber et al. 1991) 
(Gessler et al. 1992). Due to alternative transcription initiation, alternative pre-mRNA 
splicing, RNA editing and alternative translation initiation, at least 36 different isoforms 
are translated from the same DNA template (Kramarzova et al. 2012). An isoform 
(P19544-1, UniProtKB) consisting of 449 amino acids, has been chosen as canonical 
sequence. It is translated from the first AUG site in exon 1 of the gene and the two splices 
are present. Depending on presence of the two splices, there are four major isoforms of 
WT1: WT1_A (exon5-/KTS-), WT1_B (exon5+/KTS-), WT1_C (exon5-/KTS+), and WT1_D 
(exon5+/KTS+). Consisting of 522 amino acids, WT1_D (P19544-7, UniProtKB) is the 
longest isoform described so far, because its translation is initiated from non-AUG site at 
upstream of the gene.  
 
Figure 4. Scheme structure of WT1 gene (top) and WT1_D protein (bottom).  
Red frames, alternative splices; black triangles, nuclear localization signals; Zn, zinc ion in the 





Three functional domains have been defined within WT1 protein: RNA 
recognition and homodimerisation, transcriptional regulatory, and DNA binding (zinc 
finger) domains. The zinc finger domains of WT1 bind to GC-rich sequences, or (TCC)n 
motif of thereby regulating the expression of downstream target genes (Tatsumi et al. 
2015). An array of genes involved in MAPK, Wnt, and TET signaling, epithelial-
mesenchymal transition etc. is supposed to be potential WT1 targets. Moreover, WT1 
function is complicated by its ability to bind RNA (Larsson et al. 1995). In general, several 
opposing functions of WT1: as an activator or repressor in transcriptional processes, a 
role for WT1 in RNA metabolism, and posttranscriptional regulation has been described 
(Hohenstein and Hastie 2006).  
WT1 plays significant roles in human diseases. The WT1 gene was originally 
defined as a tumor suppressor gene in Wilms tumor, a pediatric kidney cancer of 
embryonic origin. Virtually, 10-20 % of Wilms tumor cases have a mutated WT1 gene and 
over 50 % of cases have decreased expression of wild type WT1 (Huff 1998). A mutation 
or deletion affecting WT1 gene induces rare genetic disorders presenting symptoms of 
nephropathy, genitourinary anomaly, Wilms tumor, mental and physical retardation 
(WAGR, Denys-Drash syndromes) in humans. In these diseases, WT1 serves as a tumor 
suppressor gene. In contrast, WT1 gene is able to act as an oncogene in leukemogenesis 
(Sugiyama 2005) (Osaka et al. 1997) (Menke et al. 1998). It is highly expressed in most 
cases of acute myeloid and lymphoid leukemia (Inoue et al. 1997), advanced 
myelodysplastic syndrome (Tamaki et al. 1999), chronic myelogenous leukemia (Inoue 
et al. 1994), and multiple myeloma  (Hatta et al. 2005). Sugiyama et al. conceptualized 
that WT1-expressing progenitor cells can differentiate into tissue-specific cells by down-
regulation of WT1 expression, but if this down-regulation is impaired, the WT1-
expressing progenitor cells continue to proliferate and transform as a result of 
occurrence of secondary, tertiary or further genetic alterations (Sugiyama 2010). 
Consistent with the cell survival and oncogenic roles of the WT1 protein, increased WT1 
levels have prognostic significance and are associated with a poor response to therapy 
(Barragan et al. 2004, Casalegno-Garduno et al. 2015). For AML cases, WT1_D is the most 





Due to the supporting evidences of its oncogenic function, WT1 has been 
extensively targeted for immunotherapy to treat cancer. WT1-derived peptide specific 
cytotoxic CD8+ T cells are induced by stimulation with WT1 peptide pools and efficiently 
kill leukemic cells (Oka et al. 2000), (Gao et al. 2000), (Tsuboi et al. 2002), (Azuma et al. 
2002). In patients with haematological malignancies, serum titers of IgM and IgG, specific  
 
for WT1 have been detected at higher levels than those in healthy donors (Elisseeva et al. 
2002). Importantly, in previous vaccination trials using WT1-peptide loaded or WT1 
mRNA transfected DCs, there were no reports about autoimmunity induced by the 
vaccine (Oka et al. 2004), (Kitawaki et al. 2008), (Van Tendeloo et al. 2010). Van 
Driessche et al. have reviewed early clinical trials targeting WT1 protein for patients with 
haematological malignancies and solid tumors (Van Driessche et al. 2012). Based on the 
WT1 antigen source, the clinical trials can be divided into four groups: (a) human 
leukocyte antigen (HLA)-restricted peptide vaccines, (b) non-HLA restricted long peptide 
vaccines, (c) dendritic cell (DC) vaccines loaded with HLA-restricted peptide and (d) DC 
vaccines loaded with mRNA encoding full-length WT1. These vaccines could elicit WT1-
specific immune responses and exhibited objective clinical responses in up to 64% of 
evaluable vaccinated patients with haematological malignancies. Although several 
antigenic epitopes are known for induction of T cell response, it is still needed to detect 
more antigenic epitopes from WT1. Contributing to this, Doubrovina et al. identified 
clusters of antigenic epitopes in WT1 protein sequence and these epitopes are spread 
mainly in N-terminal and middle part of WT1 (Figure 5) (Doubrovina et al. 2012).  
Because of the strong binding to nucleotide sequences (Hamilton et al. 1995) and 
its complex interactions with posttranscriptional regulators (Ladomery et al. 1999), WT1 
 
Figure 5. Potential antigenic epitopes spread in WT1 protein sequence.  
White, N-terminal extension of WT1_D; blue, canonical sequence of WT1; green, two alternative 
splices; yellow, potential epitopes restricted to HLA class I; pink, epitopes restricted to HLA class 






is assumed to be hardly expressed as a full-length protein (Geng and Carstens 2006). So 
far, using different soluble tags and buffer conditions, full-length human WT1 and its zinc 
finger domain has been expressed and purified  for functional studies (Nurmemmedov 




Dendritic cells (DCs) are present in all tissues and involved in the initiation of 
immune responses. They are part of the myeloid lineage of haematopoietic cells and arise 
from a precursor that can also differentiate into monocytes but nor granulocytes. 
Maturation of DCs is dependent on a cytokine called Flt3 ligand, which binds to the Flt3 
tyrosine kinase receptor on the precursor cells. All subsets of human DCs are defined by 
high levels of MHC class II (HLA-DR) and lack of lineage markers (CD11c+HLA-DR+lin- 
cells). Those cells are divided into three classes: myeloid (mDCs), plasmocytoid (pDCs) 
and monocyte derived (moDCs) DCs (Collin et al. 2013). There are also very specialized 
DC  subsets in the skin (Langerhans cells) and the parenchyma of the brain (microglia).  
Immature DCs in extra-lymphoid tissues endocytose foreign proteins. If they are 
activated or matured by various co-stimuli, DCs migrate to the draining lymph nodes and 
present antigenic determinants via HLA class I and II molecules to T cells. By virtue of 
especial cytokines, different types of DCs are able to prime distinct helper T cell subsets 
(Table 4). In the presence of immunostimulatory cytokines IL-12 and IFN-, mature DCs 
prime TH1 cells which provide help in priming CD8+ effector T cells. TH2 cells that drive 
humoral responses are primed with mature DCs secreting IL-4, IL-6, and IL-10. Whereas 
DCs which are either unable to secrete cytokines, or secrete immunosuppressive 
cytokines IL-10, TGF-β can be responsible for regulatory T cells (Treg) (Mays and Wilson 
2011). In the absence of activation signals, immature DCs elicit immunological tolerance 
toward the antigen (Bonifaz et al. 2002). However, in combination with activation signals 
such as CD40 agonists, protective antigen-specific CD4+ and CD8+ T cell responses can be 
stimulated (Bonifaz et al. 2004) (Gurer et al. 2008).  
Usually, antigens derived from intracellular origins are presented by the HLA class 
I presentation system while extracellular antigens are preferentially presented on the 
HLA class II molecules. However, DCs have a unique ability to cross present antigens: 





antigens escaped from endosome) whereas intracellular antigens on the HLA class II 
molecules (mediated by autophagy) (Romao et al. 2013). Antigen cross-presentation by 
DCs is of key importance for the induction of anti-tumor immunity thereby CD8+ 
cytotoxic T cells  specific to tumor derived antigens are primed. Furthermore, it could be 
inevitable to sustain the anti-tumor immunity because tumor cell autophagy-derived 
endogenous antigen presentation on MHC class II molecules by tumor cells activate CD4+ 
T cells which in turn endorse the effector function of cytotoxic T cells.  
Table 4. Cytokines and helper T cell priming of DCs. 
 
The type of receptors on the surface of DCs and their interaction with cognitive 
antigen are involved in the maturation and cytokine secretion of different subsets of 
either immunogenic or tolerogenic DCs. DCs express various C-type lectin receptors such 
as macrophage mannose receptor (MMR), DC-SIGN, DEC205 (Figure 6) which all function 
as endocytic receptors (van Kooyk 2008). The extra-cellular domain of those molecules 
contains a cysteine-rich domain (CysR), a fibronectin type II domain (FNII), and multiple 
C-type lectin-like domains (CTLD). The cytoplasmic domains contain motifs for tyrosine 
(Tyr-) and/or dihydrophobic amino acid-based endocytosis.  
Maturation 








Mature IL-12, IFN- TH1 IFN-g, TNF-a, 
IL-2 
Cytotoxic T cell 
response 
Mature IL-4, IL-6, 
IL-10, low IL-12 
TH2 IL-4, IL-6, 
IL-10, IL-13 
















The DEC205 (CD205, Ly75, 205kDa) receptor was first identified in mice (Jiang et 
al. 1995). Its expression in human  was mainly identified on DCs and thymic epithelial 
cells. Park et al. reported that DEC205 is the only endocytic receptor that has been 
visualized on most DCs in the T cell areas of lymph nodes in humans (Park et al. 2012). 
Similar to other members of C-type lectin receptors, the DEC205 consists of CysR, FNII 
and ten CTLDs. Depending on environmental pH, the 12 extracellular domains undergo 
conformational changes (Figure 7), i.e., form a compact double ring-shaped conformation 
at acidic pH and become linear at basic or physiological pH (~7.4). This pH-dependent 
conformational change of the DEC205 may result in ligand binding and release. The 
DEC205 only binds to apoptotic and necrotic cells at acidic pH, whereas live cells cannot 
be recognized by DEC205 at either acidic or basic conditions (Cao et al. 2015). These 
results suggest that DEC205 is an immune receptor that recognizes apoptotic and 
necrotic cells specifically through a pH-dependent mechanism.    
Figure 6. Structural scheme of C-type lectin receptors on the surface of DCs.                               
MMR, macrophage mannose receptor; CysR, Cysteine rich domain; FNII, Fibronectin type II 
repeat; CTLD, C-type lectin (carbohydrate recognition) domains; TBM, Tyrosine-based motif;  
taaa, triad of acidic amino acids;  DM, Di-leucine motif; TR, tandem repeat. (Adapted from Fidgor 






The DEC205 has been supposed to be an attractive target for therapeutic antigen 
delivery in the areas of autoimmunity, as well as vaccination strategies for infections or 
tumors (Erbacher et al. 2009). When antigens (for instance, HIV gag-p24 protein) are 
targeted to the DEC205 in vivo (mice and rhesus macaques) by conjugation to a 
monoclonal antibody directed against the DEC205, antigen presentation is significantly, 
100-fold enhanced (Bonifaz et al. 2004). Recently DEC205-targeting has been evaluated 
 
for its efficiency of HLA class I and II antigen presentation  (Reuter et al. 2015). As they 
determined, nearly 80% of surface DEC205 was internalized by both human BDCA-1+ and 
BDCA-3+ DCs within 90 min, with the time to maximum internalization being 30 min. A 
considerably less internalization of antigens targeted to DEC205 ensued under 
conditions of in vivo inflammation, but the efficiency of antigen presentation on the 
molecules of MHC class I and MHC II was not impaired, i.e. “DEC205 continues to elicit 
efficient MHC I and MHC II antigen presentation outcomes in vivo”. This finding is 
important because activation of DCs using inflammatory cytokines is necessary for 
induction of immunity by tumor vaccines.  
 
Figure 7. pH-dependent conformational change of the DEC205 receptor.  
Left: linear “steady”conformation; CysR, cysteine rich domain; FNII, fibronectin II 
domain, CTLD, C-type lectin domain. Right: ring-shaped “active” conformation. (Adapted 






Since DCs initiate specific T cell immunity and harmonize innate and adaptive 
immune response (Banchereau and Steinman 1998, Steinman and Banchereau 2007), it 
is important to test targeting of  WT1 protein to DCs either ex vivo or in vivo. Indeed the 
targeting of several other tumor associated antigens  such as MAGE (Birkholz et al. 2010), 
NY-ESO1 (Tsuji et al. 2011), HER2/neu (Wang et al. 2012) to DCs via antibodies specific 
for the endocytic receptor DEC205 has been studied using in vitro and in vivo models and 
appreciated to induce an improved immune response to tumors expressing these 
antigens. The targeted, matured DCs trigger the specific CD8+ and CD4+ T cell response 
against the antigen processed and presented by the DCs. To initiate stronger anti-tumor 
immune response to haematological malignancies, a highly effective antigen delivery 
system to APCs is important, especially it is essential for protein antigens which are 




T cell responses to tumors are initiated when their antigens are ingested by host 
antigen presenting cells (APCs), particularly DCs. The ingested tumor derived protein 
antigens are processed inside the DCs and peptides from these antigens are then 
displayed bound to MHC class I molecules for recognition by CD8+ T cells (cross 
priming/presentation). DCs express co-stimulators that provide the signals needed for 
differentiation of CD8+ T cells into anti-tumor cytotoxic T lymphocytes (CTLs). Thus, the 
predominant mechanism of adaptive immunity to tumor is stimulation of  the killing 
function of CD8+ T cells that is orchestrated by DCs. Also, MHC class II molecules on the 
surface of DCs may present internalized tumor antigens and activate CD4+ helper T cells. 
As a result of TH1 polarization, helper T cells play a crucial role in establishment of 
sustained anti-tumor immunity by providing cytokines for effective CTL development 
(Figure 8). In addition, helper T cells specific for tumor antigens may secrete cytokines, 
such as TNF and IFN-γ, that can increase the expression of MHC class I molecules by 
tumor cells. Cytolytic CD4+ T cells can exert direct functions against malignancies by 
lysing HLA class II expressing targets, therefore, vaccine strategies should aim to induce 
this subset of cells (Brown 2010). For a sustained T-cell protection, the presence of both 






Figure 8. T cell activation mediated by DCs. 
Signal 1 is the antigen-specific signal that is mediated through T cell receptor triggering by 
MHC class I- or II-associated peptides processed from tumor antigens after internalization 
through endocytosis or pattern recognition receptors. Signal 2 is the co-stimulatory signal, 
mainly mediated by triggering of CD28 by CD80 and CD86 that are expressed by mature DCs. 
Signal 3 is the polarizing signal that is mediated by various soluble or membrane-bound factors, 
such as IL-12, that promote the development of TH1 cells. Adapted from (Mays and Wilson 2011). 
 
T cells reactive to self-proteins, e.g. to WT1 are deleted by the mechanism of 
central and peripheral tolerances. However, WT1-specific CD8+ T cells exist at low 
frequency in healthy donors (Rezvani et al. 2003) and occur with elevated frequency in 
allo-HSC transplanted patients with leukemia  (Rezvani et al. 2005). In healthy donors, 
the frequency of WT1-specific T cells ranges from 10-7 to 10-5 in the CD8+ T cell subset 
and from 10-6 to 10-5 in the CD4+ T cell subset in the natural repertoire (Schmied et al. 
2015). An interesting phenomenon is that during early trimesters of pregnancy, there 
were increased frequencies of WT1-specific T cells to decline after delivery (Lutz et al. 
2015). Due to the rare number in whole T cell repertoire, analyses of WT1-specific T cells 
are performed after enrichment or expansion of the specific T cells.  
With regard to phenotype of WT1-specific T cells and their functional capacity, a 
couple of studies have been performed. Rezvani et al.  showed that central 
(CD45RO+CD27+CD57-) or effector memory (CD45RO-CD27-CD57+) T cells constitute the 
WT1-specific T cell population in leukemia patients received HSCT. Whereas Schmied et 
al. demonstrated that two distinct phenotypes of WT1-specific T cells are present in 
healthy donors: one is CD4+ T cells in the memory pool, the other is CD8+ T cells in the 
naïve population. An early report on the functional capacity of WT1-specific T cells was 
that these T cells recognize leukemic CD34+ cells expressing WT1 and exert anti-leukemia 





(WT1126-134 and WT1235-243 in Montanide adjuvant) peptides, WT1-specific T cells were 
emerged and WT1 mRNA level was declined in responding patients. However, the raise 
of WT1-specific T cells was temporary and did not correlated with disease response. A 
deletion of high avidity T cells by self-tolerance mechanism and short life expectance of 
T cells induced by single peptide stimulation could be an explanation (Uttenthal et al. 
2014). Nevertheless, WT1-specific T cells can be detected in both peripheral blood and 
bone marrow of patients with leukemia and they are supposed to be functional in terms 
of interferon- and granzyme B production (Casalegno-Garduno et al. 2015). Casalegno-
Garduno et al. could also show that WT1-specific T cell presence corresponds to the 
clinical outcome.  
Taken together, very low frequencies of T cells specific to WT1 protein are present 
in both healthy donors and patients. Those T cells are functional, but may be short-lived. 
To analyze the low frequency of WT1-specific T cells without prior enrichment or 
expansion, an improvement of responsiveness of those cells is necessary.  










Section 2. Central hypothesis,  
aim, and design of the study 
 
 
2.1.  Central hypothesis:  
WT1 involvement in leukemogenesis, overexpression along with disease progress 
and proved GvL effect mediated by WT1-specfic T cells after HSCT render WT1 a 
promising target for immunotherapy. Due to its intracellular localization as well as close 
interaction with nucleotides and proteins, WT1 protein is thought to be not easily 
expressed as s recombinant protein. Therefore, full-length human WT1 has not yet been 
expressed for vaccination studies although its expression for functional studies were 
optimized. The current WT1-based immunotherapies are mainly based on peptide 
vaccination. However, WT1 peptides presented on various HLA alleles are not completely 
defined yet. In addition, a short-lived T cell response to the peptide stimulations hampers 
the effectiveness of WT1 peptide vaccination. It seemed that targeting of WT1 to dendritic 
cells could be a feasible approach to improve DC-mediated WT1-specific T cell response 
either ex vivo or in vivo. A potential experimental approach was the fusion of WT1 to an 
antibody specific to the endocytic receptor DEC205 expressed on DCs. After binding to 
DEC205, the antibody fusion protein is taken up by the DC and processed intracellularly, 
resulting in the better and broader presentation of WT1-derived peptides on MHC 
molecules on the surface of the DCs (Figure 9). This way, an efficiency of WT1 protein 
expression and peptide variety of WT1 to be loaded on HLA class I and II molecules might 
be better and broader. Thereby, T-cell immune responses to WT1-positive tumors could 
be effective and sustainable.  






2.2.  Aim  
The prior aim of this work was the generation and production of an anti-hDEC205-
WT1 antibody fusion protein as a recombinant vaccine candidate for AML 
immunotherapy. The second aim was the directly ex vivo detection of the anti-hDEC205-
WT1 loaded mature moDC-mediated T cell response. Moreover, we wanted to check 
WT1-specific cytotoxicity function of T cells stimulated with this approach by in vitro 
experiments.  
 
2.3.  Study design 
This work was designed as a two phase sequential study as depicted in Figure 10. 
The first package of the work included molecular cloning of the antibody fusion protein 
and production, purification as well as functional tests of the anti-hDEC205-WT1 
antibody fusion proteins. In the second phase of the work, the immune stimulatory 
capacity of the anti-hDEC205-WT1 were tested ex vivo and in vitro corresponding to the 
aims of the study. Healthy donors and HSC transplanted patients (divided into two 
blocks: healthy and diseased) with AML were randomly selected and blood samples were 
collected for the planned investigations.     
 
Figure 9. Targeting WT1 protein to DCs. 
 







Figure 10. Study design 










Section 3. Materials and methods 
 
 
3.1.  Materials 
 
3.1.1.1. Human primary cells 
Sample types:  Leukoreduction system chambers 
                Buffy coats 
            Peripheral venous blood samples 
Cell types:   PBMCs 
          Monocyte derived dendritic cells (moDCs)  
          CD3+ T cells 
3.1.1.2. Cell lines  
The human cancer cell lines used for this work were available in the Division of 
Molecular Internal Medicine, and Laboratory for Immunotherapy, University Hospital of 
Würzburg. CHO-hDEC205 cells were kindly provided by Professor Dudziak D. (Erlangen, 
Germany). Adherent cells were cultured in a culture flask supplied with RPMI 1640/10 
% FCS/1 % Penicillin and Streptomycin until full confluency and were harvested from 
the flasks by incubation of cells with 1 % trypsin at 37°, 5 % CO2 for one min. Suspension 
cells were cultured in a culture flask supplied with RPMI 1640 GlutaMax/10 % FCS and 
50μg/mL gentamycin at density of 1 x 106 cells per mL. All cells were split at 1:10 or 1:5 
when cell confluency had reached 90-100 %. 




Table 5. Cell lines 
Cell line Species and cell types 
CHO Chinese hamster ovary 
CHO-hDEC205 h-DEC205 stably expressing CHO 
DG75 Human Burkitt lymphoma 
HEK293 Human embryonic kidney 
HeLa Human cervical carcinoma 
ML2 Human myelomonocytic leukemia 
NALM-6 Human B cell precursor leukemia 
THP1 Human acute monocytic leukemia 
 
3.1.1.3. Prokaryotic cells 
Chemically competent cells were transformed for cloning of the expression 
plasmids.   
Table 6. Prokaryotic cells. 
Bacterial   
competent cells 
Strain  Manufacturer, Country 
E. Coli 
K12                                        
(NEB 5low competent) 
New England Biolabs, 
Frankfurt, Germany 
E. Coli 
K12                                         
(NEB 5high competent  ) 




The expression plasmids for each construct used in this work were derived from 
pCR3 expression plasmid (Invitrogen, Darmstadt, Germany). A scFv:hDEC205 construct 
was encoded in pMA-T plasmid (Life Technologies, Darmstadt, Germany). 
 
Cell culture media were supplemented with 2-10 % FCS and appropriate 
antibiotics prior to use. Cytokines were solubilized and aliquoted in accordance with 
manufacturers’ protocol.   




Table 7. Culture media and cytokines. 
Culture medium, cytokine Manufacturer, Country 
RPMI 1640  Sigma-Aldrich, Deisenhofen, Germany 
RPMI 1640 GlutaMax Life Technologies, Darmstadt, Germany 
Granulocyte-macrophage colony-
stimulating factor (GM-CSF) 
Miltenyi Biotec, Bergisch Gladbach, 
Germany 
Interleukin-4 (IL-4) R&D Systems, Wiesbaden, Germany 
Interleukin-2 (IL-2, Proleukin)  Novartis, Nürnberg, Germany 
Interleukin-7 (IL-7) Peprotech, Hamburg, Germany  
Interleukin-15 (IL-15) Peprotech, Hamburg, Germany  
TNFα R&D Systems, Wiesbaden, Germany 
 
 
Table 8. Enzymes. 
Enzyme Manufacturer, Country 
T4-Ligase Fermentas, St. Leon-Rot, Germany 
BamHI New England Biolabs, Frankfurt, Germany 
BglII New England Biolabs, Frankfurt, Germany 
EcoRI New England Biolabs, Frankfurt, Germany 
HindIII New England Biolabs, Frankfurt, Germany 
Mfe New England Biolabs, Frankfurt, Germany 
SalI New England Biolabs, Frankfurt, Germany 
Calf Intestinal alkaline Phosphatase 
(SIP) 
New England Biolabs, Frankfurt, Germany 
XbaI New England Biolabs, Frankfurt, Germany 









Table 9. Antibodies. 
Antibody Source Manufacturer, Country 
Anti-CD3-FITC 














Anti-CD137-PE or -APC Mouse anti-human CD137 
BD Biosciences, 
Heidelberg, Germany 
Anti-Interferon-γ-PE Mouse anti-human IFN- 
Beckman Coulter, Krefeld, 
Germany 
Anti-CD14-APC 
Mouse anti-human CD14 
Clone HCD14 
BioLegend, Fell, Germany 
Anti-CD86-PE Mouse anti-human CD86 
BD Biosciences, 
Heidelberg, Germany 
Anti-CD80-PE Mouse anti-human CD80 
BD Biosciences, 
Heidelberg, Germany 










Mouse anti-human CCR7 
IgG2A 
 







Anti-CD1a-APC Mouse anti-human CD1a 
BD Biosciences, 
Heidelberg, Germany 
Anti-CD205-PE Mouse anti-human CD205 
Miltenyi Biotec, Bergisch 
Gladbach, Germany 




Anti-Flag mAb M2 Mouse IgG1 monoclonal 
Sigma-Aldrich, 
Deisenhofen, Germany 
Anti-mouse IRDye 800 
 
Goat, polyclonal 
















Mouse anti-human CD56 
Clone HCD56 
















Mouse anti-human IFN- 
BD Biosciences, 
Heidelberg, Germany 
Mouse IgG1 isotype 








R&D Systems, Wiesbaden, 
Germany 
 
Table 10. Peptide and recombinant protein. 
Peptide Manufacturer, Country 
WT1 peptivator 15-mer peptide pool Miltenyi Biotec, Bergisch Gladbach, 
Germany 
WT1 A24 100018 single peptide University of Tübingen, Germany 
WT1 A02 3181 single peptide University of Tübingen, Germany 
CMV pp65 recombinant protein Miltenyi Biotec, Bergisch Gladbach, 
Germany 




Table 11. Chemicals and reagents. 
Substance Manufacturer, Country 
1kb DNA-ladder Fermentas, St. Leon-Rot, Germany 
Acetic acid J. T. Baker, Leipzig, Germany 
Acrylamide (30 %) Carl Roth, Karlsruhe, Germany 
Agar Carl Roth, Karlsruhe, Germany 
Agarose Carl Roth, Karlsruhe, Germany 
Ammonium persulfate (APS) AppliChem, Darmstadt, Germany 
Ampicillin Carl Roth, Karlsruhe, Germany 
Anti-Flag M2 agarose beads Sigma-Aldrich, Deisenhofen, Germany 
BCIP/NBT liquid substrate system Sigma-Aldrich, Deisenhofen, Germany 
Bovine serum albumin (BSA) Sigma-Aldrich, Deisenhofen, Germany 
Crystal violet (CV) powder Carl Roth, Karlsruhe, Germany 
Dimethyl sulfoxide (DMSO) Carl Roth, Karlsruhe, Germany 
Ethanol J. T. Baker, Leipzig, Germany 
Ethylenediaminetetraacetic acid (EDTA) Carl Roth, Karlsruhe, Germany 
Fetal calf serum (FCS) Life Technologies, Darmstadt, Germany 
Flag peptide Sigma-Aldrich, Deisenhofen, Germany 
Geneticin disulfate (G418-Sulfate) Carl Roth, Karlsruhe, Germany 
Gentamycin Life Technologies, Darmstadt, Germany 
Lymphocyte separation medium PAA, Pasching, Austria 
Methanol J. T. Baker, Leibzig, Germany 
Midori Green Advance DNA stain 
Intas Science Imaging, Göttingen , 
Germany 
Nonfat dried milk powder Sigma-Aldrich, Deisenhofen, Germany 
Paraformaldehyde Carl Roth, Karlsruhe, Germany 
Penicillin-Streptomycin (100 x) PAA, Pasching, Austria 
Peptone Carl Roth, Karlsruhe, Germany 
Phosphatase inhibitor II Sigma-Aldrich, Deisenhofen, Germany 
Phosphate buffered saline (PBS) PAA, Pasching, Austria 
DPBS Life Technologies, Darmstadt, Germany 




Polyethylenimine (PEI) Sigma-Aldrich, Deisenhofen, Germany 
Prestained protein marker (broad 
range) 
New England Biolabs, Frankfurt, 
Germany 
Protease inhibitor cocktail Roche, Mannheim, Germany 
Silver gel marker (low molecular 
weight) 
GE Healthcare, Garching, Dassel, 
Germany 
Sodium dodecyl sulfate (SDS) Carl Roth, Karlsruhe Garching, Germany 
Streptavidin-AP (Alkaline Phosphatase) Southern Biotech, Eching, Germany 
Tetramethylethylenediamine (TEMED) Sigma-Aldrich, Deisenhofen, Germany 
Tris Carl Roth, Karlsruhe, Germany 
Triton X-100 Sigma-Aldrich, Deisenhofen, Germany 
Trypsin-EDTA solution (10X) PAA, Pasching, Austria 
Tween-20 Carl Roth, Karlsruhe, Germany 
Yeast extract Carl Roth, Karlsruhe, Germany 
ß-Mercaptoethanol Sigma-Aldrich, Deisenhofen, Germany 
 
Table 12. Kits. 
Kit Manufacturer, Country 
CD3+ pan T cell untouched selection kit Miltenyi Biotec, Bergisch Gladbach, 
Germany 
CD137-PE isolation kit Miltenyi Biotec, Bergisch Gladbach, 
Germany 
Gaussia Luciferase Assay kit New England Biolabs, Frankfurt, 
Germany 
Pierce® Silver Stain kit Fermentas, St. Leon-Rot, Germany 
Pure Yield Plasmid Miniprep/Midiprep 
System 
Promega, Mannheim, Germany 
Kod Hot Start DNA polymerase kit Merckmillipore, Darmstadt, Germany 
PCR clean-up, Gel extraction kit Macherey-Nagel, Düren, Germany 
RNeasy mini kit Qiagen, Hilden, Germany 
QuantiTect Rev. Transcription Kit Qiagen, Hilden, Germany 




Rapid DNA ligation kit Fermentas, St. Leon-Rot, Germany 
 
 
Table 13. Equipments and disposable  materials. 
Instrument or material/equipment Manufacturer, Country 
96-well ELISA plates (high binding) Greiner, Frickenhausen, Germany 
Black 96-well ELISA plates Greiner, Frickenhausen, Germany 
96-well ELISPOT plates Merckmillipore, Darmstadt, Germany 
Casting chambers for SDS-PAGE PeqLab, Erlangen, Germany 
Cell culture flasks Greiner, Frickenhausen, Germany 
Cell culture petri dishes Greiner, Frickenhausen, Germany 
Cell culture plates Greiner, Frickenhausen, Germany 
Centrifuge Rotana 460R Hettich, Tuttlingen, Germany 
CO2 incubator Heraeus Cell Safe Heraeus, Hanau, Germany 
Dialysing tubes, Viking, MWCO 15kDa Carl Roth, Karlsruhe, Germany 
Cryotubes Greiner, Frickenhausen, Germany 
ELISPOT reader/C.T.L USA 
Eppendorf tubes, 1,5 ml und 2 ml Eppendorf, Hamburg, Germany 
Equibio EasyjecT Plus electroporator PeqLab, Erlangen, Germany 
Flow cytometer FACS Calibur BD Biosciences, Heidelberg, Germany 
Flow cytometry tubes Falcon, Heidelberg, Germany 
Heat block PeqLab, Erlangen, Germany 
LI-COR Odyssey® Infrared Imager LI-COR Biosciences, Lincoln, USA 
Lucy 2 luminometer/ELISA-reader Anthos Labtec, Krefeld, Germany 
MACS LS and MS columns 
Miltenyi Biotec, Bergisch Gladbach, 
Germany 
MACS multistand 
Miltenyi Biotec, Bergisch Gladbach, 
Germany 
Microcentrifuge 5417C Eppendorf, Hamburg, Germany 
Nitrocellulose membranes, 0,2 µM pore 
size 
Whatman, Dassel, Germany 





Primus MWG Biotech, Ebersberg, 
Germany 
Pipetus 
Hirschmann Laborgeräte, Eberstadt, 
Germany 
Polyallomer tubes Seton, Los Gatos, CA, USA 
Polypropylene tubes Greiner, Frickenhausen, Germany 
Sterile filters (0,2µm) Sarstedt, Nümbrecht, Germany 
Sterile plastic Pasteur pipettes Hartenstein, Würzburg, Germany 
Ultracentrifuge OPTIMA-L70 Beckman Coulter, Krefeld, Germany 
UV-transilluminator PeqLab, Erlangen, Germany 
Well plates for cell culture Greiner, Frickenhausen, Germany 
Wet/tank blotting system PeqLab, Erlangen, Germany 
Whatman papers Hartenstein, Würzburg, Germany 
 
 
Table 14. Preparations and buffers. 
Preparation Prescription 
Assay diluent 
1 x PBS 
10 % (v/v) FCS 
Blot buffer 10x 
 
0,025 M Tris 
0,192 M glycin 
20 % (v/v) methanol 
pH 8,3 
Laemmli lysis buffer (SDS-PAGE, 4 x) 
8 % (w/v) SDS 
10 % ß-Mercaptoethanol 
40 % gycerol 
0,2 M Tris 




10 g peptone 
5 g yeast extract 




10 g/l NaCl 
Lysis buffer for immunoprecipitation 
(IP) 
 
1 M Tris-HCl 
pH 7.4 
2M NaCl 
100 % glycerol 
100 % triton 
volume adjusted to 1 L with distilled 
water 
MACS buffer 
1 x PBS 
1 % (w/v) FCS 
2 mM EDTA 
PBST 
1 x PBS 
0,05 % (v/v) tween-20 
Milk in PBST 
 
1 x PBS 
0,05 % (v/v) tween-20 
5 % (w/v) nonfat dried milk powder 
Running buffer 10x (SDS-PAGE) 
 
0,05 M Tris 
0,38 M glycin 
0,004 M SDS 
pH 8,3 
Separating gel buffer (SDS-PAGE) 
 
1,5 M Tris 
0,015 M SDS 
pH 8,8 
Stacking gel buffer (SDS-PAGE) 
 
0,5 M Tris 




2 M Tris 
1 M acetic acid 
0,1 M EDTA 
pH 8,3 
TBS 
0,02 M Tris 
8 % (w/v) NaCl 
pH 7,6 
ELISPOT detection buffer 
RPMI 1640 
10  FCS 




3.2.  Methods 
 
3.2.1.1. Cloning of single chain variable fragment of anti-hDEC205 fused to GpL 
(scFv:hDEC205-GpL) and anti-hDEC205 antibody 
 
To clone scFv:hDEC205-GpL, IgG1 isotype (accession number P01857 (heavy 
constant domain), AAA59000 (kappa constant domain)) of anti-hDEC205 antibody, the 
following expression constructs were digested with restriction endonucleases listed in 
the Table 15.  
Table 15. Vectors and inserts for expression constructs encoding scFv:hDEC205-GpL and anti-
hDEC205 antibody. 
 
The digested and dephosphorylated vectors were ligated with the corresponding 
insert DNAs with help of T4 DNA ligase. The ligation mix were then transformed in NEB 
5high competent cells by heat shock at 42°C and plated onto LB agar plates. After 
overnight incubation at 37°C, positive colonies were selected. To replicate the expression 
constructs, the selected colonies were cultured in midi preps overnight. Subsequently, 
the expression constructs were isolated from the microbial host via PureYield Plasmid 
Midiprep system according to the manufacturer’s protocol. The concentration of the 
plasmid DNA yields were measured by spectrophotometer at 260 nm and purities were 
calculated on the basis of A260/A280 ratio. The DNA sequences were proved by an external 













































3.2.1.2.  Cloning of anti-hDEC205-WT1major and anti-hDEC205-WT_Dfull constructs 
 
Of the cDNAs obtained from the indicated leukemia cell lines, four different DNA 
sequences encoding major fragments of WT1 isoform D (WT1_D), so named WT1_D1-227, 
WT1_D217-351,  WT1_D217-487,  WT1_D217-522 were amplified using corresponding primer 
pairs (Table 18). With exclusion of four amino acids, cDNA encoding  the full-length 
WT1_D was cloned by combining WT1_D1-227 with WT1_D217-522 using its internal Xho1 
site. Each of WT1_D major fragments were cloned C-terminally to the heavy chain of the 
anti-hDEC205 antibody to obtain anti-hDEC205-WT1_D1-227, anti-hDEC205-WT1_D217-
351, anti-hDEC205-WT1_D217-487, and anti-hDEC205-WT1_D217-522 expression constructs. 
In addition, the WT1_D major fragments were cloned to the single chain variable 
fragment of anti-hDEC205 (scFv:hDEC205), as well as to the C-terminus of light chain of 
the anti-hDEC205 antibody to identifying better producibility for the antibody fusion 
proteins (Table 16).  
 








































































































































































































































































































3.2.1.3. Cloning of anti-hDEC205-WT1small constructs:  
 
Different primer pairs (Table 18) were designed for various DNA sequences 
encoding small fragments of the WT1_D protein. Those primers encoded additionally a 
flexible spacer consisting of four amino acids (ASTA). In total, eight different small DNAs 
were amplified and cloned to the carboxyl terminus of the heavy chain of anti-hDEC205 
(Table 17).   
 




































































































First, mRNAs were extracted from three different leukemia cell lines (THP-1, ML-
2, NALM-6) by RNA easy extraction kit (Qiagen, Hilden, Germany) according to 
instructions of the manufacturer. The extracted mRNAs were then reversibly transcribed 
to cDNAs by RT-PCR using QuantiTect Rev. Transcription Kit (Qiagen, Hilden, Germany). 
PCR was performed using Kod Hot Start DNA polymerase kit (Merckmillipore, Darmstadt, 
Germany) according to the manufacturer’s instructions. An array of primer pairs were 
designed for various sequences encoding WT1 protein. The used primer pairs and 















Table 18. Sequences of the designed primer pairs and templates for PCR. 
Template Forward primers 5’-3’ Reverse primers 3’-5’ PCR product 
Human cDNA (ML2, 
THP-1, NALM-6 cell 
lines) 
ATTCGCAATCAGGGTTACAGCA TCAGAAGGGCTTTTCACTTGTTTTACC WT1_D217-487 
ATTCGCAATCAGGGTTACAGCA TTAAAGCGCCAGCTGGAGTTTGGTCAT WT1_D217-522 
Human cDNA (ML2 cell 
line) 
TTCCTCTTGCTGCAGGACCCGG TTAGAAGGTGACCGTGCTGTAACC WT1_D1-227 
scFv:2xFlag-anti-
hDEC205-WT1_D212-517 
ATTCGCAATCAGGGTTACAGCA TTACGTTGTGTGGTTATCGCTCTCG WT1_D217-351 
GATAACCACACAACGCCCATCC TTAAAGCGCCAGCTGGAGTTTGGTCAT WT1_D347-522 
scFv:2xFlag-anti-
hDEC205-WT1_D1-222 
TTCCTCTTGCTGCAGGACCCGG TTAGCCGCCCAACGACCCGTAAGCC WT1(-73)-53 
GCGCTGCTGCCCGCCGTCC TTACGCCCACTGCGCCGCGCCGCTC WT110-35 




AGTGACAATTTATACCAAA TTAGCTCTCGTACCCTGTGCTGTGG WT1223-273 
ATGTGTGCTTACCCAGGCT TTATTTGAGCTGGTCTGAACGAGAA WT1324-371 
scFv:2xFlag-anti-
hDEC205-WT1_Dfull 








AGTGACAATTTATACCAAA TTATTTGAGCTGGTCTGAACGAGAA WT1223-373 
anti-DEC205(h)-Mg38-
3-pMA-T 
GAGGTGCAGCTGCAGCAGTCTG GCTAGACACTGTCAGGGTTGTGCCC anti-hDEC205-VH 










light const full 
 




Gel electrophoresis was performed for qualification of the expression vectors and 
insert DNAs as well as for DNA purification. Depending on the size of DNAs, 1.2-1.8% 
agarose gels were used in this study. To prepare 1.2% agarose gel, 0.7 g of dry agarose 
was mixed with 60 mL of 1x TAE buffer in Erlenmeyer flask. Then the agarose was 
completely dissolved by cooking and swirling the flask. After short cooling down, 4 L of 
Midori Green Advance DNA stain (Intas, Göttingen, Germany) was added into the agarose 
gel to visualize DNAs under ultraviolet (UV) light. The agarose gel was poured into a gel 
tray placed well combs in and incubated at room temperature until its complete 
solidification. Then the gel was placed in an electrophoresis unit filled with 1x TAE  buffer. 
DNA samples mixed with 2 L of the loading buffer and DNA ladder (10L) were loaded 
into wells of the gel and the gel was run at 80-150V until DNA separation was completed. 
DNA bands were then visualized using UV-transilluminator (PeqLab, Erlangen, 
Germany). In cases of DNA purification, the appropriate DNA band was sliced under a 
short exposure of the UV light and melted at 52°C. DNA was purified from the melted gel 
using PCR clean-up, Gel extraction kit (Macherey-Nagel, Düren, Germany) according to 
the manufacturer’s instructions. 
 
For protein production two transient transfection methods were used: 
electroporation and polyethylenimine (PEI) transfection.  
3.2.4.1. Electroporation:  
 
Electroporation is a highly efficient method for the introduction of foreign nucleic 
acids into many cell types, including bacteria and mammalian cells. By applying an 
electrical pulse, cell membranes are temporarily permeabilized resulting in forming tiny 
pores through which DNA can enter into cells (Rols 2008). Approximately 5x107 HEK293 
cells were harvested from the bottom of 175 cm2 cell culture flask by trypsinization. Cells 
were pelleted by centrifugation at 1200 rpm, room temperature (RT) for 4 min and 
resuspended in 1 mL of culture media (RPMI 1640 supplied with 10% FCS and 1% 
penicillin-streptomycin). Then cells were transferred to 4 millimetre electroporation 




cuvette. After adding 40 µg of expression plasmid (in case of antibody, two plasmids 
encoding light and heavy chains were mixed at 1:1 ratio) to the cuvette, cells were 
electrically pulsed by Easyject Plus equipment with adjustment of 250 V, 1800 µF, 
maximum resistance. The electroporated cells were immediately transferred to 58 cm2 
cell culture dish with 17 mL of serum reduced culture media (2 % FCS)  and cultured at 
37°C, 5 % CO2 for 6-7 days for production.  
 
3.2.4.2. PEI transfection:  
 
Polyethylenimine (PEI) is a stable cationic polymer and condenses DNA into 
positively charged particles, that bind to anionic cell surface.  Consequently, the DNA:PEI 
complex is endocytosed by the cells and the DNA released into the cytoplasm (Longo et 
al. 2013). HEK293 cells were cultured in 58 cm2 cell culture dish at 80-100% confluency. 
Then culture media of cells were replaced by 17 mL of serum-free media (only RPMI 
1640). All reagents, expression plasmids were at RT. Expression plasmid and PEI at 1:3 
ratio (DNA : PEI = 12 µg : 36 µg) were added to 2 mL of RPMI 1640 in Eppendorf tubes 
and mixed well by vortex. After 10 min of incubation at RT, the DNA and PEI mixtures 
were added drop-wise to the cells and left cells at 37°C, 5 % CO2 for overnight. The next 
day, culture media were changed by 17 mL of fresh serum reduced culture media (2 % 
FCS)  and the transfected cells were cultured at 37°C, 5 % CO2 for 6-7 days for production.  
After production period, cell culture supernatants were collected into 50 mL 
conical tube and removed cell debris by centrifugation at 4600rpm, RT for 10 min. The 
culture supernatants were analyzed for their antibody content and kept at -20°C in the 
dark until protein purification.  
 
 
The antibody fusion proteins were purified from culture supernatants of the 
transfected HEK293 cells by column affinity chromatography using anti-Flag M2 affinity 
gel. The anti-Flag M2 affinity gel (Sigma-Aldrich, Deisenhofen, Germany) is a glycerol 
suspension containing a purified murine IgG1 monoclonal antibody covalently attached 
to agarose by hydrazide linkage. Anti-Flag M2 antibody binds to Flag peptide in a calcium 
independent manner. To purify proteins, first, a clean chromatography column and 
column reservoir were assembled. Then 3 mL of anti-Flag M2 agarose beads were 




transferred to the column and allowed beads to form a bed on the bottom by running 
glycerol through the column. After washing the agarose bed twice with 5 column volumes 
of sterile 1% TBS, 200-400 mL of culture supernatants were loaded onto the assembled 
column without disturbing the agarose bed. A gravitational flow rate was adjusted to 
allow the Flag-tagged antibody fusion proteins in culture supernatants are bound to the 
anti-Flag M2. The column was left at 4°C until whole volume of culture supernatants were 
passed through the agarose bed. Afterwards, unbound proteins within the agarose bed 
were removed by washing with 10 column volumes of 1% TBS. Flag-tagged antibody 
fusion proteins bound to the anti-Flag M2 were eluted by 2-3 column volumes of TBS 
containing 100 µg/mL Flag peptide. The eluted proteins were dialysed against 1% PBS at 
4°C overnight. The next day, the antibody fusion proteins were sterile filtered (200m) 
and stored at -20°C for further usage. The purification quality was evaluated by checking 
contents of antibody fusion proteins in culture supernatant, flow through, elutes, and 
washes before and after elution using SDS-PAGE and western blotting. The used agarose 
beads were extensively washed with 1% TBS and stored in 50% glycerol/TBS buffer 
containing 0.02% sodium azide at -20°C. Protein elutes were pooled depending on 
determined concentration on silver stained gel and stored at -20°C until their use.   
 
 
SDS-PAGE and Western blotting were used for detection and determination of 
concentration of the antibody fusion proteins after production and purification.  
3.2.6.1. SDS-PAGE: The proteins were separated by their size and molecular mass 
using SDS-PAGE. First, 6% stacking gel and 12% resolving gel were prepared and 
solidified in the assembled rack. The gel was placed in electrophoresis unit filled with 1x 
running buffer. All antibody fusion protein samples and standards (Flag-TNF60 fusion 
protein, 3 g/mL) were boiled at 96°C for 3 min in presence of 8 L of 4x Laemmli lysis 
buffer to be converted from complex to primary structures of proteins. After 
centrifugation at RT 14000 rpm for 1 min, the samples, standards and broad range 
protein marker were applied into corresponding wells of stacking gel layered on the top 
of resolving gel. Then the electrophoresis was run at 90-120V and 400mA for 105 min.  
3.2.6.2. Blotting: Proteins separated by SDS-PAGE were transferred to solid 
support, a nitrocellulose membrane using wet blotting and electrophoresis system. The 




membrane was carefully placed  together with the gel between anode and cathode in a 
sandwich consisting of fiber sponge at each outer side, and filter papers protecting the 
gel and blotting membrane.  Afterwards, the blotting sandwich was placed inside the 
blotting electrophorator filled with transfer buffer. The proteins were electrically (90V, 
400mA) transferred onto the nitrocellulose membrane for 180 min. 
3.2.6.3. Blocking: Blotted membranes were incubated in 5% nonfat milk in 1x PBST 
for 45 min to block a nonspecific binding of detection antibodies to the membrane. Then 
membranes were washed three times with 1x PBST for 5-10 min. 
3.2.6.4. Protein detection: Membranes were incubated with anti-Flag M2 antibody 
(primary antibody) diluted 1:2000 in PBST at 4°C overnight. The next day the membranes 
were washed three times with PBST for 10 min. Then IRDye 800CW-conjugated goat anti-
mouse IgG (secondary antibody) diluted 1:10000 in PBST was added to the membranes 
and incubated at room temperature for one hour. After three times washing with PBST, 
the proteins were detected in the 800 nm channel of the LI-COR Odyssey Imager. 
 
 
Silver staining is the most sensitive method for detection of proteins in 
polyacrylamide gels. Proteins bind silver ions, which are reduced into metallic silver 
under appropriate conditions. This phenomenon develops a visible image in the gel. In 
this study, silver staining was used for quantification of the antibody fusion proteins as 
well as for analysis of purity and integrity of their light and heavy chains. The silver 
staining was performed using Pierce® Silver Stain kit (Fermentas, St. Leon-Rot, 
Germany) according to the manufacturer’s protocol. Briefly, all purified proteins were 
sampled as 100 ng protein in each calculated volume and  boiled at 96°C for 3 min with 5 
L of loading buffer either presence of DTT or not. The protein samples and 10 L of 1x 
silver gel marker were loaded into wells of the gel and separated by SDS-PAGE as 
described in western blot technique. Then gels were fixed with 30% ethanol and 10% 
acetic acid mix for 30 min to remove background signal. Following the sensitization, gels 
were incubated with silver stain to impregnate silver ions to the gel. The stained gels 
were developed until the protein bands clearly visualized. The development was stopped 
by addition of 5 % acetic acid solution. By comparing the intensity of the protein band to 








To check if the purified antibody fusion proteins were contaminated with 
endotoxin of gram-negative bacteria, each batch of the purification were tested for 
endotoxin content using Pierce® LAL Chromogenic Endotoxin Quantitation Kit (Thermo 
Scientific) according to instructions of the manufacturer.   
 
 
Parental and hDEC205-stably expressing CHO cells (CHO-hDEC205, kindly 
provided by Prof. D. Dudziak, Erlangen, Germany) were seeded into wells of a 24-well 
plate at a density of 2x105 cells per well and cultured overnight at 37°C.  
 
3.2.9.1. Equilibrium binding studies  
 
For equilibrium binding studies, a GpL fusion protein of a single chain variable 
fragment (scFv) variant of the anti-hDEC205 antibody (scFv:hDEC205-GpL) was used. 
Supernatants of parental CHO and CHO-hDEC205 cells were pairwise replaced by a 
medium containing increasing concentrations of the scFv:hDEC205-GpL and incubated 
at 37°C for one hour. Unbound scFv:hDEC205-GpL molecules were removed by washing 
the cells 10 times with ice-cold PBS. Cells with bound GpL fusion protein molecules were 
scraped into a 96- -bound 
GpL activity was measured using the Gaussia Luciferase assay kit (NEB) and a Lucy2 
Luminometer according to manufacturers’ instructions. Specific binding values of 
scFv:hDEC205-GpL to hDEC205 were obtained by subtracting parental CHO-derived 
values (non-specific binding) from the corresponding values derived of the CHO-
hDEC205 cells (total binding). In another series of equilibrium binding studies, CHO-
hDEC205 cells were blocked with a constant concentration (2g/mL) of the various anti-
hDEC205-WT1 antibody fusion proteins at 37°C for one hour prior to incubation with 




increasing concentrations of scFv:hDEC205-GpL for an additional hour to obtain total and 
nonspecific binding to calculate the Kd values.  
 
3.2.9.2. Heterologous competition binding studies 
 
For the heterologous competition binding assay, CHO-hDEC205 cells were 
incubated with mixtures of a constant concentration (50 ng/mL (660 pM, CGpL)) of the 
scFv:hDEC205-GpL and increasing concentrations of the conventional anti-hDEC205 
IgG1 antibody at 37 °C for 1.5 hours. The Ki (Kd) of the antibody was calculated by help of 
the Kd-value of scFv:hDEC205-GpL and IC50 concentration of the anti-hDEC205 antibody 
using following formula: Ki = IC50 / (1 + CGpL / Kd). 
 
 
3.2.10.1. Blood samples 
 
Blood samples from healthy donors were obtained as leukoconcentrate in 
leukoreduction system chamber or buffy coats in blood collection bag after aphaeresis 
procedures from the Department of Clinical Transfusion Medicine and Haemotherapy of 
the University Hospital of Würzburg. Peripheral venous blood samples of haematopoietic 
stem cell transplanted patients with acute myeloid leukemia or myelodysplastic 
syndrome in EDTA-Vacutainers were obtained from the Outpatient Clinic of HSCT unit of 
the University Hospital of Würzburg. All blood samples were collected after written 
informed consent approved by the Institutional Ethical Board of the University of 
Würzburg. 
 
3.2.10.2.  Isolation of the peripheral blood mononuclear cells (PBMCs)  
 
The obtained blood samples were transferred into 50 mL collection tube. 
Leukoconcentrates and buffy coats were diluted with 10-20 mL of D-PBS. Then the blood 
samples were carefully layered onto the 15 mL of Ficoll gradient solution in 50 mL tube 
and centrifuged at 1800 rpm room temperature for 20 minutes to separate blood 
components by their density gradient. PBMCs between plasma and Ficoll solution were 




isolated by careful pipetting into the 10mL pipette and transferred to 50 mL tube. By 
washing twice with 50 mL of D-PBS and centrifugation at 1500 rpm 4°C for 10 min, 
platelets were removed. The isolated PBMCs were resuspended in 10-20 mL of culture 
microscope with haemocytometer using 0.04 % trypan blue dye. The cell numbers in one 
mL volume were then calculated using a formula:  
Viable cells counted at two diagonal large squares/2 x 10 (dilution factor) x 
104 (volume of one large square) 
 
3.2.10.3. Freezing and thawing of PBMCs 
 
After isolation, PBMCs were used directly or frozen as 1.2-1.8x107 cell aliquots in 
1.5 ml freezing medium at -80°C using Mr. Frosty. The frozen cells were stored at -196°C 
in liquid nitrogen tank unless they were used within 1-2 days. When needed, the 
cryopreserved PBMCs were taken from the liquid nitrogen and quickly thawed in 37°C 
water bath. Surface of the cryovial containing partially thawed PBMCs were desinfected 
with 70% ethanol before opening them under safety cabinet. The half thawed PBMCs 
were transferred into 50 ml conical tube with 15 ml prewarmed media. The PBMCs were 
then centrifuged at 1500 rpm room temperature for 10 min. The cell pellets were 
resuspended in 10 ml of media and rested at 37°C 5% CO2 overnight prior to further 
usage. Avoiding osmotic cell death, the freezing and thawing procedures were carried out 
in cold chain condition as quick as possible. 
 
 
3.2.11.1.  CD14+ cell isolation 
 
CD14+ cells were separated from freshly isolated PBMCs using CD14+ positive 
selection kit according to the manufacturer’s protocol (Miltenyi Biotec). The determined 
number of PBMCs was resuspended in 20 mL MACS buffer (PBS /2mM EDTA/ 0.5 % FCS) 
and centrifuged at 1500 rpm, 4°C for 10 min. After the washing, cells were incubated with 
80 µL MACS buffer and 20 µL CD14 magnetic microbeads per 107 cells at 4°C in the dark 




for 15 min to magnetically label CD14+ cells. After washing with 20 mL of MACS buffer as 
described above, cells were resuspended in 500 µL MACS buffer and loaded onto LS 
column which was placed in the magnetic field of MACS separator. During gravitational 
flow of the cell suspension, the CD14+ labeled cells were retained in the column. Then the 
column was three times washed with 3 ml of MACS buffer and removed from the 
magnetic field. The positively selected CD14+ cells were eluted in 2 ml MACS buffer and 
cell number were determined.  
 
3.2.11.2. Generation of monocyte derived DCs (moDCs)  
 
Monocytes (CD14+ cells) were suspended in culture medium (RPMI1640 
GlutaMax with 10 % FCS and 50μg/mL gentamycin) supplemented with 100 ng/mL GM-
CSF, 20 ng/mL IL-4  and seeded into a 6-well culture plate at 3x106 cells per well. On day 
two and four, one third of the media was changed with fresh media supplemented with 
GM-CSF and IL-4. Maturation of monocyte-derived DCs (moDCs) was triggered by adding 
10 ng/mL TNF-α on day four and six. On day six, prior to cytokine supplementation, semi-
mature moDCs dedicated for loading with the antibody fusion proteins were harvested 
and seeded into the wells of 96- or 48-well plates. Maturation of moDCs were monitored 
by flow cytometry using  following antibody staining: anti-CD1a-APC, anti-CD86-PE, anti-
CD14-APC, anti-CD80-PE, anti-CD40-APC, anti-HLA-ABC-PE, anti-CD83-APC, anti-HLA-
DR-PerCP (BD Biosciences), anti-CCR7-APC, and anti-CD205-PE (Myltenyi Biotec).  
 
 
CD3+ T cells were selected by depletion of mononuclear cells including monocytes, 
B cells, stem cells, dendritic cells, NK cells and residual granulocytes, erythroid cells using 
flow through fraction of the CD14+ cell selection from PBMCs. First, cell number in the 
flow through was determined and centrifuged at 1500 rpm for 10 min. After decanting 
supernatant, cells were mixed well with 40 µL of MACS buffer and 10 µL of Pan T Cell 
Biotin-Antibody cocktail per 107 cells and incubated at 4°C in the dark for 5 min. Then 
the cells were along incubated with 30 µL of the buffer and 20 µL of Pan T Cell Microbead 
Cocktail per 107 cells for 10 min. MACS separator system was prepared as described in 
9.1. Cells were loaded onto LS column and the column were washed once with 3 ml of 
MACS buffer. Finally, unlabeled CD3+ T cells that passed through the column were 




collected and counted. The CD3+ T cells were directly cryopreserved after the selection 
until necessary experiments. 
 
 
On day six, 7.5x105 semi-mature moDCs were incubated with 2 µg/mL of the anti-
hDEC205-WT191-138 antibody fusion protein at 37°C for 1.5 hours to allow internalization. 
Then GM-CSF, IL-4 and TNF- were added and cells were further incubated for 20-22 
hours. On day seven, the loaded, fully matured moDCs were washed twice with 2 mL 
RPMI1640 GlutaMax and resuspended in 1 mL media. Parallel to this, autologous CD3+ T 
cells were counted and resuspended at a density of 3x106/mL in media. Then moDCs and 
T cells were mixed in one well of a 24-well culture plate and co-cultured at 37°C. After 
two days co-cultures were supplemented with 5 ng/mL IL-7 and IL-15 (Peprotech). 
Cytokines were then added every 2-3 days when half of the media was replenished. On 
day 12-13, cells were restimulated with 2 μg/mL of the antibody fusion protein for 24 
hours, then CD137 frequencies were assessed by flow cytometry. 
 
 
When frequencies of CD137-expressing cells reached more than 3 % as 
determined by flow cytometry, activated T cells were selected using the CD137 selection 
kit in accordance with the manufacturer’s protocol (Miltenyi Biotec). Parallel to, 
allogeneic PBMC pool prepared from buffy coats of ten different healthy donors were 
thawed and cell division was inhibited by irradiation (35Gy) prior to add them as feeder 
cells to the CD137+ T cells. The CD137+ T cells  and allogeneic irradiated feeder cells were 
seeded into the wells of a 48-well plate at a ratio of 1:10 and supplemented with 1 µg/mL 
PHA-L and 50 IU/mL IL-2. Specific T cells were expanded further for 14-83 days by 
supplementation of IL-2, IL-7 and IL-15 every 2-3 days, together with a half media 
change, and restimulation of autologous moDCs loaded with the antibody fusion protein 
every 14 days.   
 




ICS assay was used to detect interferon-γ producing T cells induced by moDCs 
loaded with the anti-hDEC205-WT1 antibody fusion proteins. ICS assay was performed 
as described previously (Lamoreaux et al. 2006) with modifications. Briefly, 1x105 semi-
mature moDCs per well of a 96-well plate were left unstimulated or loaded with 2 µg/mL 
anti-hDEC205 antibody (negative control), 2 µg/mL anti-hDEC205-WT1small antibody 
fusion proteins, 5 µg/mL WT1 peptide pool, or 1 µg/mL CMV pp65 recombinant protein 
(positive control) for 1.5 hours prior to supplementation with GM-CSF, IL-4 and TNF-α. 
After 20-22 hours of incubation at 37°C, cells were washed twice with 200 µL RPMI1640 
and resuspended in 100 µL medium. Then, 4x105 autologous CD3+ T cells were added to 
the corresponding wells. The mixtures of  moDCs and T cells were incubated  at 37°C for 
1 hour, before addition of 10 µg/mL Brefeldin A (Sigma-Aldrich). At the same time, 0.5 
µg/mL PMA and 1 µg/mL Ionomycin were added into a well for the assay control. For 
CD107a degranulation assay, 1 L monensin and 2 L anti-CD107a-APC (both BD 
Biosciences) were added. After 16 hours of co-incubation, cells were harvested and 
stained with the following antibodies: anti-CD3-FITC or -PerCP, anti-CD8-FITC or -PerCP 
or -APC, anti-CD4-APC or -PerCP (BD Biosciences). After surface staining, cells were 
permeabilized with FACS Permeabilizing Solution 2 (BD Biosciences) and stained with 
anti-IFN-γ-PE (Beckman Coulter). Cells were analysed with the FACS Calibur and 
CellQuest software (both from BD Biosciences). 
 
 
Semi-mature moDCs (5 x 104 per well) unloaded or loaded with 2 μg/mL anti-
hDEC205-WT191-138 or control anti-hDEC205 or 5 μg/mL WT1 peptide pool (Miltenyi 
Biotec) were co-incubated with PBMCs (2 x 105 per well) in a 96-well ELISPOT plate 
(Millipore) precoated with anti-IFN-γ capture antibody (BD Biosciences) for 16 hours. 
After co-incubation, cells were removed from the wells and the biotinylated anti-IFN-γ 
detection antibody (BD Biosciences) was added  prior to visualization with Streptavidin-
AP (Southern BioTech) and NBT/BCIP liquid substrate system (Sigma-Aldrich). Spots 
were determined on Immunospot S5 ELISPOT reader (C.T.L).   
    




 VITAL-FarRed assays were performed as described elsewhere (Stanke et al. 2010) 
with modifications. Briefly, 5x106 THP-1 cells were labelled with 5 μM CFSE and the same 
number of DG-75 cells were labelled with 5 μM FarRed (Invitrogen) for 5 min at 37°C. 
Both cell lines were HLA A02 positive. Specific T cells derived from HLA A02 positive 
patients were serially diluted and each dilution of T cells was mixed with 5x104 CFSE+ 
target and 5x104 FarRed+ control cells, resulting in graded effector : target (E:T) ratios. 
After 22 hours of incubation at 37°C in 5 % CO2, the cytotoxicity was assessed on the basis 
of specific lysis of the target cells compared to that of the control cells by flow cytometry 
using previously described method (Stanke et al. 2010).  
 
 
Data are shown as median with IQR, mean ± SEM, or mean ± SD. Statistical 
significance was analyzed with GraphPad Prism 5.0 (GraphPad Software Inc.) using 
unpaired t test or one-and two-way analysis of variance (ANOVA) followed by Tukey’s 
and Bonferroni’s post hoc test as indicated. p ≤ 0.05 was regarded to be significant.   
 














4.1.  Generation of anti-hDEC205-WT1 antibody fusion proteins  
The anti-hDEC205-WT1 antibody fusion protein encoding plasmids were cloned 
in three steps using standard techniques (Figure 11). The final constructs also encoded a 
Flag-tag to facilitate purification and detection of the various recombinant proteins.  
Therapeutic antibodies can be expressed as single chain variable fragments 
(scFvs) or as whole antibodies. As a basis of the anti-hDEC205-WT1 antibody fusion 
proteins, scFv:hDEC205 consisting of the variable heavy and variable light chain domains 
of the anti-hDEC205 clone MG-38.3 (Birkholz et al. 2010) connected by (GGGGS)3-linker 
were designed. The cDNA encoding scFv:hDEC205 was synthesized by GeneArt AG (Life 
Tecnologies Co. Ltd.). Then the scFv:hDEC205 DNA fragment was inserted 5’ into a pCR3-
based (Invitrogen) expression vector encoding Gaussia princeps luciferase (GpL), a highly 
traceable molecule, to obtain a scFv:hDEC205-GpL fusion construct (Figure 12).  
Simultaneously, DNA fragments encoding the variable heavy  and light chain 
domains of anti-hDEC205 were separately amplified by PCR using primers with 
 
4.1.1 Cloning of anti-
hDEC205 antibody
4.1.2 Cloning of WT1 
fragments
4.1.3 Fusion of WT1 
fragments to  anti-
hDEC205 
Figure 11. Cloning workflow of anti-hDEC205-WT1 antibody fusion proteins. 




restriction sites for later cloning. To construct the heavy and light full-length chain 
encoding expression plasmids, the amplicons were then inserted into another pCR3-
derived expression vectors encoding the human IgG1 constant heavy or kappa light chain 
domains (Figure 12). Concentration and purity of the cloned expression constructs were 
measured at 260nm by spectrophotometer while sequences of the expression constructs 
were proved by DNA sequencing (GATC Biotech, a worldwide provider of DNA 
sequencing). The expression vectors passed all these quality tests were left at -20°C until 
transient transfection. 
 
WT1_D was reported as the dominant WT1 isoform in AML cases (Kramarzova et 
al. 2012). Since it represents the longest isoform, WT1-derived peptide variations to be 
presented to T cells should be maximized with this isoform. For this reason, we intended 
to fuse WT1_D to the anti-hDEC205 antibody. Due to the difficulty in amplifying a cDNA 
for full-length WT1_D from various leukemia cell lines, we generated five different 
WT1_D amplicons covering the whole protein sequence (Figure 13). Then, with an 
exclusion of four amino acids, a full-length WT1_D was cloned by combining WT1_D1-227 
with WT1_D217-522 using an internal Xho1 restriction site (Table 19). 
Figure 12. Scheme of anti-hDEC205 antibody constructs.  
Top: The scFv:hDEC205-GpL single chain variable fragment of anti-hDEC205 consisting of the 
variable heavy and light chains (anti-hDEC-VH and anti-hDEC-VL) was C-terminally fused to 
Gaussia princeps Luciferase and tagged N-terminally by a double Flag epitope. Bottom: Primary 
structure of anti-hDEC205 antibody. The heavy and light chains of the antibody were 
constructed by inserting respective variable heavy and light chain domain into the N-terminus 
of the corresponding constant domains of the human IgG1 isotype. Each chain of the antibody 
was Flag-tagged N-terminally. 
 
 





Each WT1_Dmajor fragment as well as the full-length WT1_D was genetically fused 
to the C-terminus of the heavy chain of anti-hDEC205 antibody to obtain various anti-
hDEC205-WT1 antibody fusion proteins (Figure 14) and expressed by transient 
transfection of HEK293 cells.  
 
 
Western blot analyses of culture supernatants from cells transiently transfected 
with expression plasmids encoding the parental anti-hDEC205 and the aforementioned 
 
Figure 14. Scheme of anti-hDEC205-WT1 antibody fusion proteins.  
The anti-hDEC205-WT1major and -WT1small fusion proteins were constructed by C-terminal 
linking of the respective WT1 fragments to the anti-hDEC205 heavy chain. Small fragments of 
WT1 were fused through a flexible spacer of four amino acids (blue). 
Figure 13. PCR amplification of cDNA encoding three major fragments of WT1_D of the five 
obtained amplicons.  
SM, size marker for DNA; bp, base pairs; cDNA obtained from leukemia cell lines (THP-1, ML-
2, NALM-6) by RT-PCR.  
  




anti-hDEC205-WT1_D fusion variants revealed good production of anti-hDEC205 but no 
relevant production of the anti-hDEC205-WT1_D variants. To figure out whether the anti-
hDEC205-WT1_D fusion proteins were not expressed at all or simply not secreted, 
transfected cells were pelleted and analyzed in parallel with the supernatants. In lanes 
loaded with cell lysates there were significant amounts of the WT1 antibody fusion 




Cloning to different sites or proteins was expected to be a possible solution to the 
poor secretion of the anti-hDEC205-WT1_D fusion constructs. Thus, we cloned N- and C-
terminal as well as middle parts of WT1_D to the either C-terminus of the light chain of 
anti-hDEC205 or scFv:hDEC205 (Table 19) to test our expectation. As shown in Figure 16, 
these fusion proteins were again not secreted. Collectively, these results suggest that 
large fragments of WT1 interfere with efficient secretion. 
 
Figure 15. Production and secretion characteristics of anti-hDEC205-WT1_D antibody fusion 
proteins by SDS-PAGE and Western blot analysis.  
Proteins were detected with mouse anti-Flag M2 IgG (primary antibody) and goat anti-mouse 
IgG-IRDye 800CW (secondary antibody). S culture supernatant collected from transfected 
HEK293 cells, P lysate of pelleted HEK293 cells mock transfected or transfected with different 
anti-hDEC205-WT1_D antibody fusion proteins. 
 
 






To overcome the insufficient yields due to the poor secretion, we also evaluated 
purification of the intracellularly trapped fusion protein anti-hDEC205-WT1_D1-227 by 
triton extraction and affinity chromatography on anti-Flag agarose. In principle, 
purification of intracellular anti-hDEC205-WT1_D1-227 was possible, but the obtained 
yields were not sufficient for extensive work due to the poor solubility of the antibody 
fusion protein (Figure 17). However, 3 g of the anti-hDEC205-WT1_D1-227 antibody fusion 





Figure 16. Western blot analysis of three different anti-hDEC205-WT1_D217-522 fusion constructs.  
The WT1_D217-522 fragment was cloned to three different cloning sites as indicated HC heavy 
chain, LC light chain, and scFv single chain variable fragment of anti-hDEC205 antibody. Ab 




Figure 17. Extraction of the intracellularly retained anti-hDEC205-WT1_D1-227 antibody fusion 
protein by triton-100 lysis followed by sonication.  
S0 initial yields of protein extract, S1 S2 S3 protein yields in supernatant after  each 
centrifugation, N1 N2 N3 Non-soluble pelleted proteins. Boxes and numbers were used for 
calculation of protein concentrations.   
 




Table 19. Summary of all cloned anti-hDEC205-WT1 antibody fusion proteins containing different 
fragments of WT1. 
aa  amino acids; VH-CH  heavy chain and VL-CL light chain of anti-hDEC205 antibody; scFv:single 
chain fragment variable of anti-hDEC205; + cloned, - not cloned;  ┼  four amino acids (aa213-
216:SQPA) were excluded; Bold: WT1 protein sequence with good secretory capacity. Note that 
there is a difference for numbering of amino acid sequences between isoform D and canonical 














Since the large parts of  WT1 protein showed poor secretion, we generated and 
screened a panel of anti-hDEC205 antibody fusion proteins containing different small 
fragments (26-51 aa) of WT1 for efficient secretion. First, small fragments of WT1 cDNA 
were selected on the basis of the encoded immunogenic epitopes that were previously 
published elsewhere (Rezvani et al. 2008), (Kobayashi et al. 2006), (Doubrovina et al. 
2012). Then by primer combinations, more fragments were propagated. Finally, eight 
different anti-hDEC205-WT1small antibody fusion protein constructs were successfully 
generated. This way, we identified four different anti-hDEC205-WT1small (Table 20) 
antibody fusion proteins yielding 2-4,4 g/mL in supernatants of transiently transfected 
HEK293 cells. Out of the four, anti-hDEC205-WT191-138, anti-hDEC205-WT1223-273, and 
anti-hDEC205-WT1324-371 were purified for further analyses. After purification, the anti-
hDEC205-WT1small fusion proteins reached concentrations of 40-400 g/mL with high 
purity and good integrity (Figure 18).  
No 




VH-CH VL-CL scFv:  
1 WT1_D1-227 WT1(-73)-154 + + + 
2 WT1_D217-351 WT1144-278 + + + 
3 WT1_D217-487 WT1144-414 + - + 
4 WT1_D217-522 WT1144-449 + + + 
5 WT1_D347-522 WT1274-414 + - - 
6 WT1_D1-522 ┼ WT1(-73)-449 + - + 
7 WT1_D1-126 WT1(-73)-53 + - - 
8 WT1_D83-108 WT110-35 + - - 
9 WT1_D164-211 WT191-138 + - - 
10 WT1_D296-346 WT1223-273 + - - 
11 WT1_D397-444 WT1324-371 + - - 
12 WT1_D83-126 WT110-53 + - - 
13 WT_D217-346 WT1144-273 + - - 
14 WT1_D296-444 WT1223-371 + - - 







Figure 18. Purity and integrity of anti-hDEC205-WT1small fusion proteins by SDS-PAGE and 
silver staining.  
PM, protein marker; molecular weights in kDa; +, reducing; -, non-reducing condition; DTT, 
dithiothreitol. 
 









Protein sequence of the WT1 cloned to the C-terminus  
of the a-hDEC205 







































4.2. Binding capacity of anti-hDEC205-WT1small antibody fusion 
proteins 
 
To confirm the DEC205 receptor-specific binding capacity of the various anti-
hDEC205-WT1 antibody fusion proteins, parental and human DEC205-stably expressing 





Then the antibody fusion proteins bound to DEC205 were detected with anti-Flag M2 and 
PE-conjugated anti-mouse IgG antibodies by flow cytometry. The parental anti-hDEC205 
antibody as well as anti-hDEC205-WT191-138, anti-hDEC205-WT1223-273, and anti-
hDEC205-WT1324-371 bound to human DEC205-expressing CHO cells but not to parental 





Figure 19. FACS analysis to assess binding capacities of the antibody fusion proteins to human 
DEC205.  
Top: CHO-hDEC205 cells. Bottom: parental CHO cells. Humira, anti-hTNF- antibody served as a 
negative control. 
. 





4.1.2.1. DEC205 binding specificity of scFv:hDEC205-GpL 
 
To quantify binding of anti-hDEC205 to cell surface expressed hDEC205, we 
performed equilibrium binding studies with scFv:hDEC205-GpL, a highly traceable 
luciferase fusion protein of the single chain variable fragment variant of the hDEC205-
specific antibody clone MG-38.3. CHO-hDEC205 and parental CHO cells were incubated 
with increasing concentrations of the scFv:hDEC205-GpL protein to allow binding of the 
antibody variable fragment luciferase fusion protein to cell expressed hDEC205. After 1 
hour incubation, non-bound scFv:hDEC205-GpL was removed by 10 times washing with 
PBS and GpL activity of the remaining cell-bound molecules was measured with a 
Luminometer. The specific binding of the scFv:hDEC205-GpL was determined by 
subtracting non-specific binding to parental CHO cells from the total binding to CHO-
hDEC205 cells. On the base of the concentration dependent binding data, a non-linear 
regression curve was fitted and the dissociation constant (Kd) was calculated by help of 
the GraphPad Prism 5 software. There was nearly no non-specific binding to parental 
CHO cells (Figure 20). The mean Kd of scFv:hDEC205-GpL was found to be 1445 pM 
(average of 7 experiments).  
 
 
Figure 20. Equilibrium binding study of the scFv:hDEC205-GpL to the cell expressed hDEC205.  
Filled circles total binding values, empty circles nonspecific binding values, and filled rombs 
specific binding values. 
 




4.1.2.2. Binding of anti-hDEC205 antibody 
 
The binding of the scFv:hDEC205-GpL to DEC205 on the cell surface can be 
blocked by heterologous inhibitor molecules such as the parental antibody or the various 
anti-hDEC205-WT1 antibody fusion proteins. The rate of the inhibition capacity of 
inhibitors is concentration dependent. The binding capacity of the inhibitor can be 
calculated on the basis of the constant concentration and the Kd value of the 
scFv:hDEC205-GpL molecule and the IC50 of the inhibitor using the formula: Ki = IC50 / (1 
+ CGpL / Kd). By such heterologous competition assay analyses with 660 pM 
scFv:hDEC205-GpL, we obtained an IC50-value of the conventional anti-hDEC205 
antibody of 1175 pM on average (Figure 21). This allowed the Ki calculation of the parental 
anti-hDEC205 antibody which resulted in a value of 810±310 pM. The obtained Ki value 








Figure 21. Heterologous competition binding assay.  
RLU, relative light unit; pM, picoMolar. The binding value (Kd) of the scFv:hDEC205-GpL 
interaction with hDEC205 and IC50 of the anti-hDEC205 antibody were calculated by non-linear 
regression using the GraphPad Prism 5.0 software. 
 




4.1.2.3. Binding of the anti-hDEC205-WT1small antibody fusion proteins 
 
In equilibrium binding studies, the specific binding of scFv:hDEC205-GpL was 
comparably well blocked by each of the anti-hDEC205-WT1small antibody fusion proteins 
and the parental anti-hDEC205 IgG1 leading to the conclusion that these fusion molecules 
bind to hDEC205 with a similar efficacy (Figure 22).  
 
 
Since binding of the anti-hDEC205 antibody variants was not significantly altered 
by C-terminal extension of the heavy chain with the various WT1small fragments, we 
proved binding to endogenously expressed DEC205 only for the parental antibody using 
human immature moDCs (Figure 23).  
Figure 22. Equilibrium binding study confirming the binding capability of the anti-hDEC205-
WT1small antibody fusion proteins to hDEC205. 
  total binding, specific binding,  non-specific binding of the scFv:hDEC205-GpL by 
blocking with the parental antibody or the respective anti-hDEC205-WT1small fusion proteins: 
anti-hDEC205 antibody (i), anti-hDEC205-WT191-138 (ii), anti-hDEC205-WT1223-273  (iii), anti-
hDEC205-WT1324-371 (iv). 
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4.3. Screening of endotoxin content in the purified anti-hDEC205-
WT1 antibody fusion proteins 
Endotoxins are complex lipopolysacharides found in outer cell membrane of 
gram-negative bacteria and have many biological impacts such as triggering of TLR4 
activation (Gorbet and Sefton 2005). Cell growth and function are both affected by 
endotoxin effects in vitro and in vivo. Therefore, all purified antibody fusion proteins were 
tested for their endotoxin level using the Limulus Amebocyte Lysate (LAL) chromogenic 
assay. This assay is based on the fact that bacterial endotoxin activates a proenzyme in 
the modified LAL. The activated proenzyme leads to release of p-nitroaniline from the 
colorless substrate, Ac-Ile-Glu-Ala-Arg-p-nitroaniline; the activation rate is proportional 
to the endotoxin concentration of the sample considered. The released p-nitroaniline is 
photometrically measured at 405-410nm. The correlation between photo absorbance 
and endotoxin concentration is linear in the 0.1-1.0 endotoxin unit (EU) per mL range. 
The developed color intensity is proportional to the amount of endotoxin present in the 
sample and can be calculated using a standard curve. As showed in Table 1, besides the 
parental antibody, levels of endotoxin in all antibody fusion protein samples were below 
the threshold accepted for preclinical use of recombinant vaccines (Brito and Singh 
2011). The estimated endotoxin levels in cell cultures were ranged between 0.004-1.9 
EU/mL (Table 21). 
 
Figure 23. Specific binding of anti-hDEC205 antibody to DEC205 on immature human monocyte-
derived DCs.  
Left: FACS analysis, Right: equilibrium binding study. 
 




Table 21. Endotoxin levels of the purified antibody fusion proteins and cell cultures. 
 
 
4.4. Frequency of DEC205-expressing DCs in PBMCs was not 
sufficient to induce DC-dependent T-cell response ex vivo  
 
At the outset, we stimulated human PBMCs with the anti-hDEC205-WT191-138, 
anti-hDEC205-WT1223-273, anti-hDEC205-WT1324-371 fusion proteins and anti-hDEC205 
antibody alone. However, we could not detect any T cell response ex vivo, which resulted 
from the fact that DEC205-expressing DCs were barely detectable in PBMCs (Figure 24). 
Therefore, priming/activating of T cells ex vivo was performed with moDCs in the 
following experiments. Moreover, the maturation of moDCs was not negatively affected 
by DEC205-targeting (Figure 27). 
 
Antibody fusion protein Concentration of 
stock solution 
Endotoxin 




in cell culture 
a-hDEC205 Ab 130 μg/mL 127,02EU/mL 1,9 EU/mL 
a-hDEC205-WT191-138 40 μg/mL 12 EU/mL 0,6 EU/mL 
a-hDEC205-WT1223-273 400 μg/mL 0,8 EU/mL 0,004 EU/mL 
a-hDEC205-WT1324-371 200 μg/mL 0,9 EU/mL 0,009 EU/mL 










Figure 24. Frequency of DEC205+ cells in human PBMCs.  
SSC side scatter; Left: frequency of peripheral blood mononuclear cell subsets: CD14+ monocytes;, 
CD3+ T cells, CD19+ B lymphocytes, CD56+ NK cells, CD1a+ DCs; Right: DEC205 expression on the 








4.5. Evaluation of monocyte derived dendritic cells (moDCs)  
 
On day seven of DC generation from CD14+ cells, a maturation state of moDCs were 
checked morphologically on the phase-contrast inverted microscope and phenotypically 
by flow cytometry using anti-CD80, anti-CD83, anti-CD86, anti-CD1a, anti-CD14, anti-
CD40, anti-CD205, anti-HLA-ABC, anti-HLA-DR, anti-CCR7 antibodies conjugated with 
APC or PE fluorescence molecules. On the phase-contrast microscope, the protein loaded 




By immunophenotyping, the strong expression of CD80, CD86, CD83, CD1a, HLA-
ABC, HLA-DR molecules were detected on the cell surface. The expression of CD40 and 





Figure 26. Mature moDCs at the beginning of DC-T cell co-culture.  
Cells with large size and more extended dendrites projecting from the cell body are 
moDCs, round small cells are CD3+ T cells.  
 







4.6. Evaluation of quality of CD3+ T cells  
 
To accurately check T cell response to the anti-hDEC205-WT1small antibody fusion 
proteins, it is essential to monitor T cell quality. Therefore, CD3+  T cells were monitored 
for their purity after the pan-T cell selection procedure (Figure 28). Specifically, T cells 
were stained with anti-CD3-FITC, anti-CD8-APC, anti-CD4-PerCP, anti-iNKT-PE, anti-
CD56-APC, and anti-CD16-FITC and detected by flow cytometry. As shown in Figure 27, 
the purity of CD3+ T cells in average was 95.8 ± 4.1 %. NK cells were detected at 








Figure 27. The expression of maturation markers on moDCs after the anti-hDEC205-WT1 
antibody fusion protein loading (day seven).   
Empty histograms are isotype controls, filled histograms are the expression of the indicated 
markers on moDCs. 
 







4.7. Anti-hDEC205-WT1_D1-227 is able to activate T cells 
 
To test the immunogenic capacity of anti-hDEC205-WT1_D1-227, purified from 
HEK293 cell lysates, we performed interferon- ELISPOT assay. The anti-hDEC205-
WT1_D1-227 antibody fusion protein was used at a concentration of 0.5 g/mL to load  
 
 
mature moDCs, however, the greatest number of IFN- spots were counted (Figure 29). 
This result indicated that the anti-hDEC205-WT1_D1-227 protein might have stronger T 
Figure 28. The purity of CD3+ T cells after pan T cell selection.  
The columns are the mean ± SD obtained from flow cytometry analyses of six different CD3+ T 
cell preparations. 
 
Figure 29. IFN-γ response of DC/T cell co-incubation from one patient assessed by IFN-γ 
ELISPOT assay.  
Actual numbers of IFN-γ spots are shown at the top right. 




cell stimulatory capacity compared to the smaller fragments contained in anti-hDEC205-
WT1small antibody fusion proteins. Unfortunately, the major fragment bearing antibody 
fusion protein could not be further evaluated due to the insufficient yields after 
inadequate secretion and unsatisfactory purification from the whole cell compartment 
(see 4.1.3.).  
 
 
4.8. WT1-specific T-cells are better detected via anti-hDEC205-
targeted delivery of WT191-138 than non-targeted WT1 peptide 
pool  
 
To investigate T cell responses triggered by anti-hDEC205-WT1 protein loaded 
mature moDCs, we measured the frequency of IFN-+ T cells after stimulation by flow 
cytometry. Unloaded or anti-hDEC205 parental antibody loaded DCs were used as 
negative controls, while 15-mer WT1 peptide pool loaded DCs were used as positive and 
comparison controls. We also considered CMV status of the study subjects, because CMV 
pp65 recombinant protein was used to determine general kinetics of protein uptake and 
 
Figure 30. DC-mediated T cell response to anti-hDEC205-WT1small antibody fusion proteins.  
Compiled data from all individuals (n = 16) analyzed for IFN- T cell responses by ICS. Shown 
are median frequencies with interquartile range (IQR), one-way ANOVA, Tukey’s test **p < 0.01. 
 




processing by moDCs. As well as the CMV status was helpful to control the quality of the 
performed assays. Of the three antibody fusion proteins tested, only the anti-hDEC205-
WT191-138 showed a significant T cell stimulatory effect ex vivo (Figure 30). 
The anti-hDEC205-WT191-138 loaded mature moDCs were able to activate freshly 
isolated T cells while treatment of mature moDCs with the parental a-hDEC205 antibody 
or with a WT1 15-mer peptide pool showed no effect (Figure 31). Of note the IFN- 
producing cells induced by anti-hDEC205-WT191-138 loaded mature moDCs were mostly 
CD8+ T cells. It was interesting that the frequency of T cells activated by the targeted self-
antigen WT191-138 stimulation was higher than that of T cells activated by the non-
targeted viral protein CMVpp65 in the shown case. However, the mean frequency of the 
WT1-specific T cells was 2.3-fold lower than the CMVpp65-specific counterparts in total 




Figure 31. IFN-ICS and FACS analysis of cells from one of the patients (PN2).  
Top: CD3+IFN-γ+ T cell frequencies gated on lymphocytes, Middle and Bottom: frequencies of 
CD3+-gated CD3+CD4+IFN-γ+ (middle) and CD3+CD8+IFN-γ+ T cells (bottom). T cells were co-
incubated with unloaded moDCs (Unstimul.), with moDCs loaded with anti-hDEC205-antibody, 
anti-hDEC205-WT191-138 antibody fusion protein, WT1 peptide pool, or CMV pp65 protein. 
 




Table 22. Patient details.  
R recipient, D donor, AML acute myeloid leukemia, CMML chronic myelomonocytic leukemia, MDS 
























































8 62/F AML 




9 56/M AML 












Immunogenicity of the anti-hDEC205-WT191-138 was tested with CD3+ T cells 
derived from 10 patients (Table 22). In eight cases, we detected T cell responses against 
the fusion protein mainly in the CD8+ subset. The median frequencies of CD3+IFN-γ+, 
CD8+IFN-γ+ and CD4+IFN-γ+ cells upon overnight stimulation with anti-hDEC205-WT191-
138 loaded moDCs were 0.44%, 0.45% and 0.05% (Figure 32). 
 
 
The majority of the responders was determined to be HLA A02. However, one 
patient (PN8) was HLA A03 positive but HLA A02 negative, suggesting that WT191-138-
derived peptides can be presented by several HLA alleles. In contrast, only one patient 
showed an IFN-+ T cell response to mature moDCs loaded with a WT1 peptide pool.  
Figure 32. Summary of IFN-γ ICS results from all patients (n = 10).  
Plots show frequencies of IFN-γ+CD3+ (top),  IFN-γ+CD8+ (left bottom) and IFN-γ+CD4+ (right 
botom) T cells. Each data point represents one individual, bars indicate median frequencies with 
IQR, Tukey’s test *p < 0.05. 




It is broadly accepted that GvL effects after allo-HSCT are mediated by donor 
derived T cells. Therefore, we tested blood samples of healthy individuals as potential 
haematopoietic stem cell donors to evaluate whether DEC205 targeted WT191-138 is able 
to stimulate WT1-specific T cells in healthy donors (Figure 33). A T cell response was 




intensities than that of the patient derived cells. Three of the six healthy donors were HLA 
A02 negative. This suggested again that processed peptides from the WT191-138 fragment 
Figure 33. Summary of IFN-γ ICS results from all healthy individuals (n = 6).  
Plots show frequencies of IFN-γ+CD3+ (top),  IFN-γ+CD8+ (left bottom) and IFN-γ+CD4+ (right 
bottom) T cells. Each data point represents one individual, bars indicate median frequencies 
with IQR, Tukey’s test *p < 0.05;  **p < 0.01. 
 




are presented on different HLA alleles. Nevertheless, without prior expansion or 
enrichment, the median frequency of CD3+IFN-γ+ and CD8+IFN-γ+ cells obtained after co-
incubation with anti-hDEC205-WT191-138 loaded moDCs was significantly higher than 
after co-incubation with moDCs treated with the parental antibody or a non-targeted 
WT1 peptide pool in both patients and donors. With regard to CD4+IFN-γ+ cells, there 
seemed to be a minor but not significant shift. Notably, we did not use co-stimulating 





Figure 34. IFN-γ response of PBMCs from one patient assessed by IFN-γ ELISPOT assay.  
Top: triplicate of one representative IFN-γ ELISPOT assay. Bottom: graphical analysis 
of the IFN-γ ELISPOT assay shown above. Shown are means with SEM, unpaired Student 
T test ***p < 0.001. 
 




4.9. Activation of T cells in PBMCs by anti-hDEC205-WT191-138-loaded 
moDCs 
 
Since the use of PBMCs is less laborious and more time-saving, compared to the 
use of purified CD3+ T cells, we tested if T cells could be activated without selection from 
the whole PBMCs by this approach. For this, anti-hDEC205-WT191-138 loaded autologous 
mature moDCs and PBMCs from two patients were co-incubated to measure IFN- by 
ELISPOT assay (Figure 34). The average number of IFN-γ spots induced by anti-hDEC205-
WT191-138, was more than 4-fold higher (239.3) than that of the negative controls 
(unstimulated 52.3; parental antibody 49.3). Thus, both purified T cells and unselected T 









Figure 35. Cytotoxicity of T cells ex vivo by IFN-
assay. 
  unstimulated,  anti-hDEC205 Ab,  anti-hDEC205-WT191-138, WT1 peptide pool 
stimulation. Shown are means ± SD from five patients including PN 2, 3, 4.  
 




4.10.  Cytotoxic activity of T cells activated by moDC-targeted WT191-
138 protein fragment  
 
 The main function of CD8+ CTLs is direct cell-mediated killing of target cells 
presenting cognate antigens which are recognized specifically by the CTL T cell receptors. 
Two distinct mechanisms of killing by effector T cells are known. The first mechanism is 
production of TNF-, Fas ligand (FasL) or TRAIL. These ligands induce multimerization 
of their corresponding receptors on the surface of target cells what leads to apoptotic 
death of the target cells (Peter and Krammer 2003). The second mechanism is the 
activation of diverse lytic pathways in target cells resulting from the release of cytotoxic 
granules comprising a pore-forming toxin, perforin, and granzymes, pro-apoptotic serine 
proteases from cytotoxic effector cells into the immunological synapse assembled 
between effector and target cells (Lieberman 2003). The lipid bilayer surrounding 
cytotoxic granules contains exclusively lysosomal-associated membrane glycoproteins 
 
 
Figure 36. In vitro T cell expansion by co-culturing with mature moDCs loaded with anti-
hDEC205-WT191-138 antibody fusion protein.  
Left: Numbers of T cells obtained from four patients after 12 days of DC/T cell co-culture. Each 
line represents one patient. Right: Summarized data of CD137 expression in co-cultured T cells. 
Shown are means ± SD of data from all four patients. Black, unstimulated; gray, restimulated 
cells. 
 




(LAMPs) including CD107a (LAMP-1), CD107b (LAMP-2), and CD63 (LAMP-3). During 
the degranulation process,  lysosomal and cellular membranes are fused, as a 
consequence, LAMPs are exposed to the cell surface. This process is assessed by flow 
cytometry-based CD107a staining (Zaritskaya et al. 2010). Therefore, we used IFN- ICS 
combined with a CD107a degranulation assay for the ex vivo assessment of the cytotoxic 
potential of T cells activated by anti-hDEC205-WT191-138 loaded moDCs. The results of 
five independent assays are summarized in Figure 34. While CD4+ T cells treated with 
anti-hDEC205-WT191-138 showed a slight CD107a degranulation parallel to IFN- 
production, CD8+ T cells displayed a significant cytotoxic profiles directly ex vivo in 
comparison to the included controls (Figure 35). 
Since CD107a degranulation in conjunction with IFN-production was superior to 
CD8+ T cells treated with the anti-hDEC205-WT191-138, it was assumed that they would 
have a potential to lyse WT1 endogenously expressing leukemic cells. To validate this 
assumption T cells of four AML patients that received allo-HSCT were in vitro expanded. 
Autologous CD3+ T cells and the fusion protein loaded moDCs were co-cultured in 
presence of IL-7 and IL-15. In order to avoid an early T cell terminal differentiation, the 
co-cultures were not supplemented by IL-2 until CD137 selection. T cells dominated by 
CD8+ subsets were expanded 1.3 to 2 fold in numbers within 10-14 days (Figure 36). 
Frequencies of CD137+ T cells of the patients on this time point were ranged between 1.6-
10 % (Figure 37). In addition to the CD3+CD8+, CD3+CD4+ subset was also able to express 
CD137 in the cases that they were expanded. Then WT1-specific T cells selected based on 
the CD137 expression were further expanded until number of the specific T cells was 
sufficient to perform cytotoxicity assays. Thus, it seemed to be that the expanded WT1-
specific T cells were composed of the both subsets of T cells. However, unfortunately, the 
expanded T cells were not identified in terms of their subset and phenotype in these 
experiments. 








The VITAL-FR, a classical cytotoxicity assay, is ideally suited for monitoring T cell-
mediated cytotoxicity for vaccination studies in scientific and diagnostic applications. 
Thus, to test specific lysis of WT1 positive leukemia cells via T cells stimulated with our 
antibody fusion protein, the VITAL-FR assay was performed using expanded CD137+ T 
cells derived from three HLA A02 positive patients. There was HLA A02-restricted lysis 
of THP-1 cells at relatively low effector to target (E : T) ratios indicating that the WT191-
138 specific T-cells possess a strong cytotoxic activity (Figure 38). It is worth mentioning 
that one of three T cell donors in this kind of experiment was patient 4 who showed no 
T-cell response directly ex vivo (Figure 39). Interestingly, expanded T cells from patient 2 
showed an inferior cytotoxicity, although their IFN-+ T cell response was the strongest 
in the ex vivo experiments. 
Figure 37. Representative FACS analysis of CD137 expression on T cells.  
After 12 days of co-culture, T cells were left unstimulated (left) or restimulated (right) with anti-
hDEC205-WT191-138 antibody fusion protein.  
 





Taken together, the ex vivo detected cytotoxic capacity of T cells by IFN- ICS 
combined with CD107a degranulation assay (Figure 35) could be confirmed by the VITAL-
FR cytotoxicity test. Specifically, when targeted to DEC205 on mature moDCs, the WT191-









Figure 38. Cytotoxic effector function of in vitro expanded WT1-specific T cells induced by anti-
hDEC205-WT191-138 loaded mature moDCs.  
VITAL-FarRed cytotoxicity assay. Each experiment was duplicated and each replicate was 
shown from three different patients (PN 2, 3, 4). 
 





Figure 39. Representative FACS-plots of the flow cytometry-based VITAL-FR assays (PN4).  
CFSE+ THP-1 (target) and FarRed+ DG-75 (control) cells were gated in R1. The R2-gated 
target cell frequencies were detected compared with constant frequencies of the control cells 
gated through R1 and R3. At each E : T ratio, specific lysis was calculated as described by 












Section 5. Discussion 
 
 
5.1.  Actual challenges in AML therapy  
 Acute myeloid leukemia is one of the haematological malignancies which have a 
poor prognosis after conventional therapy. An older age (60<), high numbers of white 
blood cells, existence of prior MDS and previous cytotoxic therapy to treat other diseases 
strongly contribute to the poor prognosis. Only one fourth of the adult AML patients 
survive more than 5 years (NCI 2015). Genetic alterations that play a key role in disease 
development indicate the prognosis and clinical outcome for both, remission and post-
remission therapy. Intermediate and adverse  genetic groups have a high risk of therapy 
resistance and relapse. To date, allo-HSCT in the first or second complete remission phase 
is the only curative treatment option for patients with high risk AML. Unfortunately, not 
all patients achieve complete remission prior to HSCT (Pfrepper et al. 2015), which in 
turn, remarkably increases relapse risk. Correspondingly, relapse remains as a major 
cause of death after HSCT. The therapeutic effect of allo-HSCT is mainly based on GvL 
effect, but partially opposed by treatment-related mortality and loss of quality of life 
caused by acute and chronic GvHD (van Besien 2013). Therefore, strengthening GvL 
effects without provoking GvHD is the major challenge to augment the therapeutic 
efficiency of HSCT. HSCT itself is a complex procedure which starts from finding a suitable 
donor who matches the recipient’s HLA profile, and conditions recipients by an 
aggressive myelo- and immune suppressive therapy etc. Thus, disease course of patients 
is further negatively affected by circumstances like a treatment delay, lack of a suitable 
donor, exclusion from treatment due to an older age or severe comorbidity can occur in 
patients during their disease course. Overall, the aforementioned aspects call for an 
improvement of the current treatment modalities as well as for alternative strategies in 





 As immune cells are able to detect and destroy malignant cells, various 
immunotherapeutic strategies have been developed either to promote immune 
responses against tumors or to counteract tumor immune escape mechanisms. 
Vaccination to induce T cell responses against leukemia, one of the immunotherapeutic 
approaches, seems to be promising to strengthening the GvL effect after HSCT. Moreover, 
effective therapeutic vaccines could be alternative options in an autologous setting for 
patients who are not eligible to HSCT. DCs and TAAs have been thoroughly investigated 
for the vaccination strategies. Within the TAAs, WT1 is prioritized for the therapeutic 
vaccine against cancer due to its oncogenic function, immunogenic capability, tissue 
restricted expression, and progress-dependent abundance in leukemic cells (Cheever et 
al. 2009). Although various WT1 peptide vaccines have been established, their 
therapeutic use is generally limited due to the high diversity of individual immune 
responses. The known WT1-derived peptides are restricted mostly to the HLA A0201 and 
A2401 which reduces their wide clinical application. To expand the clinical application, there 
is a need for prior identification of immunogenic epitopes (Benteyn et al. 2013) in the protein 
sequence. Furthermore, the peptide-elicited immune responses can be short-lived and 
non-functional (Kuball et al. 2011) due to the tolerance mechanisms to WT1 as a self-
protein. To overcome the aforementioned limitations, a proper optimization of WT1-
specific T cell responses in terms of induction, amplitude, and duration is essential.  
The most crucial prerequisites to achieve more effective and sustained T-cell 
responses are variety and immunogenicity of the presented peptides as well as co-
stimulatory signaling, provision of cytokines and direct cell contact by the antigen 
presenting DCs . Thus, the aim of this study was to generate DC-targeted anti-hDEC205-
WT1 antibody fusion proteins as an anti-leukemia vaccine and explore their 
immunogenicity by directly ex vivo and in vitro assays. The main hypothesis was that by 
triggering DEC205 receptor-mediated endocytosis through anti-hDEC205-WT1 antibody 
fusion protein, DCs are stimulated to uptake the WT1. The directly delivered WT1 whole 
protein or longer protein fragments to DCs for intracellular processing should lead to 
MHC class I- and II-mediated presentation of a great diversity of WT1-derived peptides. 
This approach leads to improved WT1-specific T-cell response and gives an opportunity 
for immunotherapy to the broad patient collective independently from ethnic 






5.2.  Generation and evaluation of the anti-hDEC205-WT1 antibody 
fusion proteins  
A Flag-tagged anti-hDEC205 IgG1 antibody was correctly constructed and 
effectively produced. Production and purification did not affect antibody function. 
Functional characteristics were verified by binding to hDEC205-expressing CHO cells and 
human immature moDCs using flow cytometry. The affinity of the anti-hDEC205 was 
determined by binding studies and found to be high. A N-terminally fused Flag tag exerted 
minimal effects on the structure and function of the anti-hDEC205 antibody as described 
elsewhere (Hopp 1988).  
Since a delivery of the longest sequence of WT1 to DCs was the initial aim of this 
study, obtaining cDNA encoding full-length WT1_D was necessary. As described in the 
introduction (see 1.2.4), more than 36 different isoforms of WT1 are detected in cells as 
a result of alternative transcription, translation initiations, RNA editing, and splice events. 
In particular, a discovery of WT1 longer isoforms including WT1_D by Bruening et al. 
demonstrated that WT1 gene expression is more complex than anticipated, with a non-
AUG translational initiation event producing additional protein isoforms of 54 –56 kDa 
in addition to the known isoforms of 47-49 kDa (Bruening and Pelletier 1996). Due to the 
above mentioned complexities, a cDNA encoding full-length WT1_D could not be cloned 
in one step, hence, we cloned two cDNAs, each encoding the respective other part of 
WT1_D protein. Linkage of the two cDNAs through an internal XhoI restriction site 
resulted in a cDNA encoding the full-length WT1_D protein. After obtaining the WT1-
encoding cDNAs, it was easy to construct anti-hDEC205-WT1 antibody fusion proteins. 
Expression and purification of the full-length canonical isoform of murine and 
human WT1 and its zinc finger domains for functional studies were performed by a 
couple of groups beforehand (Geng and Carstens 2006, Nurmemmedov and Thunnissen 
2006, Fagerlund et al. 2012). To improve the stability and solubility of WT1, which are 
major obstacles in intracellular protein expression, in these studies, various expression 
systems, and buffers as well as soluble tags have been tested. By means of the huge 
efforts, sufficient amounts of WT1 protein were purified from inclusion bodies of E. Coli 
or eukaryotic HEK293T cell lysates. By contrast, we aimed to yield the anti-hDEC205-
WT1 antibody fusion proteins from cell culture supernatant in a soluble and secreted 





production and purification of our antibody fusion proteins. First, anti-hDEC205 
antibody fusion proteins containing full-length and major fragments of WT1_D were 
produced with different efficiencies. The production of the anti-hDEC205-WT1_D1-227 
was the most superior while the anti-hDEC205-WT1_Dfull showed the less efficiency of 
expression. Second, all constructed anti-hDEC205-WT1_Dmajor antibody fusion proteins 
possessed poor secretory characteristics, namely, these proteins were left largely cell-
associated instead they were secreted into culture supernatants. Next, in principle, 
purification of anti-hDEC205-WT1_D1-227 variant from triton extract of HEK293 cell 
lysates was possible, however, the final yields were reduced significantly due to the 
precipitation/aggregation of the antibody fusion protein, confirming results from 
Fagerlund et al. (Fagerlund et al. 2012).  
Of note, the purified anti-hDEC205-WT1_D1-227  fusion protein was once evaluated 
by IFN- ELISPOT assay. The relatively high number of IFN-spots shown by this assay 
indicated that the DEC205-targeted WT1_D1-227 major fragment could be more potent to 
induce WT1-specific T-cell responses compared to smaller fragments of WT1. Although 
it could not be reproduced by more experiments due to insufficient protein yields, it is 
meaningful to demonstrate a general feasibility of DEC205 targeting approach for WT1.      
In view of the poor secretion of WT1 major fragment containing hDEC205-specific 
antibody fusion proteins, smaller fragments encoding immunogenic epitopes that were 
previously published elsewhere (Rezvani et al. 2008), (Kobayashi et al. 2006), 
(Doubrovina et al. 2012) were screened for efficient expression and secretion. It seemed 
that anti-hDEC205 antibody bearing WT1 fragments of more than 50 amino acids are not 
able to excrete through transfected cells. All four antibody fusion proteins identified with 
sufficient production and secretion compose 26 to 51 amino acids. This could probably 
be explained by the fact that biochemical properties authorizing the intracellular nature 
of the protein may be lost in smaller sequences of WT1 within the antibody fusion 
protein. However, despite the relative shortness of the found WT1small fragments, more 
than ten of variable peptides are possibly be generated by the antigen processing 
machinery of DCs. The finally identified four different fragments of WT1 targeted to DCs 
through anti-hDEC205 antibody are obtainable in sufficient yields by routine protein 
expression and purification system. This would be an advantage for WT1 vaccination 
strategy. Furthermore, anti-hDEC205-WT191-138, anti-hDEC205-WT1223-273, and anti-





It is of importance that all three anti-hDEC205-WT1small antibody fusion proteins were 
functional with respect to antibody integrity and antigen binding.  
The direct stimulation of PBMCs with each of the three antibody fusion proteins 
did not induce IFN- responses in T cells directly ex vivo, probably due to the low 
frequencies of DCs in PBMCs. Therefore, the uptaken amount of antibody fusion proteins 
and the resulting amount of processed and presented peptides in the given time might be 
insufficient to result in an optimal T-cell activation. Moreover, instead of immunity a 
possible tolerance could have been induced, as different APC subtypes in PBMCs undergo 
distinct maturation processes resulting in different functional profiles. Thus, fully 
matured and protein loaded moDCs were used to fairly investigate the T-cell stimulatory 
capacity of the DC-targeted anti-hDEC205-WT1 antibody fusion proteins.  
An effective adaptive immune response to a tumor is mainly triggered/mediated 
by tumor antigen specific cytotoxic CD3+ T cells (Rosenberg et al. 1988, Celluzzi et al. 
1996). To evaluate CD3+ T-cell responses to anti-hDEC205-WT1, we selected CD3+ T cells 
from PBMCs. Purity of the CD3+ T cells tested prior to the antigenic stimulation via mature 
moDCs was 95 % in average, thereby ensuring low variability of the performed ICS and 
ELISPOT assays. Of importance, the results from PBMC/moDC co-incubation experiments 
showed that T cells in PBMCs were able to respond to anti-hDEC205-WT191-138 when the 
loaded moDCs triggered the strong enough stimulation. This indicates an optimized 
priming and/or activation is a crucial factor to induce WT1-specific T cell response 
towards the antigen-expressing cells.    
Patients’ blood samples were drawn between six and 192 months post-
transplantation meaning that patients were in different phases of immune reconstitution. 
However, WT1-specific T cells were detected in freshly isolated T cells from PBMCs of 
most patients indicating a possibility of T cell repopulation driven by encountered tumor 
associated peptides in allo-HSC transplanted patients (Goldrath and Bevan 1999). In this 
context, it was important to investigate T-cell responses of the participants with diverse 
HLA patterns to ensure a variability of moDC-generated and presented peptides derived 
from the WT1 protein fragments.  
Anti-hDEC205-WT191-138 was the only one that improved directly ex vivo T cell 
responses in healthy donors and allo-HSC transplanted AML patients. The contained 





2012, Kobayashi et al. 2006) with immunogenic potential including the well documented 
WT1126-134 peptide (Oka et al. 2000, Rezvani et al. 2008). Since responders to anti-
hDEC205-WT191-138 stimulation were not exclusively HLA A0201 positive, the good 
immunogenicity of anti-hDEC205-WT191-138 might be explained by relatively broad 
epitope variety presented on different HLA molecules of efficiently targeted DCs.  
It is known that DEC205-targeting protein vaccines strongly enhance cross 
presentation (Bonifaz et al. 2004, Cheong et al. 2010). Accordingly, the strongest T cell 
response was observed for CD8+ T cells, but there was also a tendency for activation of 
CD4+ helper T cells after DEC205-targeted WT191-138 stimulation. This finding confirms 
previous studies showing that a combination of HLA class I and II restricted peptides 
induces both, cytotoxic and helper T-cell responses (Maslak et al. 2010, Koido et al. 2014). 
Due to natural processing by DCs, peptides derived from the endocytosed protein could 
be presented via HLA class I and II molecules resulting in improved T cell responses. 
An important aim that we reached in the study was the detection of an upgraded 
and robust WT1-specific T-cell response directly  ex vivo. T cells responded substantially 
stronger to DEC205-targeted WT191-138 than to a 15-mer WT1 peptide pool, 
demonstrating a successful targeting of the moDCs by the antibody fusion protein. 
However, it is not clear why only one of the three anti-hDEC205-WT1small constructs 
induced a decent response. Previous studies showed that prior T cell enrichment 
(Schmied et al. 2015) or expansion (Krishnadas et al. 2011) using WT1 peptide pool is 
necessary to enhance detection of low frequency of WT1-specific T cells in healthy 
donors. Our results indicate that such rare T cells could be better monitored by targeting 
of the WT191-138 to DCs at least in the context of allo-HSCT.  
Although anti-hDEC205-WT1223-273 and anti-hDEC205-WT1324-371 did not induce 
detectable ex vivo T cell responses, their stimulatory capacity should be further tested by 
in vitro T cell expansion prior to detection. Of note, sequences of the other two antibody 
fusion proteins: anti-hDEC205-WT1223-273, and anti-hDEC205-WT1324-371 also contain 
previously identified HLA class I- and II- restricted epitopes (Oka et al. 2000) (Fujiki et 
al. 2007). Repeated stimulations of T cells by moDCs loaded with these WT1 fusion 
proteins might be an option to increase low or undetectable frequencies of specific T cells. 
Specifically, supplementation of various epitopes may enhance T-cell responses even 





To augment the therapeutic efficacy of HSCT, strengthening GvL effect 
independently of GvHD progression is essential. The targeting of these small fragments 
of WT1 protein to DEC205 on DCs should be further explored in vivo for its potential to 
support the GvL effect through WT1-specific T cells within an allo-HSCT setting and its 
ability to induce an effective immunity against the underlying disease. Generally, anti-
hDEC205-WT1small antibody fusion proteins may directly reach to DCs in vivo and show 
their immune stimulatory effect in presence of an adjuvant that is indispensable to 
maturing DCs. However, in individuals with insufficient frequency or function of DCs, an 
improvement of the immune response could possibly be achieved by donor-derived 
moDC vaccination loaded with these proteins. This strategy may allow an efficient in vivo 
T cell stimulation even early after allo-HSCT. Of importance, using CMV-derived peptide 
loaded moDCs, Grigoleit et al. previously showed that DC vaccination can be performed 
safely in allo-HSCT setting (Grigoleit et al. 2007).  
The first FDA-approved therapeutic vaccine, Sipuleucel-T (PROVENGE), 
demonstrated that ex vivo activated and matured APCs are able to prime T cells both ex 
vivo and in vivo. Prostate cancer antigen so called prostate acetyl phosphatase (PAP)-
specific T cells then recognize and kill the PAP-positive cancer cells (Cheever and Higano 
2011). Resembling the Sipuleucel-T effect, in this study, the anti-hDEC205-WT191-138-
loaded moDCs were capable to prime and/or activate T cells which were freshly isolated 
from patients with AML. Therefore, it seems likely that such DCs have enough potential 
to prime and activate T cells in vivo as well. Thus, our earliest results confirming WT1-
specific T-cell responses induced by the DC-targeting anti-hDEC205-WT191-138  approach 
could be a basis for a therapeutic vaccine against WT1-expressing malignancies and 
furthermore, be applicable for induction of a WT1-specific immune response to solid 
tumors since WT1 is overexpressed in various cancers (Sugiyama 2010). 
In conclusion, a transplantation-vaccine or -adoptive transfer of leukemia-specific 
T cells to boost GvL effect and reduce relapse after HSCT has been considered as a highly 
effective strategies for the control of high-risk leukemia (Rezvani 2011). WT1 has been a 
real basis for the both strategies to evoke antileukemia T-cell immune responses. 
However, intracellular nature of this TAA is a development barrier to advance such 
promising strategies. With this regard, DC-targeting approaches offer whole potential for 
intracellular antigen-targeted immunotherapy compared to direct T-cell manipulating 





to overcome the barrier in WT1-based vaccine approaches. Raising this issue, we 
developed hDEC205-targeted WT1 antibody fusion proteins as anti-leukemia vaccines 
and explored their immune stimulatory capacity by studies in vitro and directly ex vivo. 
Our approach contributes to overcoming the challenge of poor expression of the 
intracellular tumor associated antigen WT1 and introduces an alternative that could be 
easily translated into clinical practice to improve antileukemia immune response. 
Furthermore, because anti-hDEC205-WT1small antibody fusion proteins are able to 
directly target DCs in vivo, their potential clinical application would need a lower costs 
and less ex vivo manipulation (Sehgal et al. 2014).  
 
 
5.3.  Future outlook 
T cells recognizing peptides derived from TAAs are generally short-lived and of 
low avidity, as most of those antigens are self-proteins. The known explanation is that 
maturing TAA-specific T cells  with high avidity are depleted in the thymus by negative 
selection due to self-tolerance mechanisms. A possible approach to sustain or reestablish 
the usually “undesired” immunity, a frequent vaccination mode could be an option. In this 
case, recombinant therapeutic vaccines with appropriate therapeutic efficacy as well as 
a simple administration and low costs of production are inevitable. The anti-hDEC205-
WT191-138 could be an example of such a recombinant vaccine.  
In addition, the anti-hDEC205-WT1223-273 and anti-hDEC205-WT1324-371 antibody 
fusion proteins could be potential “team players” for improvement of T cell responses 
against relapse of the underlying malignancies. Specifically, leukemia cells that are 
ignored by particular T cells specific for WT191-138 -derived peptides can potentially be 
recognized by T cells specific for epitopes from the other two WT1 protein fragments. 
Thus, the latter two antibody fusion proteins need to be further investigated to reveal 
their immune stimulatory capacity. Furthermore, in vivo tests of anti-hDEC205-WT1 
antibody fusion proteins should be initiated to provide evidence for the immunogenicity 
of these vaccine constructs. Another perspective is the generation of more anti-hDEC205-
TAA antibody fusion proteins using other TAAs (e.g. Bcl-2, MUC-1) to induce multi-





Ultimately, two areas of data drive WT1-based vaccination strategies to be 
intensely improved and combined with other treatment options: first, the growing data 
of clinical studies demonstrating that vaccination using WT1-derived peptides is safe and 
feasible for patients with advanced MDS/AML (Di Stasi et al. 2015), and; second, distinct 
data confirming the significant correlation between WT1 overexpression and worse 
clinical outcomes in either hematological (Woehlecke et al. 2015, Yi-Ning et al. 2015) or 
solid tumor patients (Qi et al. 2015). In light of these data, our alternative approach offers 
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6.2.  Sequences of antibody fusion constructs 
 
 Nucleotide Amino acid 
Leader 1-78 1-26 
Flag tag 85-109 29-36 
Variable heavy chain domain 115-463 39-154 


















































 M  N  F  G  F  R  L  I  F  L  V  L  V  L  K  G  V  Q  C  E  V  K  
CTGGTGCCCCGGCAATTGGACTACAAGGACGACGACGACAAAGAATTCGAGGTGCAGCTGCAGCAG 
 L  V  P  R  Q  L  D  Y  K  D  D  D  D  K  E  F  E  V  Q  L  Q  Q  
TCTGGCCCCGTGCTCGTGAAACCTGGCGCCTCCGTGAAGATGAGCTGCAAGGCCAGCGGCAACACC 
 S  G  P  V  L  V  K  P  G  A  S  V  K  M  S  C  K  A  S  G  N  T  
TTCACCGACAGCTTCATGCACTGGATGAAGCAGAGCCACGGCAAGAGCCTGGAATGGATCGGCATC 
 F  T  D  S  F  M  H  W  M  K  Q  S  H  G  K  S  L  E  W  I  G  I  
ATCAACCCCTACAACGGCGGCACCTCCTACAACCAGAAGTTCAAGGGCAAGGCCACCCTGACCGTG 
 I  N  P  Y  N  G  G  T  S  Y  N  Q  K  F  K  G  K  A  T  L  T  V  
GACAAGAGCAGCAGCACCGCCTACATGGAACTGAACAGCCTGACCAGCGAGGACAGCGCCGTGTAC 
 D  K  S  S  S  T  A  Y  M  E  L  N  S  L  T  S  E  D  S  A  V  Y  
TACTGCGCCAGAAACGGCGTGCGGTACTACTTCGACTACTGGGGCCAGGGCACAACCCTGACAGTG 
 Y  C  A  R  N  G  V  R  Y  Y  F  D  Y  W  G  Q  G  T  T  L  T  V  
TCTAGCAGATCCTCTAGCGCCAGCACAAAGGGCCCCAGCGTGTTCCCTCTGGCCCCTAGCAGCAAG 
 S  S  R  S  S  S  A  S  T  K  G  P  S  V  F  P  L  A  P  S  S  K  
AGCACATCTGGCGGAACAGCCGCCCTGGGCTGCCTCGTGAAGGACTACTTTCCCGAGCCCGTGACA 
 S  T  S  G  G  T  A  A  L  G  C  L  V  K  D  Y  F  P  E  P  V  T  
GTGTCCTGGAACTCTGGCGCCCTGACAAGCGGCGTGCACACCTTTCCAGCCGTGCTGCAGAGCAGC 
 V  S  W  N  S  G  A  L  T  S  G  V  H  T  F  P  A  V  L  Q  S  S  
GGCCTGTACTCTCTGAGCAGCGTCGTGACTGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATC 
 G  L  Y  S  L  S  S  V  V  T  V  P  S  S  S  L  G  T  Q  T  Y  I  
TGCAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAACCCAAGAGCTGCGAC 
 C  N  V  N  H  K  P  S  N  T  K  V  D  K  K  V  E  P  K  S  C  D  
AAGACCCACACCTGTCCCCCTTGTCCTGCCCCTGAACTGCTGGGCGGACCTTCCGTGTTCCTGTTC 
 K  T  H  T  C  P  P  C  P  A  P  E  L  L  G  G  P  S  V  F  L  F  
CCCCCAAAGCCCAAGGACACCCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGAT 
 P  P  K  P  K  D  T  L  M  I  S  R  T  P  E  V  T  C  V  V  V  D  
GTGTCCCACGAGGACCCTGAAGTGAAGTTTAATTGGTACGTGGACGGCGTGGAAGTGCACAACGCC 
 V  S  H  E  D  P  E  V  K  F  N  W  Y  V  D  G  V  E  V  H  N  A  
AAGACCAAGCCCAGAGAGGAACAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACAGTGCTG 
 K  T  K  P  R  E  E  Q  Y  N  S  T  Y  R  V  V  S  V  L  T  V  L  
CACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGCCCTGCCTGCCCCC 
 H  Q  D  W  L  N  G  K  E  Y  K  C  K  V  S  N  K  A  L  P  A  P  
ATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAACCCCAGGTGTACACACTGCCTCCC 
 I  E  K  T  I  S  K  A  K  G  Q  P  R  E  P  Q  V  Y  T  L  P  P  
AGCAGGGACGAGCTGACCAAGAACCAGGTGTCCCTGACCTGTCTCGTGAAAGGCTTCTACCCCTCC 
 S  R  D  E  L  T  K  N  Q  V  S  L  T  C  L  V  K  G  F  Y  P  S  
GATATCGCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTG 
 D  I  A  V  E  W  E  S  N  G  Q  P  E  N  N  Y  K  T  T  P  P  V  
CTGGACAGCGACGGCTCATTCTTCCTGTACAGCAAGCTGACCGTGGACAAGTCCCGGTGGCAGCAG 
 L  D  S  D  G  S  F  F  L  Y  S  K  L  T  V  D  K  S  R  W  Q  Q  
GGCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAACCACTACACCAAGTCCCTGAGC 
 G  N  V  F  S  C  S  V  M  H  E  A  L  H  N  H  Y  T  K  S  L  S  
CTGAGCCCCGGCAAGTAA 
 L  S  P  G  K  *  
 




 Nucleotide Amino acid 
Leader 1-78 1-26 
Flag tag 85-109 29-36 
Variable light chain domain 115-441 39-147 




























 M  N  F  G  F  R  L  I  F  L  V  L  V  L  K  G  V  Q  C  E  V  K  
CTGGTGCCCCGGCAATTGGACTACAAGGACGACGACGACAAAGAATTCCAGGCTGTCGTGACCCAG 
 L  V  P  R  Q  L  D  Y  K  D  D  D  D  K  E  F  Q  A  V  V  T  Q  
GAAAGCGCCCTGACAACCAGCCCTGGCGAGACAGTGACCCTGACCTGCAGATCCTCTACAGGCGCC 
 E  S  A  L  T  T  S  P  G  E  T  V  T  L  T  C  R  S  S  T  G  A  
GTGACCATCAGCAACTACGCCAACTGGGTGCAGGAAAAGCCCGACCACCTGTTCACCGGCCTGATC 
 V  T  I  S  N  Y  A  N  W  V  Q  E  K  P  D  H  L  F  T  G  L  I  
GGCGGCACAAACAACAGAGCACCTGGCGTGCCCGCCAGATTCAGCGGCTCTCTGATCGGAGATAAG 
 G  G  T  N  N  R  A  P  G  V  P  A  R  F  S  G  S  L  I  G  D  K  
GCCGCACTGACCATCACAGGCGCCCAGACCGAGGACGAGGCCATCTACTTTTGCGCCCTGTGGTAC 
 A  A  L  T  I  T  G  A  Q  T  E  D  E  A  I  Y  F  C  A  L  W  Y  
AACAACCAGTTCATCTTCGGCAGCGGCACCAAAGTGACCGTGCTGAGATCCGAAATCAAGCGTACG 
 N  N  Q  F  I  F  G  S  G  T  K  V  T  V  L  R  S  E  I  K  R  T  
GTGGCCGCTCCCAGCGTGTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCT 
 V  A  A  P  S  V  F  I  F  P  P  S  D  E  Q  L  K  S  G  T  A  S  
GTCGTGTGCCTGCTGAACAACTTCTACCCCCGCGAGGCCAAGGTGCAGTGGAAGGTGGACAATGCC 
 V  V  C  L  L  N  N  F  Y  P  R  E  A  K  V  Q  W  K  V  D  N  A  
CTGCAGAGCGGCAACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTG 
 L  Q  S  G  N  S  Q  E  S  V  T  E  Q  D  S  K  D  S  T  Y  S  L  
AGCAGCACCCTGACCCTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACC 
 S  S  T  L  T  L  S  K  A  D  Y  E  K  H  K  V  Y  A  C  E  V  T  
CACCAGGGCCTGTCTAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGCTAA 
 H  Q  G  L  S  S  P  V  T  K  S  F  N  R  G  E  C  *  
    
 
 Nucleotide Amino acid 
Leader 1-78 1-26 
Variable heavy chain domain 85-438 29-146 
Linker 439-474 147-158 
Variable light chain domain 475-801 159-267 
Flag tag 2x 808-861 270-287 















 M  N  F  G  F  R  L  I  F  L  V  L  V  L  K  G  V  Q  C  E  V  K  
CTGGTGCCCCGGCAATTGGAGGTGCAGCTGCAGCAGTCTGGCCCCGTGCTCGTGAAACCTGGCGCC 
 L  V  P  R  Q  L  E  V  Q  L  Q  Q  S  G  P  V  L  V  K  P  G  A  
TCCGTGAAGATGAGCTGCAAGGCCAGCGGCAACACCTTCACCGACAGCTTCATGCACTGGATGAAG 
 S  V  K  M  S  C  K  A  S  G  N  T  F  T  D  S  F  M  H  W  M  K  
CAGAGCCACGGCAAGAGCCTGGAATGGATCGGCATCATCAACCCCTACAACGGCGGCACCTCCTAC 
 Q  S  H  G  K  S  L  E  W  I  G  I  I  N  P  Y  N  G  G  T  S  Y  
AACCAGAAGTTCAAGGGCAAGGCCACCCTGACCGTGGACAAGAGCAGCAGCACCGCCTACATGGAA 
 N  Q  K  F  K  G  K  A  T  L  T  V  D  K  S  S  S  T  A  Y  M  E  
CTGAACAGCCTGACCAGCGAGGACAGCGCCGTGTACTACTGCGCCAGAAACGGCGTGCGGTACTAC 



































 L  N  S  L  T  S  E  D  S  A  V  Y  Y  C  A  R  N  G  V  R  Y  Y  
TTCGACTACTGGGGCCAGGGCACAACCCTGACAGTGTCTAGCGGCGGAGGAAGCGGAGGCGGATCT 
 F  D  Y  W  G  Q  G  T  T  L  T  V  S  S  G  G  G  S  G  G  G  S  
GGCGGAGGATCTCAGGCTGTCGTGACCCAGGAAAGCGCCCTGACAACCAGCCCTGGCGAGACAGTG 
 G  G  G  S  Q  A  V  V  T  Q  E  S  A  L  T  T  S  P  G  E  T  V  
ACCCTGACCTGCAGATCCTCTACAGGCGCCGTGACCATCAGCAACTACGCCAACTGGGTGCAGGAA 
 T  L  T  C  R  S  S  T  G  A  V  T  I  S  N  Y  A  N  W  V  Q  E  
AAGCCCGACCACCTGTTCACCGGCCTGATCGGCGGCACAAACAACAGAGCACCTGGCGTGCCCGCC 
 K  P  D  H  L  F  T  G  L  I  G  G  T  N  N  R  A  P  G  V  P  A  
AGATTCAGCGGCTCTCTGATCGGAGATAAGGCCGCACTGACCATCACAGGCGCCCAGACCGAGGAC 
 R  F  S  G  S  L  I  G  D  K  A  A  L  T  I  T  G  A  Q  T  E  D  
GAGGCCATCTACTTTTGCGCCCTGTGGTACAACAACCAGTTCATCTTCGGCAGCGGCACCAAAGTG 
 E  A  I  Y  F  C  A  L  W  Y  N  N  Q  F  I  F  G  S  G  T  K  V  
ACCGTGCTGGGATCCGACTACAAGGACGACGACGACAAAGAATTCGACTACAAGGACGACGACGAC 
 T  V  L  G  S  D  Y  K  D  D  D  D  K  E  F  D  Y  K  D  D  D  D  
AAACTCGAGAAACCAACCGAGAATAATGAGGATTTCAACATCGTGGCTGTGGCATCCAATTTTGCT 
 K  L  E  K  P  T  E  N  N  E  D  F  N  I  V  A  V  A  S  N  F  A  
ACCACCGACCTCGATGCCGATCGGGGAAAACTGCCTGGCAAAAAACTGCCCCTGGAAGTGCTGAAA 
 T  T  D  L  D  A  D  R  G  K  L  P  G  K  K  L  P  L  E  V  L  K  
GAGATGGAGGCCAACGCTAGAAAAGCTGGCTGTACTAGAGGATGTCTCATCTGCCTGTCCCACATC 
 E  M  E  A  N  A  R  K  A  G  C  T  R  G  C  L  I  C  L  S  H  I  
AAGTGTACCCCAAAAATGAAAAAATTCATCCCTGGCCGGTGTCACACATACGAGGGCGACAAGGAA 
 K  C  T  P  K  M  K  K  F  I  P  G  R  C  H  T  Y  E  G  D  K  E  
TCTGCTCAGGGCGGAATCGGAGAGGCTATTGTGGATATTCCTGAAATTCCTGGATTCAAGGACCTG 
 S  A  Q  G  G  I  G  E  A  I  V  D  I  P  E  I  P  G  F  K  D  L  
GAGCCTATGGAACAGTTTATCGCCCAGGTGGACCTCTGTGTCGATTGTACAACTGGCTGCCTGAAA 
 E  P  M  E  Q  F  I  A  Q  V  D  L  C  V  D  C  T  T  G  C  L  K  
GGGCTGGCCAATGTCCAGTGTAGTGACCTGCTGAAAAAATGGCTGCCCCAGAGATGTGCCACTTTC 
 G  L  A  N  V  Q  C  S  D  L  L  K  K  W  L  P  Q  R  C  A  T  F  
GCCTCTAAAATTCAGGGCCAGGTCGACAAAATCAAAGGCGCTGGAGGAGACTCTGGAGCTTAA 
 A  S  K  I  Q  G  Q  V  D  K  I  K  G  A  G  G  D  S  G  A  * 
 
 Nucleotide Amino acid 
Leader 1-78 1-26 
Flag tag 85-109 29-36 
Heavy chain variable domain 116-468 39-156 
Heavy chain constant domain of IgG1 475-1468 159-489 
WT1_D1-227 
1469-2148 
At 1812: silent 




















 M  N  F  G  F  R  L  I  F  L  V  L  V  L  K  G  V  Q  C  E  V  K  
CTGGTGCCCCGGCAATTGGACTACAAGGACGACGACGACAAAGAATTCGAGGTGCAGCTGCAGCAG 
 L  V  P  R  Q  L  D  Y  K  D  D  D  D  K  E  F  E  V  Q  L  Q  Q  
TCTGGCCCCGTGCTCGTGAAACCTGGCGCCTCCGTGAAGATGAGCTGCAAGGCCAGCGGCAACACC 
 S  G  P  V  L  V  K  P  G  A  S  V  K  M  S  C  K  A  S  G  N  T  
TTCACCGACAGCTTCATGCACTGGATGAAGCAGAGCCACGGCAAGAGCCTGGAATGGATCGGCATC 
 F  T  D  S  F  M  H  W  M  K  Q  S  H  G  K  S  L  E  W  I  G  I  
ATCAACCCCTACAACGGCGGCACCTCCTACAACCAGAAGTTCAAGGGCAAGGCCACCCTGACCGTG 
 I  N  P  Y  N  G  G  T  S  Y  N  Q  K  F  K  G  K  A  T  L  T  V  
GACAAGAGCAGCAGCACCGCCTACATGGAACTGAACAGCCTGACCAGCGAGGACAGCGCCGTGTAC 
 D  K  S  S  S  T  A  Y  M  E  L  N  S  L  T  S  E  D  S  A  V  Y  
TACTGCGCCAGAAACGGCGTGCGGTACTACTTCGACTACTGGGGCCAGGGCACAACCCTGACAGTG 
 Y  C  A  R  N  G  V  R  Y  Y  F  D  Y  W  G  Q  G  T  T  L  T  V  
TCTAGCAGATCCTCTAGCGCCAGCACAAAGGGCCCCAGCGTGTTCCCTCTGGCCCCTAGCAGCAAG 























































 S  S  R  S  S  S  A  S  T  K  G  P  S  V  F  P  L  A  P  S  S  K  
AGCACATCTGGCGGAACAGCCGCCCTGGGCTGCCTCGTGAAGGACTACTTTCCCGAGCCCGTGACA 
 S  T  S  G  G  T  A  A  L  G  C  L  V  K  D  Y  F  P  E  P  V  T  
GTGTCCTGGAACTCTGGCGCCCTGACAAGCGGCGTGCACACCTTTCCAGCCGTGCTGCAGAGCAGC 
 V  S  W  N  S  G  A  L  T  S  G  V  H  T  F  P  A  V  L  Q  S  S  
GGCCTGTACTCTCTGAGCAGCGTCGTGACTGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATC 
 G  L  Y  S  L  S  S  V  V  T  V  P  S  S  S  L  G  T  Q  T  Y  I  
TGCAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAACCCAAGAGCTGCGAC 
 C  N  V  N  H  K  P  S  N  T  K  V  D  K  K  V  E  P  K  S  C  D  
AAGACCCACACCTGTCCCCCTTGTCCTGCCCCTGAACTGCTGGGCGGACCTTCCGTGTTCCTGTTC 
 K  T  H  T  C  P  P  C  P  A  P  E  L  L  G  G  P  S  V  F  L  F  
CCCCCAAAGCCCAAGGACACCCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGAT 
 P  P  K  P  K  D  T  L  M  I  S  R  T  P  E  V  T  C  V  V  V  D  
GTGTCCCACGAGGACCCTGAAGTGAAGTTTAATTGGTACGTGGACGGCGTGGAAGTGCACAACGCC 
 V  S  H  E  D  P  E  V  K  F  N  W  Y  V  D  G  V  E  V  H  N  A  
AAGACCAAGCCCAGAGAGGAACAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACAGTGCTG 
 K  T  K  P  R  E  E  Q  Y  N  S  T  Y  R  V  V  S  V  L  T  V  L  
CACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGCCCTGCCTGCCCCC 
 H  Q  D  W  L  N  G  K  E  Y  K  C  K  V  S  N  K  A  L  P  A  P  
ATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAACCCCAGGTGTACACACTGCCTCCC 
 I  E  K  T  I  S  K  A  K  G  Q  P  R  E  P  Q  V  Y  T  L  P  P  
AGCAGGGACGAGCTGACCAAGAACCAGGTGTCCCTGACCTGTCTCGTGAAAGGCTTCTACCCCTCC 
 S  R  D  E  L  T  K  N  Q  V  S  L  T  C  L  V  K  G  F  Y  P  S  
GATATCGCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTG 
 D  I  A  V  E  W  E  S  N  G  Q  P  E  N  N  Y  K  T  T  P  P  V  
CTGGACAGCGACGGCTCATTCTTCCTGTACAGCAAGCTGACCGTGGACAAGTCCCGGTGGCAGCAG 
 L  D  S  D  G  S  F  F  L  Y  S  K  L  T  V  D  K  S  R  W  Q  Q  
GGCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAACCACTACACCAAGTCCCTGAGC 
 G  N  V  F  S  C  S  V  M  H  E  A  L  H  N  H  Y  T  K  S  L  S  
CTGAGCCCCGGCAAGCTCGACTTCCTCTTGCTGCAGGACCCGGCTTCCACGTGTGTCCCGGAGCCG 
 L  S  P  G  K  L  D  F  L  L  L  Q  D  P  A  S  T  C  V  P  E  P  
GCGTCTCAGCACACGCTCCGCTCCGGGCCTGGGTGCCTACAGCAGCCAGAGCAGCAGGGAGTCCGG 
 A  S  Q  H  T  L  R  S  G  P  G  C  L  Q  Q  P  E  Q  Q  G  V  R  
GACCCGGGCGGCATCTGGGCCAAGTTAGGCGCCGCCGAGGCCAGCGCTGAACGTCTCCAGGGCCGG 
 D  P  G  G  I  W  A  K  L  G  A  A  E  A  S  A  E  R  L  Q  G  R  
AGGAGCCGCGGGGCGTCCGGGTCTGAGCCGCAGCAAATGGGCTCCGACGTGCGGGACCTGAACGCG 
 R  S  R  G  A  S  G  S  E  P  Q  Q  M  G  S  D  V  R  D  L  N  A  
CTGCTGCCCGCCGTCCCCTCCCTGGGTGGCGGCGGCGGCTGTGCCCTGCCTGTGAGCGGCGCGGCG 
 L  L  P  A  V  P  S  L  G  G  G  G  G  C  A  L  P  V  S  G  A  A  
CAGTGGGCGCCGGTGCTGGACTTTGCGCCTCCGGGCGCTTCGGCTTACGGGTCGTTGGGCGGCCCC 
 Q  W  A  P  V  L  D  F  A  P  P  G  A  S  A  Y  G  S  L  G  G  P  
GCGCCGCCACCGGCTCCGCCGCCACCCCCGCCGCCGCCGCCTCACTCCTTCATCAAACAGGAGCCG 
 A  P  P  P  A  P  P  P  P  P  P  P  P  P  H  S  F  I  K  Q  E  P  
AGCTGGGGCGGCGCGGAGCCGCACGAGGAGCAGTGCCTGAGCGCCTTCACTGTCCACTTTTCCGGC 
 S  W  G  G  A  E  P  H  E  E  Q  C  L  S  A  F  T  V  H  F  S  G  
CAGTTCACTGGCACAGCCGGAGCCTGTCGCTACGGGCCCTTCGGTCCTCCTCCGCCCAGCCAGGCG 
 Q  F  T  G  T  A  G  A  C  R  Y  G  P  F  G  P  P  P  P  S  Q  A  
TCATCCGGCCAGGCCAGGATGTTTCCTAACGCGCCCTACCTGCCCAGCTGCCTCGAGAGCCAGCCC 
 S  S  G  Q  A  R  M  F  P  N  A  P  Y  L  P  S  C  L  E  S  Q  P  
GCTATTCGCAATCAGGGTTACAGCACGGTCACCTTCTAA 
 A  I  R  N  Q  G  Y  S  T  V  T  F  *  
 
 Nucleotide Amino acid 
Leader 1-78 1-26 
Flag tag 85-109 29-36 
Heavy chain variable domain 116-468 39-156 
Heavy chain constant domain of IgG1 475-1468 159-489 
WT1_D217-522 1475-2391 492-797 



































































 M  N  F  G  F  R  L  I  F  L  V  L  V  L  K  G  V  Q  C  E  V  K  
CTGGTGCCCCGGCAATTGGACTACAAGGACGACGACGACAAAGAATTCGAGGTGCAGCTGCAGCAG 
 L  V  P  R  Q  L  D  Y  K  D  D  D  D  K  E  F  E  V  Q  L  Q  Q  
TCTGGCCCCGTGCTCGTGAAACCTGGCGCCTCCGTGAAGATGAGCTGCAAGGCCAGCGGCAACACC 
 S  G  P  V  L  V  K  P  G  A  S  V  K  M  S  C  K  A  S  G  N  T  
TTCACCGACAGCTTCATGCACTGGATGAAGCAGAGCCACGGCAAGAGCCTGGAATGGATCGGCATC 
 F  T  D  S  F  M  H  W  M  K  Q  S  H  G  K  S  L  E  W  I  G  I  
ATCAACCCCTACAACGGCGGCACCTCCTACAACCAGAAGTTCAAGGGCAAGGCCACCCTGACCGTG 
 I  N  P  Y  N  G  G  T  S  Y  N  Q  K  F  K  G  K  A  T  L  T  V  
GACAAGAGCAGCAGCACCGCCTACATGGAACTGAACAGCCTGACCAGCGAGGACAGCGCCGTGTAC 
 D  K  S  S  S  T  A  Y  M  E  L  N  S  L  T  S  E  D  S  A  V  Y  
TACTGCGCCAGAAACGGCGTGCGGTACTACTTCGACTACTGGGGCCAGGGCACAACCCTGACAGTG 
 Y  C  A  R  N  G  V  R  Y  Y  F  D  Y  W  G  Q  G  T  T  L  T  V  
TCTAGCAGATCCTCTAGCGCCAGCACAAAGGGCCCCAGCGTGTTCCCTCTGGCCCCTAGCAGCAAG 
 S  S  R  S  S  S  A  S  T  K  G  P  S  V  F  P  L  A  P  S  S  K  
AGCACATCTGGCGGAACAGCCGCCCTGGGCTGCCTCGTGAAGGACTACTTTCCCGAGCCCGTGACA 
 S  T  S  G  G  T  A  A  L  G  C  L  V  K  D  Y  F  P  E  P  V  T  
GTGTCCTGGAACTCTGGCGCCCTGACAAGCGGCGTGCACACCTTTCCAGCCGTGCTGCAGAGCAGC 
 V  S  W  N  S  G  A  L  T  S  G  V  H  T  F  P  A  V  L  Q  S  S  
GGCCTGTACTCTCTGAGCAGCGTCGTGACTGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATC 
 G  L  Y  S  L  S  S  V  V  T  V  P  S  S  S  L  G  T  Q  T  Y  I  
TGCAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAACCCAAGAGCTGCGAC 
 C  N  V  N  H  K  P  S  N  T  K  V  D  K  K  V  E  P  K  S  C  D  
AAGACCCACACCTGTCCCCCTTGTCCTGCCCCTGAACTGCTGGGCGGACCTTCCGTGTTCCTGTTC 
 K  T  H  T  C  P  P  C  P  A  P  E  L  L  G  G  P  S  V  F  L  F  
CCCCCAAAGCCCAAGGACACCCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGAT 
 P  P  K  P  K  D  T  L  M  I  S  R  T  P  E  V  T  C  V  V  V  D  
GTGTCCCACGAGGACCCTGAAGTGAAGTTTAATTGGTACGTGGACGGCGTGGAAGTGCACAACGCC 
 V  S  H  E  D  P  E  V  K  F  N  W  Y  V  D  G  V  E  V  H  N  A  
AAGACCAAGCCCAGAGAGGAACAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACAGTGCTG 
 K  T  K  P  R  E  E  Q  Y  N  S  T  Y  R  V  V  S  V  L  T  V  L  
CACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGCCCTGCCTGCCCCC 
 H  Q  D  W  L  N  G  K  E  Y  K  C  K  V  S  N  K  A  L  P  A  P  
ATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAACCCCAGGTGTACACACTGCCTCCC 
 I  E  K  T  I  S  K  A  K  G  Q  P  R  E  P  Q  V  Y  T  L  P  P  
AGCAGGGACGAGCTGACCAAGAACCAGGTGTCCCTGACCTGTCTCGTGAAAGGCTTCTACCCCTCC 
 S  R  D  E  L  T  K  N  Q  V  S  L  T  C  L  V  K  G  F  Y  P  S  
GATATCGCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTG 
 D  I  A  V  E  W  E  S  N  G  Q  P  E  N  N  Y  K  T  T  P  P  V  
CTGGACAGCGACGGCTCATTCTTCCTGTACAGCAAGCTGACCGTGGACAAGTCCCGGTGGCAGCAG 
 L  D  S  D  G  S  F  F  L  Y  S  K  L  T  V  D  K  S  R  W  Q  Q  
GGCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAACCACTACACCAAGTCCCTGAGC 
 G  N  V  F  S  C  S  V  M  H  E  A  L  H  N  H  Y  T  K  S  L  S  
CTGAGCCCCGGCAAGCTCGAGATTCGCAATCAGGGTTACAGCACGGTCACCTTCGACGGGACGCCC 
 L  S  P  G  K  L  E  I  R  N  Q  G  Y  S  T  V  T  F  D  G  T  P  
AGCTACGGTCACACGCCCTCGCACCATGCGGCGCAGTTCCCCAACCACTCATTCAAGCATGAGGAT 
 S  Y  G  H  T  P  S  H  H  A  A  Q  F  P  N  H  S  F  K  H  E  D  
CCCATGGGCCAGCAGGGCTCGCTGGGTGAGCAGCAGTACTCGGTGCCGCCCCCGGTCTATGGCTGC 
 P  M  G  Q  Q  G  S  L  G  E  Q  Q  Y  S  V  P  P  P  V  Y  G  C  
CACACCCCCACCGACAGCTGCACCGGCAGCCAGGCTTTGCTGCTGAGGACGCCCTACAGCAGTGAC 
 H  T  P  T  D  S  C  T  G  S  Q  A  L  L  L  R  T  P  Y  S  S  D  
AATTTATACCAAATGACATCCCAGCTTGAATGCATGACCTGGAATCAGATGAACTTAGGAGCCACC 
 N  L  Y  Q  M  T  S  Q  L  E  C  M  T  W  N  Q  M  N  L  G  A  T  
TTAAAGGGAGTTGCTGCTGGGAGCTCCAGCTCAGTGAAATGGACAGAAGGGCAGAGCAACCACAGC 
 L  K  G  V  A  A  G  S  S  S  S  V  K  W  T  E  G  Q  S  N  H  S  
ACAGGGTACGAGAGCGATAACCACACAACGCCCATCCTCTGCGGAGCCCAATACAGAATACACACG 
 T  G  Y  E  S  D  N  H  T  T  P  I  L  C  G  A  Q  Y  R  I  H  T  
CACGGTGTCTTCAGAGGCATTCAGGATGTGCGACGTGTGCCTGGAGTAGCCCCGACTCTTGTACGG 
 H  G  V  F  R  G  I  Q  D  V  R  R  V  P  G  V  A  P  T  L  V  R  
TCGGCATCTGAGACCAGTGAGAAACGCCCCTTCATGTGTGCTTACCCAGGCTGCAATAAGAGATAT 
 S  A  S  E  T  S  E  K  R  P  F  M  C  A  Y  P  G  C  N  K  R  Y  

















 F  K  L  S  H  L  Q  M  H  S  R  K  H  T  G  E  K  P  Y  Q  C  D  
TTCAAGGACTGTGAACGAAGGTTTTCTCGTTCAGACCAGCTCAAAAGACACCAAAGGAGACATACA 
 F  K  D  C  E  R  R  F  S  R  S  D  Q  L  K  R  H  Q  R  R  H  T  
GGTGTGAAACCATTCCAGTGTAAAACTTGTCAGCGAAAGTTCTCCCGGTCCGACCACCTGAAGACC 
 G  V  K  P  F  Q  C  K  T  C  Q  R  K  F  S  R  S  D  H  L  K  T  
CACACCAGGACTCATACAGGTAAAACAAGTGAAAAGCCCTTCAGCTGTCGGTGGCCAAGTTGTCAG 
 H  T  R  T  H  T  G  K  T  S  E  K  P  F  S  C  R  W  P  S  C  Q  
AAAAAGTTTGCCCGGTCAGATGAATTAGTCCGCCATCACAACATGCATCAGAGAAACATGACCAAA 
 K  K  F  A  R  S  D  E  L  V  R  H  H  N  M  H  Q  R  N  M  T  K  
CTCCAGCTGGCGCTTTGA 
 L  Q  L  A  L  *  
 
 Nucleotide Amino acid 
Leader 1-78 1-26 
Flag tag 85-109 29-36 
Heavy chain variable domain 116-468 39-156 
Heavy chain constant domain of IgG1 472-1468 159-489 








































 M  N  F  G  F  R  L  I  F  L  V  L  V  L  K  G  V  Q  C  E  V  K  
CTGGTGCCCCGGCAATTGGACTACAAGGACGACGACGACAAAGAATTCGAGGTGCAGCTGCAGCAG 
 L  V  P  R  Q  L  D  Y  K  D  D  D  D  K  E  F  E  V  Q  L  Q  Q  
TCTGGCCCCGTGCTCGTGAAACCTGGCGCCTCCGTGAAGATGAGCTGCAAGGCCAGCGGCAACACC 
 S  G  P  V  L  V  K  P  G  A  S  V  K  M  S  C  K  A  S  G  N  T  
TTCACCGACAGCTTCATGCACTGGATGAAGCAGAGCCACGGCAAGAGCCTGGAATGGATCGGCATC 
 F  T  D  S  F  M  H  W  M  K  Q  S  H  G  K  S  L  E  W  I  G  I  
ATCAACCCCTACAACGGCGGCACCTCCTACAACCAGAAGTTCAAGGGCAAGGCCACCCTGACCGTG 
 I  N  P  Y  N  G  G  T  S  Y  N  Q  K  F  K  G  K  A  T  L  T  V  
GACAAGAGCAGCAGCACCGCCTACATGGAACTGAACAGCCTGACCAGCGAGGACAGCGCCGTGTAC 
 D  K  S  S  S  T  A  Y  M  E  L  N  S  L  T  S  E  D  S  A  V  Y  
TACTGCGCCAGAAACGGCGTGCGGTACTACTTCGACTACTGGGGCCAGGGCACAACCCTGACAGTG 
 Y  C  A  R  N  G  V  R  Y  Y  F  D  Y  W  G  Q  G  T  T  L  T  V  
TCTAGCAGATCCTCTAGCGCCAGCACAAAGGGCCCCAGCGTGTTCCCTCTGGCCCCTAGCAGCAAG 
 S  S  R  S  S  S  A  S  T  K  G  P  S  V  F  P  L  A  P  S  S  K  
AGCACATCTGGCGGAACAGCCGCCCTGGGCTGCCTCGTGAAGGACTACTTTCCCGAGCCCGTGACA 
 S  T  S  G  G  T  A  A  L  G  C  L  V  K  D  Y  F  P  E  P  V  T  
GTGTCCTGGAACTCTGGCGCCCTGACAAGCGGCGTGCACACCTTTCCAGCCGTGCTGCAGAGCAGC 
 V  S  W  N  S  G  A  L  T  S  G  V  H  T  F  P  A  V  L  Q  S  S  
GGCCTGTACTCTCTGAGCAGCGTCGTGACTGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATC 
 G  L  Y  S  L  S  S  V  V  T  V  P  S  S  S  L  G  T  Q  T  Y  I  
TGCAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAACCCAAGAGCTGCGAC 
 C  N  V  N  H  K  P  S  N  T  K  V  D  K  K  V  E  P  K  S  C  D  
AAGACCCACACCTGTCCCCCTTGTCCTGCCCCTGAACTGCTGGGCGGACCTTCCGTGTTCCTGTTC 
 K  T  H  T  C  P  P  C  P  A  P  E  L  L  G  G  P  S  V  F  L  F  
CCCCCAAAGCCCAAGGACACCCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGAT 
 P  P  K  P  K  D  T  L  M  I  S  R  T  P  E  V  T  C  V  V  V  D  
GTGTCCCACGAGGACCCTGAAGTGAAGTTTAATTGGTACGTGGACGGCGTGGAAGTGCACAACGCC 
 V  S  H  E  D  P  E  V  K  F  N  W  Y  V  D  G  V  E  V  H  N  A  
AAGACCAAGCCCAGAGAGGAACAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACAGTGCTG 
 K  T  K  P  R  E  E  Q  Y  N  S  T  Y  R  V  V  S  V  L  T  V  L  
CACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGCCCTGCCTGCCCCC 
 H  Q  D  W  L  N  G  K  E  Y  K  C  K  V  S  N  K  A  L  P  A  P  
ATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAACCCCAGGTGTACACACTGCCTCCC 
 I  E  K  T  I  S  K  A  K  G  Q  P  R  E  P  Q  V  Y  T  L  P  P  



























 S  R  D  E  L  T  K  N  Q  V  S  L  T  C  L  V  K  G  F  Y  P  S  
GATATCGCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTG 
 D  I  A  V  E  W  E  S  N  G  Q  P  E  N  N  Y  K  T  T  P  P  V  
CTGGACAGCGACGGCTCATTCTTCCTGTACAGCAAGCTGACCGTGGACAAGTCCCGGTGGCAGCAG 
 L  D  S  D  G  S  F  F  L  Y  S  K  L  T  V  D  K  S  R  W  Q  Q  
GGCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAACCACTACACCAAGTCCCTGAGC 
 G  N  V  F  S  C  S  V  M  H  E  A  L  H  N  H  Y  T  K  S  L  S  
CTGAGCCCCGGCAAGCTCGAGATTCGCAATCAGGGTTACAGCACGGTCACCTTCGACGGGACGCCC 
 L  S  P  G  K  L  E  I  R  N  Q  G  Y  S  T  V  T  F  D  G  T  P  
AGCTACGGTCACACGCCCTCGCACCATGCGGCGCAGTTCCCCAACCACTCATTCAAGCATGAGGAT 
 S  Y  G  H  T  P  S  H  H  A  A  Q  F  P  N  H  S  F  K  H  E  D  
CCCATGGGCCAGCAGGGCTCGCTGGGTGAGCAGCAGTACTCGGTGCCGCCCCCGGTCTATGGCTGC 
 P  M  G  Q  Q  G  S  L  G  E  Q  Q  Y  S  V  P  P  P  V  Y  G  C  
CACACCCCCACCGACAGCTGCACCGGCAGCCAGGCTTTGCTGCTGAGGACGCCCTACAGCAGTGAC 
 H  T  P  T  D  S  C  T  G  S  Q  A  L  L  L  R  T  P  Y  S  S  D  
AATTTATACCAAATGACATCCCAGCTTGAATGCATGACCTGGAATCAGATGAACTTAGGAGCCACC 
 N  L  Y  Q  M  T  S  Q  L  E  C  M  T  W  N  Q  M  N  L  G  A  T  
TTAAAGGGAGTTGCTGCTGGGAGCTCCAGCTCAGTGAAATGGACAGAAGGGCAGAGCAACCACAGC 
 L  K  G  V  A  A  G  S  S  S  S  V  K  W  T  E  G  Q  S  N  H  S  
ACAGGGTACGAGAGCGATAACCACACAACGTAA 
 T  G  Y  E  S  D  N  H  T  T  * 
 
 Nucleotide Amino acid 
Leader 1-78 1-26 
Flag tag 85-109 29-36 
Heavy chain variable domain 116-468 39-156 
Heavy chain constant domain of IgG1 475-1468 159-489 






























 M  N  F  G  F  R  L  I  F  L  V  L  V  L  K  G  V  Q  C  E  V  K  
CTGGTGCCCCGGCAATTGGACTACAAGGACGACGACGACAAAGAATTCGAGGTGCAGCTGCAGCAG 
 L  V  P  R  Q  L  D  Y  K  D  D  D  D  K  E  F  E  V  Q  L  Q  Q  
TCTGGCCCCGTGCTCGTGAAACCTGGCGCCTCCGTGAAGATGAGCTGCAAGGCCAGCGGCAACACC 
 S  G  P  V  L  V  K  P  G  A  S  V  K  M  S  C  K  A  S  G  N  T  
TTCACCGACAGCTTCATGCACTGGATGAAGCAGAGCCACGGCAAGAGCCTGGAATGGATCGGCATC 
 F  T  D  S  F  M  H  W  M  K  Q  S  H  G  K  S  L  E  W  I  G  I  
ATCAACCCCTACAACGGCGGCACCTCCTACAACCAGAAGTTCAAGGGCAAGGCCACCCTGACCGTG 
 I  N  P  Y  N  G  G  T  S  Y  N  Q  K  F  K  G  K  A  T  L  T  V  
GACAAGAGCAGCAGCACCGCCTACATGGAACTGAACAGCCTGACCAGCGAGGACAGCGCCGTGTAC 
 D  K  S  S  S  T  A  Y  M  E  L  N  S  L  T  S  E  D  S  A  V  Y  
TACTGCGCCAGAAACGGCGTGCGGTACTACTTCGACTACTGGGGCCAGGGCACAACCCTGACAGTG 
 Y  C  A  R  N  G  V  R  Y  Y  F  D  Y  W  G  Q  G  T  T  L  T  V  
TCTAGCAGATCCTCTAGCGCCAGCACAAAGGGCCCCAGCGTGTTCCCTCTGGCCCCTAGCAGCAAG 
 S  S  R  S  S  S  A  S  T  K  G  P  S  V  F  P  L  A  P  S  S  K  
AGCACATCTGGCGGAACAGCCGCCCTGGGCTGCCTCGTGAAGGACTACTTTCCCGAGCCCGTGACA 
 S  T  S  G  G  T  A  A  L  G  C  L  V  K  D  Y  F  P  E  P  V  T  
GTGTCCTGGAACTCTGGCGCCCTGACAAGCGGCGTGCACACCTTTCCAGCCGTGCTGCAGAGCAGC 
 V  S  W  N  S  G  A  L  T  S  G  V  H  T  F  P  A  V  L  Q  S  S  
GGCCTGTACTCTCTGAGCAGCGTCGTGACTGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATC 
 G  L  Y  S  L  S  S  V  V  T  V  P  S  S  S  L  G  T  Q  T  Y  I  
TGCAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAACCCAAGAGCTGCGAC 
 C  N  V  N  H  K  P  S  N  T  K  V  D  K  K  V  E  P  K  S  C  D  
AAGACCCACACCTGTCCCCCTTGTCCTGCCCCTGAACTGCTGGGCGGACCTTCCGTGTTCCTGTTC 
 K  T  H  T  C  P  P  C  P  A  P  E  L  L  G  G  P  S  V  F  L  F  











































 P  P  K  P  K  D  T  L  M  I  S  R  T  P  E  V  T  C  V  V  V  D  
GTGTCCCACGAGGACCCTGAAGTGAAGTTTAATTGGTACGTGGACGGCGTGGAAGTGCACAACGCC 
 V  S  H  E  D  P  E  V  K  F  N  W  Y  V  D  G  V  E  V  H  N  A  
AAGACCAAGCCCAGAGAGGAACAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACAGTGCTG 
 K  T  K  P  R  E  E  Q  Y  N  S  T  Y  R  V  V  S  V  L  T  V  L  
CACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGCCCTGCCTGCCCCC 
 H  Q  D  W  L  N  G  K  E  Y  K  C  K  V  S  N  K  A  L  P  A  P  
ATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAACCCCAGGTGTACACACTGCCTCCC 
 I  E  K  T  I  S  K  A  K  G  Q  P  R  E  P  Q  V  Y  T  L  P  P  
AGCAGGGACGAGCTGACCAAGAACCAGGTGTCCCTGACCTGTCTCGTGAAAGGCTTCTACCCCTCC 
 S  R  D  E  L  T  K  N  Q  V  S  L  T  C  L  V  K  G  F  Y  P  S  
GATATCGCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTG 
 D  I  A  V  E  W  E  S  N  G  Q  P  E  N  N  Y  K  T  T  P  P  V  
CTGGACAGCGACGGCTCATTCTTCCTGTACAGCAAGCTGACCGTGGACAAGTCCCGGTGGCAGCAG 
 L  D  S  D  G  S  F  F  L  Y  S  K  L  T  V  D  K  S  R  W  Q  Q  
GGCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAACCACTACACCAAGTCCCTGAGC 
 G  N  V  F  S  C  S  V  M  H  E  A  L  H  N  H  Y  T  K  S  L  S  
CTGAGCCCCGGCAAGCTCGAGCACTACACCCAGAAGTCCCTGAGCCTGAGCCCCGGCAAGCTCGAG 
 L  S  P  G  K  L  E  H  Y  T  Q  K  S  L  S  L  S  P  G  K  L  E  
GATAACCACACAACGCCCATCCTCTGCGGAGCCCAATACAGAATACACACGCACGGTGTCTTCAGA 
 D  N  H  T  T  P  I  L  C  G  A  Q  Y  R  I  H  T  H  G  V  F  R  
GGCATTCAGGATGTGCGACGTGTGCCTGGAGTAGCCCCGACTCTTGTACGGTCGGCATCTGAGACC 
 G  I  Q  D  V  R  R  V  P  G  V  A  P  T  L  V  R  S  A  S  E  T  
AGTGAGAAACGCCCCTTCATGTGTGCTTACCCAGGCTGCAATAAGAGATATTTTAAGCTGTCCCAC 
 S  E  K  R  P  F  M  C  A  Y  P  G  C  N  K  R  Y  F  K  L  S  H  
TTACAGATGCACAGCAGGAAGCACACTGGTGAGAAACCATACCAGTGTGACTTCAAGGACTGTGAA 
 L  Q  M  H  S  R  K  H  T  G  E  K  P  Y  Q  C  D  F  K  D  C  E  
CGAAGGTTTTCTCGTTCAGACCAGCTCAAAAGACACCAAAGGAGACATACAGGTGTGAAACCATTC 
 R  R  F  S  R  S  D  Q  L  K  R  H  Q  R  R  H  T  G  V  K  P  F  
CAGTGTAAAACTTGTCAGCGAAAGTTCTCCCGGTCCGACCACCTGAAGACCCACACCAGGACTCAT 
 Q  C  K  T  C  Q  R  K  F  S  R  S  D  H  L  K  T  H  T  R  T  H  
ACAGGTAAAACAAGTGAAAAGCCCTTCAGCTGTCGGTGGCCAAGTTGTCAGAAAAAGTTTGCCCGG 
 T  G  K  T  S  E  K  P  F  S  C  R  W  P  S  C  Q  K  K  F  A  R  
TCAGATGAATTAGTCCGCCATCACAACATGCATCAGAGAAACATGACCAAACTCCAGCTGGCGCTT 
 S  D  E  L  V  R  H  H  N  M  H  Q  R  N  M  T  K  L  Q  L  A  L  
TAA 
 * 
 Nucleotide Amino acid 
Leader 1-78 1-26 
Flag tag 85-109 29-36 
Heavy chain variable domain 116-468 39-156 
Heavy chain constant domain of IgG1 475-1468 159-489 














 M  N  F  G  F  R  L  I  F  L  V  L  V  L  K  G  V  Q  C  E  V  K  
CTGGTGCCCCGGCAATTGGACTACAAGGACGACGACGACAAAGAATTCGAGGTGCAGCTGCAGCAG 
 L  V  P  R  Q  L  D  Y  K  D  D  D  D  K  E  F  E  V  Q  L  Q  Q  
TCTGGCCCCGTGCTCGTGAAACCTGGCGCCTCCGTGAAGATGAGCTGCAAGGCCAGCGGCAACACC 
 S  G  P  V  L  V  K  P  G  A  S  V  K  M  S  C  K  A  S  G  N  T  
TTCACCGACAGCTTCATGCACTGGATGAAGCAGAGCCACGGCAAGAGCCTGGAATGGATCGGCATC 
 F  T  D  S  F  M  H  W  M  K  Q  S  H  G  K  S  L  E  W  I  G  I  
ATCAACCCCTACAACGGCGGCACCTCCTACAACCAGAAGTTCAAGGGCAAGGCCACCCTGACCGTG 
 I  N  P  Y  N  G  G  T  S  Y  N  Q  K  F  K  G  K  A  T  L  T  V  



































































 D  K  S  S  S  T  A  Y  M  E  L  N  S  L  T  S  E  D  S  A  V  Y  
TACTGCGCCAGAAACGGCGTGCGGTACTACTTCGACTACTGGGGCCAGGGCACAACCCTGACAGTG 
 Y  C  A  R  N  G  V  R  Y  Y  F  D  Y  W  G  Q  G  T  T  L  T  V  
TCTAGCAGATCCTCTAGCGCCAGCACAAAGGGCCCCAGCGTGTTCCCTCTGGCCCCTAGCAGCAAG 
 S  S  R  S  S  S  A  S  T  K  G  P  S  V  F  P  L  A  P  S  S  K  
AGCACATCTGGCGGAACAGCCGCCCTGGGCTGCCTCGTGAAGGACTACTTTCCCGAGCCCGTGACA 
 S  T  S  G  G  T  A  A  L  G  C  L  V  K  D  Y  F  P  E  P  V  T  
GTGTCCTGGAACTCTGGCGCCCTGACAAGCGGCGTGCACACCTTTCCAGCCGTGCTGCAGAGCAGC 
 V  S  W  N  S  G  A  L  T  S  G  V  H  T  F  P  A  V  L  Q  S  S  
GGCCTGTACTCTCTGAGCAGCGTCGTGACTGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATC 
 G  L  Y  S  L  S  S  V  V  T  V  P  S  S  S  L  G  T  Q  T  Y  I  
TGCAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAACCCAAGAGCTGCGAC 
 C  N  V  N  H  K  P  S  N  T  K  V  D  K  K  V  E  P  K  S  C  D  
AAGACCCACACCTGTCCCCCTTGTCCTGCCCCTGAACTGCTGGGCGGACCTTCCGTGTTCCTGTTC 
 K  T  H  T  C  P  P  C  P  A  P  E  L  L  G  G  P  S  V  F  L  F  
CCCCCAAAGCCCAAGGACACCCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGAT 
 P  P  K  P  K  D  T  L  M  I  S  R  T  P  E  V  T  C  V  V  V  D  
GTGTCCCACGAGGACCCTGAAGTGAAGTTTAATTGGTACGTGGACGGCGTGGAAGTGCACAACGCC 
 V  S  H  E  D  P  E  V  K  F  N  W  Y  V  D  G  V  E  V  H  N  A  
AAGACCAAGCCCAGAGAGGAACAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACAGTGCTG 
 K  T  K  P  R  E  E  Q  Y  N  S  T  Y  R  V  V  S  V  L  T  V  L  
CACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGCCCTGCCTGCCCCC 
 H  Q  D  W  L  N  G  K  E  Y  K  C  K  V  S  N  K  A  L  P  A  P  
ATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAACCCCAGGTGTACACACTGCCTCCC 
 I  E  K  T  I  S  K  A  K  G  Q  P  R  E  P  Q  V  Y  T  L  P  P  
AGCAGGGACGAGCTGACCAAGAACCAGGTGTCCCTGACCTGTCTCGTGAAAGGCTTCTACCCCTCC 
 S  R  D  E  L  T  K  N  Q  V  S  L  T  C  L  V  K  G  F  Y  P  S  
GATATCGCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTG 
 D  I  A  V  E  W  E  S  N  G  Q  P  E  N  N  Y  K  T  T  P  P  V  
CTGGACAGCGACGGCTCATTCTTCCTGTACAGCAAGCTGACCGTGGACAAGTCCCGGTGGCAGCAG 
 L  D  S  D  G  S  F  F  L  Y  S  K  L  T  V  D  K  S  R  W  Q  Q  
GGCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAACCACTACACCAAGTCCCTGAGC 
 G  N  V  F  S  C  S  V  M  H  E  A  L  H  N  H  Y  T  K  S  L  S  
CTGAGCCCCGGCAAGCTCGACTTCCTCTTGCTGCAGGACCCGGCTTCCACGTGTGTCCCGGAGCCG 
 L  S  P  G  K  L  D  F  L  L  L  Q  D  P  A  S  T  C  V  P  E  P  
GCGTCTCAGCACACGCTCCGCTCCGGGCCTGGGTGCCTACAGCAGCCAGAGCAGCAGGGAGTCCGG 
 A  S  Q  H  T  L  R  S  G  P  G  C  L  Q  Q  P  E  Q  Q  G  V  R  
GACCCGGGCGGCATCTGGGCCAAGTTAGGCGCCGCCGAGGCCAGCGCTGAACGTCTCCAGGGCCGG 
 D  P  G  G  I  W  A  K  L  G  A  A  E  A  S  A  E  R  L  Q  G  R  
AGGAGCCGCGGGGCGTCCGGGTCTGAGCCGCAGCAAATGGGCTCCGACGTGCGGGACCTGAACGCG 
 R  S  R  G  A  S  G  S  E  P  Q  Q  M  G  S  D  V  R  D  L  N  A  
CTGCTGCCCGCCGTCCCCTCCCTGGGTGGCGGCGGCGGCTGTGCCCTGCCTGTGAGCGGCGCGGCG 
 L  L  P  A  V  P  S  L  G  G  G  G  G  C  A  L  P  V  S  G  A  A  
CAGTGGGCGCCGGTGCTGGACTTTGCGCCTCCGGGCGCTTCGGCTTACGGGTCGTTGGGCGGCCCC 
 Q  W  A  P  V  L  D  F  A  P  P  G  A  S  A  Y  G  S  L  G  G  P  
GCGCCGCCACCGGCTCCGCCGCCACCCCCGCCGCCGCCGCCTCACTCCTTCATCAAACAGGAGCCG 
 A  P  P  P  A  P  P  P  P  P  P  P  P  P  H  S  F  I  K  Q  E  P  
AGCTGGGGCGGCGCGGAGCCGCACGAGGAGCAGTGCCTGAGCGCCTTCACTGTCCACTTTTCCGGC 
 S  W  G  G  A  E  P  H  E  E  Q  C  L  S  A  F  T  V  H  F  S  G  
CAGTTCACTGGCACAGCCGGAGCCTGTCGCTACGGGCCCTTCGGTCCTCCTCCGCCCAGCCAGGCG 
 Q  F  T  G  T  A  G  A  C  R  Y  G  P  F  G  P  P  P  P  S  Q  A  
TCATCCGGCCAGGCCAGGATGTTTCCTAACGCGCCCTACCTGCCCAGCTGCCTCGAGATTCGCAAT 
 S  S  G  Q  A  R  M  F  P  N  A  P  Y  L  P  S  C  L  E  I  R  N  
CAGGGTTACAGCACGGTCACCTTCGACGGGACGCCCAGCTACGGTCACACGCCCTCGCACCATGCG 
 Q  G  Y  S  T  V  T  F  D  G  T  P  S  Y  G  H  T  P  S  H  H  A  
GCGCAGTTCCCCAACCACTCATTCAAGCATGAGGATCCCATGGGCCAGCAGGGCTCGCTGGGTGAG 
 A  Q  F  P  N  H  S  F  K  H  E  D  P  M  G  Q  Q  G  S  L  G  E  
CAGCAGTACTCGGTGCCGCCCCCGGTCTATGGCTGCCACACCCCCACCGACAGCTGCACCGGCAGC 
 Q  Q  Y  S  V  P  P  P  V  Y  G  C  H  T  P  T  D  S  C  T  G  S  
CAGGCTTTGCTGCTGAGGACGCCCTACAGCAGTGACAATTTATACCAAATGACATCCCAGCTTGAA 
 Q  A  L  L  L  R  T  P  Y  S  S  D  N  L  Y  Q  M  T  S  Q  L  E  

























 C  M  T  W  N  Q  M  N  L  G  A  T  L  K  G  V  A  A  G  S  S  S  
TCAGTGAAATGGACAGAAGGGCAGAGCAACCACAGCACAGGGTACGAGAGCGATAACCACACAACG 
 S  V  K  W  T  E  G  Q  S  N  H  S  T  G  Y  E  S  D  N  H  T  T  
CCCATCCTCTGCGGAGCCCAATACAGAATACACACGCACGGTGTCTTCAGAGGCATTCAGGATGTG 
 P  I  L  C  G  A  Q  Y  R  I  H  T  H  G  V  F  R  G  I  Q  D  V  
CGACGTGTGCCTGGAGTAGCCCCGACTCTTGTACGGTCGGCATCTGAGACCAGTGAGAAACGCCCC 
 R  R  V  P  G  V  A  P  T  L  V  R  S  A  S  E  T  S  E  K  R  P  
TTCATGTGTGCTTACCCAGGCTGCAATAAGAGATATTTTAAGCTGTCCCACTTACAGATGCACAGC 
 F  M  C  A  Y  P  G  C  N  K  R  Y  F  K  L  S  H  L  Q  M  H  S  
AGGAAGCACACTGGTGAGAAACCATACCAGTGTGACTTCAAGGACTGTGAACGAAGGTTTTCTCGT 
 R  K  H  T  G  E  K  P  Y  Q  C  D  F  K  D  C  E  R  R  F  S  R  
TCAGACCAGCTCAAAAGACACCAAAGGAGACATACAGGTGTGAAACCATTCCAGTGTAAAACTTGT 
 S  D  Q  L  K  R  H  Q  R  R  H  T  G  V  K  P  F  Q  C  K  T  C  
CAGCGAAAGTTCTCCCGGTCCGACCACCTGAAGACCCACACCAGGACTCATACAGGTAAAACAAGT 
 Q  R  K  F  S  R  S  D  H  L  K  T  H  T  R  T  H  T  G  K  T  S  
GAAAAGCCCTTCAGCTGTCGGTGGCCAAGTTGTCAGAAAAAGTTTGCCCGGTCAGATGAATTAGTC 
 E  K  P  F  S  C  R  W  P  S  C  Q  K  K  F  A  R  S  D  E  L  V  
CGCCATCACAACATGCATCAGAGAAACATGACCAAACTCCAGCTGGCGCTTTAA 
 R  H  H  N  M  H  Q  R  N  M  T  K  L  Q  L  A  L  *  
 
 Nucleotide Amino acid 
Leader 1-78 1-26 
Variable heavy chain domain 85-438 29-146 
Linker 439-474 147-158 
Variable light chain domain 475-801 159-267 
Flag tag 2x 808-861 270-287 































 M  N  F  G  F  R  L  I  F  L  V  L  V  L  K  G  V  Q  C  E  V  K  
CTGGTGCCCCGGCAATTGGAGGTGCAGCTGCAGCAGTCTGGCCCCGTGCTCGTGAAACCTGGCGCC 
 L  V  P  R  Q  L  E  V  Q  L  Q  Q  S  G  P  V  L  V  K  P  G  A  
TCCGTGAAGATGAGCTGCAAGGCCAGCGGCAACACCTTCACCGACAGCTTCATGCACTGGATGAAG 
 S  V  K  M  S  C  K  A  S  G  N  T  F  T  D  S  F  M  H  W  M  K  
CAGAGCCACGGCAAGAGCCTGGAATGGATCGGCATCATCAACCCCTACAACGGCGGCACCTCCTAC 
 Q  S  H  G  K  S  L  E  W  I  G  I  I  N  P  Y  N  G  G  T  S  Y  
AACCAGAAGTTCAAGGGCAAGGCCACCCTGACCGTGGACAAGAGCAGCAGCACCGCCTACATGGAA 
 N  Q  K  F  K  G  K  A  T  L  T  V  D  K  S  S  S  T  A  Y  M  E  
CTGAACAGCCTGACCAGCGAGGACAGCGCCGTGTACTACTGCGCCAGAAACGGCGTGCGGTACTAC 
 L  N  S  L  T  S  E  D  S  A  V  Y  Y  C  A  R  N  G  V  R  Y  Y  
TTCGACTACTGGGGCCAGGGCACAACCCTGACAGTGTCTAGCGGCGGAGGAAGCGGAGGCGGATCT 
 F  D  Y  W  G  Q  G  T  T  L  T  V  S  S  G  G  G  S  G  G  G  S  
GGCGGAGGATCTCAGGCTGTCGTGACCCAGGAAAGCGCCCTGACAACCAGCCCTGGCGAGACAGTG 
 G  G  G  S  Q  A  V  V  T  Q  E  S  A  L  T  T  S  P  G  E  T  V  
ACCCTGACCTGCAGATCCTCTACAGGCGCCGTGACCATCAGCAACTACGCCAACTGGGTGCAGGAA 
 T  L  T  C  R  S  S  T  G  A  V  T  I  S  N  Y  A  N  W  V  Q  E  
AAGCCCGACCACCTGTTCACCGGCCTGATCGGCGGCACAAACAACAGAGCACCTGGCGTGCCCGCC 
 K  P  D  H  L  F  T  G  L  I  G  G  T  N  N  R  A  P  G  V  P  A  
AGATTCAGCGGCTCTCTGATCGGAGATAAGGCCGCACTGACCATCACAGGCGCCCAGACCGAGGAC 
 R  F  S  G  S  L  I  G  D  K  A  A  L  T  I  T  G  A  Q  T  E  D  
GAGGCCATCTACTTTTGCGCCCTGTGGTACAACAACCAGTTCATCTTCGGCAGCGGCACCAAAGTG 
 E  A  I  Y  F  C  A  L  W  Y  N  N  Q  F  I  F  G  S  G  T  K  V  
ACCGTGCTGGGATCCGACTACAAGGACGACGACGACAAAGAATTCGACTACAAGGACGACGACGAC 
 T  V  L  G  S  D  Y  K  D  D  D  D  K  E  F  D  Y  K  D  D  D  D  
AAACTCGAGATTCGCAATCAGGGTTACAGCACGGTCACCTTCGACGGGACGCCCAGCTACGGTCAC 

































 K  L  E  I  R  N  Q  G  Y  S  T  V  T  F  D  G  T  P  S  Y  G  H  
ACGCCCTCGCACCATGCGGCGCAGTTCCCCAACCACTCATTCAAGCATGAGGATCCCATGGGCCAG 
 T  P  S  H  H  A  A  Q  F  P  N  H  S  F  K  H  E  D  P  M  G  Q  
CAGGGCTCGCTGGGTGAGCAGCAGTACTCGGTGCCGCCCCCGGTCTATGGCTGCCACACCCCCACC 
 Q  G  S  L  G  E  Q  Q  Y  S  V  P  P  P  V  Y  G  C  H  T  P  T  
GACAGCTGCACCGGCAGCCAGGCTTTGCTGCTGAGGACGCCCTACAGCAGTGACAATTTATACCAA 
 D  S  C  T  G  S  Q  A  L  L  L  R  T  P  Y  S  S  D  N  L  Y  Q  
ATGACATCCCAGCTTGAATGCATGACCTGGAATCAGATGAACTTAGGAGCCACCTTAAAGGGAGTT 
 M  T  S  Q  L  E  C  M  T  W  N  Q  M  N  L  G  A  T  L  K  G  V  
GCTGCTGGGAGCTCCAGCTCAGTGAAATGGACAGAAGGGCAGAGCAACCACAGCACAGGGTACGAG 
 A  A  G  S  S  S  S  V  K  W  T  E  G  Q  S  N  H  S  T  G  Y  E  
AGCGATAACCACACAACGCCCATCCTCTGCGGAGCCCAATACAGAATACACACGCACGGTGTCTTC 
 S  D  N  H  T  T  P  I  L  C  G  A  Q  Y  R  I  H  T  H  G  V  F  
AGAGGCATTCAGGATGTGCGACGTGTGCCTGGAGTAGCCCCGACTCTTGTACGGTCGGCATCTGAG 
 R  G  I  Q  D  V  R  R  V  P  G  V  A  P  T  L  V  R  S  A  S  E  
ACCAGTGAGAAACGCCCCTTCATGTGTGCTTACCCAGGCTGCAATAAGAGATATTTTAAGCTGTCC 
 T  S  E  K  R  P  F  M  C  A  Y  P  G  C  N  K  R  Y  F  K  L  S  
CACTTACAGATGCACAGCAGGAAGCACACTGGTGAGAAACCATACCAGTGTGACTTCAAGGACTGT 
 H  L  Q  M  H  S  R  K  H  T  G  E  K  P  Y  Q  C  D  F  K  D  C  
GAACGAAGGTTTTCTCGTTCAGACCAGCTCAAAAGACACCAAAGGAGACATACAGGTGTGAAACCA 
 E  R  R  F  S  R  S  D  Q  L  K  R  H  Q  R  R  H  T  G  V  K  P  
TTCCAGTGTAAAACTTGTCAGCGAAAGTTCTCCCGGTCCGACCACCTGAAGACCCACACCAGGACT 
 F  Q  C  K  T  C  Q  R  K  F  S  R  S  D  H  L  K  T  H  T  R  T  
CATACAGGTAAAACAAGTGAAAAGCCCTTCAGCTGTCGGTGGCCAAGTTGTCAGAAAAAGTTTGCC 
 H  T  G  K  T  S  E  K  P  F  S  C  R  W  P  S  C  Q  K  K  F  A  
CGGTCAGATGAATTAGTCCGCCATCACAACATGCATCAGAGAAACATGACCAAACTCCAGCTGGCG 
 R  S  D  E  L  V  R  H  H  N  M  H  Q  R  N  M  T  K  L  Q  L  A  
CTTTGA 
 L  *  
 
 Nucleotide Amino acid 
Leader 1-78 1-26 
Flag tag 85-109 29-36 
Heavy chain variable domain 116-468 139-156 
Heavy chain constant domain of IgG1 472-1471 156-490 























 M  N  F  G  F  S  L  I  F  L  V  L  V  L  K  G  V  Q  C  E  V  K  
CTGGTGCCCCGGCAATTGGACTACAAGGACGACGACGACAAAGAATTCGAGGTGCAGCTGCAGCAG 
 L  V  P  R  Q  L  D  Y  K  D  D  D  D  K  E  F  E  V  Q  L  Q  Q  
TCTGGCCCCGTGCTCGTGAAACCTGGCGCCTCCGTGAAGATGAGCTGCAAGGCCAGCGGCAACACC 
 S  G  P  V  L  V  K  P  G  A  S  V  K  M  S  C  K  A  S  G  N  T  
TTCACCGACAGCTTCATGCACTGGATGAAGCAGAGCCACGGCAAGAGCCTGGAATGGATCGGCATC 
 F  T  D  S  F  M  H  W  M  K  Q  S  H  G  K  S  L  E  W  I  G  I  
ATCAACCCCTACAACGGCGGCACCTCCTACAACCAGAAGTTCAAGGGCAAGGCCACCCTGACCGTG 
 I  N  P  Y  N  G  G  T  S  Y  N  Q  K  F  K  G  K  A  T  L  T  V  
GACAAGAGCAGCAGCACCGCCTACATGGAACTGAACAGCCTGACCAGCGAGGACAGCGCCGTGTAC 
 D  K  S  S  S  T  A  Y  M  E  L  N  S  L  T  S  E  D  S  A  V  Y  
TACTGCGCCAGAAACGGCGTGCGGTACTACTTCGACTACTGGGGCCAGGGCACAACCCTGACAGTG 
 Y  C  A  R  N  G  V  R  Y  Y  F  D  Y  W  G  Q  G  T  T  L  T  V  
TCTAGCAGATCCTCTAGCGCCAGCACAAAGGGCCCCAGCGTGTTCCCTCTGGCCCCTAGCAGCAAG 
 S  S  R  S  S  S  A  S  T  K  G  P  S  V  F  P  L  A  P  S  S  K  
AGCACATCTGGCGGAACAGCCGCCCTGGGCTGCCTCGTGAAGGACTACTTTCCCGAGCCCGTGACA 
 S  T  S  G  G  T  A  A  L  G  C  L  V  K  D  Y  F  P  E  P  V  T  
GTGTCCTGGAACTCTGGCGCCCTGACAAGCGGCGTGCACACCTTTCCAGCCGTGCTGCAGAGCAGC 

































 V  S  W  N  S  G  A  L  T  S  G  V  H  T  F  P  A  V  L  Q  S  S  
GGCCTGTACTCTCTGAGCAGCGTCGTGACTGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATC 
 G  L  Y  S  L  S  S  V  V  T  V  P  S  S  S  L  G  T  Q  T  Y  I  
TGCAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAACCCAAGAGCTGCGAC 
 C  N  V  N  H  K  P  S  N  T  K  V  D  K  K  V  E  P  K  S  C  D  
AAGACCCACACCTGTCCCCCTTGTCCTGCCCCTGAACTGCTGGGCGGACCTTCCGTGTTCCTGTTC 
 K  T  H  T  C  P  P  C  P  A  P  E  L  L  G  G  P  S  V  F  L  F  
CCCCCAAAGCCCAAGGACACCCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGAT 
 P  P  K  P  K  D  T  L  M  I  S  R  T  P  E  V  T  C  V  V  V  D  
GTGTCCCACGAGGACCCTGAAGTGAAGTTTAATTGGTACGTGGACGGCGTGGAAGTGCACAACGCC 
 V  S  H  E  D  P  E  V  K  F  N  W  Y  V  D  G  V  E  V  H  N  A  
AAGACCAAGCCCAGAGAGGAACAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACAGTGCTG 
 K  T  K  P  R  E  E  Q  Y  N  S  T  Y  R  V  V  S  V  L  T  V  L  
CACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGCCCTGCCTGCCCCC 
 H  Q  D  W  L  N  G  K  E  Y  K  C  K  V  S  N  K  A  L  P  A  P  
ATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAACCCCAGGTGTACACACTGCCTCCC 
 I  E  K  T  I  S  K  A  K  G  Q  P  R  E  P  Q  V  Y  T  L  P  P  
AGCAGGGACGAGCTGACCAAGAACCAGGTGTCCCTGACCTGTCTCGTGAAAGGCTTCTACCCCTCC 
 S  R  D  E  L  T  K  N  Q  V  S  L  T  C  L  V  K  G  F  Y  P  S  
GATATCGCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTG 
 D  I  A  V  E  W  E  S  N  G  Q  P  E  N  N  Y  K  T  T  P  P  V  
CTGGACAGCGACGGCTCATTCTTCCTGTACAGCAAGCTGACCGTGGACAAGTCCCGGTGGCAGCAG 
 L  D  S  D  G  S  F  F  L  Y  S  K  L  T  V  D  K  S  R  W  Q  Q  
GGCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTG 
 G  N  V  F  S  C  S  V  M  H  E  A  L  H  N  H  Y  T  Q  K  S  L  
AGCCTGAGCCCCGGCAAGCTCGAGGCTAGTACAGCTGCGCTGCTGCCCGCCGTCCCCTCCCTGGGT 
 S  L  S  P  G  K  L  E  A  S  T  A  A  L  L  P  A  V  P  S  L  G  
GGCGGCGGCGGCTGTGCCCTGCCTGTGAGCGGCGCGGCGCAGTGGGCGTAA 
 G  G  G  G  C  A  L  P  V  S  G  A  A  Q  W  A  *  
 
 Nucleotide Amino acid 
Leader 1-78 1-26 
Flag tag 85-109 29-36 
Heavy chain variable domain 116-468 139-156 
Heavy chain constant domain of IgG1 472-1471 156-490 























 M  N  F  G  F  S  L  I  F  L  V  L  V  L  K  G  V  Q  C  E  V  K  
CTGGTGCCCCGGCAATTGGACTACAAGGACGACGACGACAAAGAATTCGAGGTGCAGCTGCAGCAG 
 L  V  P  R  Q  L  D  Y  K  D  D  D  D  K  E  F  E  V  Q  L  Q  Q  
TCTGGCCCCGTGCTCGTGAAACCTGGCGCCTCCGTGAAGATGAGCTGCAAGGCCAGCGGCAACACC 
 S  G  P  V  L  V  K  P  G  A  S  V  K  M  S  C  K  A  S  G  N  T  
TTCACCGACAGCTTCATGCACTGGATGAAGCAGAGCCACGGCAAGAGCCTGGAATGGATCGGCATC 
 F  T  D  S  F  M  H  W  M  K  Q  S  H  G  K  S  L  E  W  I  G  I  
ATCAACCCCTACAACGGCGGCACCTCCTACAACCAGAAGTTCAAGGGCAAGGCCACCCTGACCGTG 
 I  N  P  Y  N  G  G  T  S  Y  N  Q  K  F  K  G  K  A  T  L  T  V  
GACAAGAGCAGCAGCACCGCCTACATGGAACTGAACAGCCTGACCAGCGAGGACAGCGCCGTGTAC 
 D  K  S  S  S  T  A  Y  M  E  L  N  S  L  T  S  E  D  S  A  V  Y  
TACTGCGCCAGAAACGGCGTGCGGTACTACTTCGACTACTGGGGCCAGGGCACAACCCTGACAGTG 
 Y  C  A  R  N  G  V  R  Y  Y  F  D  Y  W  G  Q  G  T  T  L  T  V  
TCTAGCAGATCCTCTAGCGCCAGCACAAAGGGCCCCAGCGTGTTCCCTCTGGCCCCTAGCAGCAAG 
 S  S  R  S  S  S  A  S  T  K  G  P  S  V  F  P  L  A  P  S  S  K  
AGCACATCTGGCGGAACAGCCGCCCTGGGCTGCCTCGTGAAGGACTACTTTCCCGAGCCCGTGACA 
 S  T  S  G  G  T  A  A  L  G  C  L  V  K  D  Y  F  P  E  P  V  T  
GTGTCCTGGAACTCTGGCGCCCTGACAAGCGGCGTGCACACCTTTCCAGCCGTGCTGCAGAGCAGC 



































 V  S  W  N  S  G  A  L  T  S  G  V  H  T  F  P  A  V  L  Q  S  S  
GGCCTGTACTCTCTGAGCAGCGTCGTGACTGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATC 
 G  L  Y  S  L  S  S  V  V  T  V  P  S  S  S  L  G  T  Q  T  Y  I  
TGCAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAACCCAAGAGCTGCGAC 
 C  N  V  N  H  K  P  S  N  T  K  V  D  K  K  V  E  P  K  S  C  D  
AAGACCCACACCTGTCCCCCTTGTCCTGCCCCTGAACTGCTGGGCGGACCTTCCGTGTTCCTGTTC 
 K  T  H  T  C  P  P  C  P  A  P  E  L  L  G  G  P  S  V  F  L  F  
CCCCCAAAGCCCAAGGACACCCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGAT 
 P  P  K  P  K  D  T  L  M  I  S  R  T  P  E  V  T  C  V  V  V  D  
GTGTCCCACGAGGACCCTGAAGTGAAGTTTAATTGGTACGTGGACGGCGTGGAAGTGCACAACGCC 
 V  S  H  E  D  P  E  V  K  F  N  W  Y  V  D  G  V  E  V  H  N  A  
AAGACCAAGCCCAGAGAGGAACAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACAGTGCTG 
 K  T  K  P  R  E  E  Q  Y  N  S  T  Y  R  V  V  S  V  L  T  V  L  
CACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGCCCTGCCTGCCCCC 
 H  Q  D  W  L  N  G  K  E  Y  K  C  K  V  S  N  K  A  L  P  A  P  
ATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAACCCCAGGTGTACACACTGCCTCCC 
 I  E  K  T  I  S  K  A  K  G  Q  P  R  E  P  Q  V  Y  T  L  P  P  
AGCAGGGACGAGCTGACCAAGAACCAGGTGTCCCTGACCTGTCTCGTGAAAGGCTTCTACCCCTCC 
 S  R  D  E  L  T  K  N  Q  V  S  L  T  C  L  V  K  G  F  Y  P  S  
GATATCGCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTG 
 D  I  A  V  E  W  E  S  N  G  Q  P  E  N  N  Y  K  T  T  P  P  V  
CTGGACAGCGACGGCTCATTCTTCCTGTACAGCAAGCTGACCGTGGACAAGTCCCGGTGGCAGCAG 
 L  D  S  D  G  S  F  F  L  Y  S  K  L  T  V  D  K  S  R  W  Q  Q  
GGCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTG 
 G  N  V  F  S  C  S  V  M  H  E  A  L  H  N  H  Y  T  Q  K  S  L  
AGCCTGAGCCCCGGCAAGCTCGAGGCTAGTACAGCTGCCTTCACTGTCCACTTTTCCGGCCAGTTC 
 S  L  S  P  G  K  L  E  A  S  T  A  A  F  T  V  H  F  S  G  Q  F  
ACTGGCACAGCCGGAGCCTGTCGCTACGGGCCCTTCGGTCCTCCTCCGCCCAGCCAGGCGTCATCC 
 T  G  T  A  G  A  C  R  Y  G  P  F  G  P  P  P  P  S  Q  A  S  S  
GGCCAGGCCAGGATGTTTCCTAACGCGCCCTACCTGCCCAGCTGCCTCTAA 
 G  Q  A  R  M  F  P  N  A  P  Y  L  P  S  C  L  *  
 
 Nucleotide Amino acid 
Leader 1-78 1-26 
Flag tag 85-109 29-36 
Heavy chain variable domain 116-468 139-156 
Heavy chain constant domain of IgG1 472-1471 156-490 





















 M  N  F  G  F  S  L  I  F  L  V  L  V  L  K  G  V  Q  C  E  V  K  
CTGGTGCCCCGGCAATTGGACTACAAGGACGACGACGACAAAGAATTCGAGGTGCAGCTGCAGCAG 
 L  V  P  R  Q  L  D  Y  K  D  D  D  D  K  E  F  E  V  Q  L  Q  Q  
TCTGGCCCCGTGCTCGTGAAACCTGGCGCCTCCGTGAAGATGAGCTGCAAGGCCAGCGGCAACACC 
 S  G  P  V  L  V  K  P  G  A  S  V  K  M  S  C  K  A  S  G  N  T  
TTCACCGACAGCTTCATGCACTGGATGAAGCAGAGCCACGGCAAGAGCCTGGAATGGATCGGCATC 
 F  T  D  S  F  M  H  W  M  K  Q  S  H  G  K  S  L  E  W  I  G  I  
ATCAACCCCTACAACGGCGGCACCTCCTACAACCAGAAGTTCAAGGGCAAGGCCACCCTGACCGTG 
 I  N  P  Y  N  G  G  T  S  Y  N  Q  K  F  K  G  K  A  T  L  T  V  
GACAAGAGCAGCAGCACCGCCTACATGGAACTGAACAGCCTGACCAGCGAGGACAGCGCCGTGTAC 
 D  K  S  S  S  T  A  Y  M  E  L  N  S  L  T  S  E  D  S  A  V  Y  
TACTGCGCCAGAAACGGCGTGCGGTACTACTTCGACTACTGGGGCCAGGGCACAACCCTGACAGTG 
 Y  C  A  R  N  G  V  R  Y  Y  F  D  Y  W  G  Q  G  T  T  L  T  V  
TCTAGCAGATCCTCTAGCGCCAGCACAAAGGGCCCCAGCGTGTTCCCTCTGGCCCCTAGCAGCAAG 
 S  S  R  S  S  S  A  S  T  K  G  P  S  V  F  P  L  A  P  S  S  K  
AGCACATCTGGCGGAACAGCCGCCCTGGGCTGCCTCGTGAAGGACTACTTTCCCGAGCCCGTGACA 





































 S  T  S  G  G  T  A  A  L  G  C  L  V  K  D  Y  F  P  E  P  V  T  
GTGTCCTGGAACTCTGGCGCCCTGACAAGCGGCGTGCACACCTTTCCAGCCGTGCTGCAGAGCAGC 
 V  S  W  N  S  G  A  L  T  S  G  V  H  T  F  P  A  V  L  Q  S  S  
GGCCTGTACTCTCTGAGCAGCGTCGTGACTGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATC 
 G  L  Y  S  L  S  S  V  V  T  V  P  S  S  S  L  G  T  Q  T  Y  I  
TGCAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAACCCAAGAGCTGCGAC 
 C  N  V  N  H  K  P  S  N  T  K  V  D  K  K  V  E  P  K  S  C  D  
AAGACCCACACCTGTCCCCCTTGTCCTGCCCCTGAACTGCTGGGCGGACCTTCCGTGTTCCTGTTC 
 K  T  H  T  C  P  P  C  P  A  P  E  L  L  G  G  P  S  V  F  L  F  
CCCCCAAAGCCCAAGGACACCCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGAT 
 P  P  K  P  K  D  T  L  M  I  S  R  T  P  E  V  T  C  V  V  V  D  
GTGTCCCACGAGGACCCTGAAGTGAAGTTTAATTGGTACGTGGACGGCGTGGAAGTGCACAACGCC 
 V  S  H  E  D  P  E  V  K  F  N  W  Y  V  D  G  V  E  V  H  N  A  
AAGACCAAGCCCAGAGAGGAACAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACAGTGCTG 
 K  T  K  P  R  E  E  Q  Y  N  S  T  Y  R  V  V  S  V  L  T  V  L  
CACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGCCCTGCCTGCCCCC 
 H  Q  D  W  L  N  G  K  E  Y  K  C  K  V  S  N  K  A  L  P  A  P  
ATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAACCCCAGGTGTACACACTGCCTCCC 
 I  E  K  T  I  S  K  A  K  G  Q  P  R  E  P  Q  V  Y  T  L  P  P  
AGCAGGGACGAGCTGACCAAGAACCAGGTGTCCCTGACCTGTCTCGTGAAAGGCTTCTACCCCTCC 
 S  R  D  E  L  T  K  N  Q  V  S  L  T  C  L  V  K  G  F  Y  P  S  
GATATCGCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTG 
 D  I  A  V  E  W  E  S  N  G  Q  P  E  N  N  Y  K  T  T  P  P  V  
CTGGACAGCGACGGCTCATTCTTCCTGTACAGCAAGCTGACCGTGGACAAGTCCCGGTGGCAGCAG 
 L  D  S  D  G  S  F  F  L  Y  S  K  L  T  V  D  K  S  R  W  Q  Q  
GGCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTG 
 G  N  V  F  S  C  S  V  M  H  E  A  L  H  N  H  Y  T  Q  K  S  L  
AGCCTGAGCCCCGGCAAGCTCGAGGCTAGTACAGCTAGTGACAATTTATACCAAATGACATCCCAG 
 S  L  S  P  G  K  L  E  A  S  T  A  S  D  N  L  Y  Q  M  T  S  Q  
CTTGAATGCATGACCTGGAATCAGATGAACTTAGGAGCCACCTTAAAGGGAGTTGCTGCTGGGAGC 
 L  E  C  M  T  W  N  Q  M  N  L  G  A  T  L  K  G  V  A  A  G  S  
TCCAGCTCAGTGAAATGGACAGAAGGGCAGAGCAACCACAGCACAGGGTACGAGAGCTAA 
 S  S  S  V  K  W  T  E  G  Q  S  N  H  S  T  G  Y  E  S  *  
 
 Nucleotide Amino acid 
Leader 1-78 1-26 
Flag tag 85-109 29-36 
Heavy chain variable domain 116-468 139-156 
Heavy chain constant domain of IgG1 472-1471 156-490 



















 M  N  F  G  F  S  L  I  F  L  V  L  V  L  K  G  V  Q  C  E  V  K  
CTGGTGCCCCGGCAATTGGACTACAAGGACGACGACGACAAAGAATTCGAGGTGCAGCTGCAGCAG 
 L  V  P  R  Q  L  D  Y  K  D  D  D  D  K  E  F  E  V  Q  L  Q  Q  
TCTGGCCCCGTGCTCGTGAAACCTGGCGCCTCCGTGAAGATGAGCTGCAAGGCCAGCGGCAACACC 
 S  G  P  V  L  V  K  P  G  A  S  V  K  M  S  C  K  A  S  G  N  T  
TTCACCGACAGCTTCATGCACTGGATGAAGCAGAGCCACGGCAAGAGCCTGGAATGGATCGGCATC 
 F  T  D  S  F  M  H  W  M  K  Q  S  H  G  K  S  L  E  W  I  G  I  
ATCAACCCCTACAACGGCGGCACCTCCTACAACCAGAAGTTCAAGGGCAAGGCCACCCTGACCGTG 
 I  N  P  Y  N  G  G  T  S  Y  N  Q  K  F  K  G  K  A  T  L  T  V  
GACAAGAGCAGCAGCACCGCCTACATGGAACTGAACAGCCTGACCAGCGAGGACAGCGCCGTGTAC 
 D  K  S  S  S  T  A  Y  M  E  L  N  S  L  T  S  E  D  S  A  V  Y  
TACTGCGCCAGAAACGGCGTGCGGTACTACTTCGACTACTGGGGCCAGGGCACAACCCTGACAGTG 
 Y  C  A  R  N  G  V  R  Y  Y  F  D  Y  W  G  Q  G  T  T  L  T  V  
TCTAGCAGATCCTCTAGCGCCAGCACAAAGGGCCCCAGCGTGTTCCCTCTGGCCCCTAGCAGCAAG 







































 S  S  R  S  S  S  A  S  T  K  G  P  S  V  F  P  L  A  P  S  S  K  
AGCACATCTGGCGGAACAGCCGCCCTGGGCTGCCTCGTGAAGGACTACTTTCCCGAGCCCGTGACA 
 S  T  S  G  G  T  A  A  L  G  C  L  V  K  D  Y  F  P  E  P  V  T  
GTGTCCTGGAACTCTGGCGCCCTGACAAGCGGCGTGCACACCTTTCCAGCCGTGCTGCAGAGCAGC 
 V  S  W  N  S  G  A  L  T  S  G  V  H  T  F  P  A  V  L  Q  S  S  
GGCCTGTACTCTCTGAGCAGCGTCGTGACTGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATC 
 G  L  Y  S  L  S  S  V  V  T  V  P  S  S  S  L  G  T  Q  T  Y  I  
TGCAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAACCCAAGAGCTGCGAC 
 C  N  V  N  H  K  P  S  N  T  K  V  D  K  K  V  E  P  K  S  C  D  
AAGACCCACACCTGTCCCCCTTGTCCTGCCCCTGAACTGCTGGGCGGACCTTCCGTGTTCCTGTTC 
 K  T  H  T  C  P  P  C  P  A  P  E  L  L  G  G  P  S  V  F  L  F  
CCCCCAAAGCCCAAGGACACCCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGAT 
 P  P  K  P  K  D  T  L  M  I  S  R  T  P  E  V  T  C  V  V  V  D  
GTGTCCCACGAGGACCCTGAAGTGAAGTTTAATTGGTACGTGGACGGCGTGGAAGTGCACAACGCC 
 V  S  H  E  D  P  E  V  K  F  N  W  Y  V  D  G  V  E  V  H  N  A  
AAGACCAAGCCCAGAGAGGAACAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACAGTGCTG 
 K  T  K  P  R  E  E  Q  Y  N  S  T  Y  R  V  V  S  V  L  T  V  L  
CACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGCCCTGCCTGCCCCC 
 H  Q  D  W  L  N  G  K  E  Y  K  C  K  V  S  N  K  A  L  P  A  P  
ATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAACCCCAGGTGTACACACTGCCTCCC 
 I  E  K  T  I  S  K  A  K  G  Q  P  R  E  P  Q  V  Y  T  L  P  P  
AGCAGGGACGAGCTGACCAAGAACCAGGTGTCCCTGACCTGTCTCGTGAAAGGCTTCTACCCCTCC 
 S  R  D  E  L  T  K  N  Q  V  S  L  T  C  L  V  K  G  F  Y  P  S  
GATATCGCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTG 
 D  I  A  V  E  W  E  S  N  G  Q  P  E  N  N  Y  K  T  T  P  P  V  
CTGGACAGCGACGGCTCATTCTTCCTGTACAGCAAGCTGACCGTGGACAAGTCCCGGTGGCAGCAG 
 L  D  S  D  G  S  F  F  L  Y  S  K  L  T  V  D  K  S  R  W  Q  Q  
GGCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTG 
 G  N  V  F  S  C  S  V  M  H  E  A  L  H  N  H  Y  T  Q  K  S  L  
AGCCTGAGCCCCGGCAAGCTCGAGGCTAGTACAGCTATGTGTGCTTACCCAGGCTGCAATAAGAGA 
 S  L  S  P  G  K  L  E  A  S  T  A  M  C  A  Y  P  G  C  N  K  R  
TATTTTAAGCTGTCCCACTTACAGATGCACAGCAGGAAGCACACTGGTGAGAAACCATACCAGTGT 
 Y  F  K  L  S  H  L  Q  M  H  S  R  K  H  T  G  E  K  P  Y  Q  C  
GACTTCAAGGACTGTGAACGAAGGTTTTCTCGTTCAGACCAGCTCAAATAA 
 D  F  K  D  C  E  R  R  F  S  R  S  D  Q  L  K  *  
 
 Nucleotide Amino acid 
Leader 1-78 1-26 
Flag tag 85-109 29-36 
Heavy chain variable domain 116-468 139-156 
Heavy chain constant domain of IgG1 472-1471 156-490 

















 M  N  F  G  F  S  L  I  F  L  V  L  V  L  K  G  V  Q  C  E  V  K  
CTGGTGCCCCGGCAATTGGACTACAAGGACGACGACGACAAAGAATTCGAGGTGCAGCTGCAGCAG 
 L  V  P  R  Q  L  D  Y  K  D  D  D  D  K  E  F  E  V  Q  L  Q  Q  
TCTGGCCCCGTGCTCGTGAAACCTGGCGCCTCCGTGAAGATGAGCTGCAAGGCCAGCGGCAACACC 
 S  G  P  V  L  V  K  P  G  A  S  V  K  M  S  C  K  A  S  G  N  T  
TTCACCGACAGCTTCATGCACTGGATGAAGCAGAGCCACGGCAAGAGCCTGGAATGGATCGGCATC 
 F  T  D  S  F  M  H  W  M  K  Q  S  H  G  K  S  L  E  W  I  G  I  
ATCAACCCCTACAACGGCGGCACCTCCTACAACCAGAAGTTCAAGGGCAAGGCCACCCTGACCGTG 
 I  N  P  Y  N  G  G  T  S  Y  N  Q  K  F  K  G  K  A  T  L  T  V  
GACAAGAGCAGCAGCACCGCCTACATGGAACTGAACAGCCTGACCAGCGAGGACAGCGCCGTGTAC 
 D  K  S  S  S  T  A  Y  M  E  L  N  S  L  T  S  E  D  S  A  V  Y  
TACTGCGCCAGAAACGGCGTGCGGTACTACTTCGACTACTGGGGCCAGGGCACAACCCTGACAGTG 

















































 Y  C  A  R  N  G  V  R  Y  Y  F  D  Y  W  G  Q  G  T  T  L  T  V  
TCTAGCAGATCCTCTAGCGCCAGCACAAAGGGCCCCAGCGTGTTCCCTCTGGCCCCTAGCAGCAAG 
 S  S  R  S  S  S  A  S  T  K  G  P  S  V  F  P  L  A  P  S  S  K  
AGCACATCTGGCGGAACAGCCGCCCTGGGCTGCCTCGTGAAGGACTACTTTCCCGAGCCCGTGACA 
 S  T  S  G  G  T  A  A  L  G  C  L  V  K  D  Y  F  P  E  P  V  T  
GTGTCCTGGAACTCTGGCGCCCTGACAAGCGGCGTGCACACCTTTCCAGCCGTGCTGCAGAGCAGC 
 V  S  W  N  S  G  A  L  T  S  G  V  H  T  F  P  A  V  L  Q  S  S  
GGCCTGTACTCTCTGAGCAGCGTCGTGACTGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATC 
 G  L  Y  S  L  S  S  V  V  T  V  P  S  S  S  L  G  T  Q  T  Y  I  
TGCAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAACCCAAGAGCTGCGAC 
 C  N  V  N  H  K  P  S  N  T  K  V  D  K  K  V  E  P  K  S  C  D  
AAGACCCACACCTGTCCCCCTTGTCCTGCCCCTGAACTGCTGGGCGGACCTTCCGTGTTCCTGTTC 
 K  T  H  T  C  P  P  C  P  A  P  E  L  L  G  G  P  S  V  F  L  F  
CCCCCAAAGCCCAAGGACACCCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGAT 
 P  P  K  P  K  D  T  L  M  I  S  R  T  P  E  V  T  C  V  V  V  D  
GTGTCCCACGAGGACCCTGAAGTGAAGTTTAATTGGTACGTGGACGGCGTGGAAGTGCACAACGCC 
 V  S  H  E  D  P  E  V  K  F  N  W  Y  V  D  G  V  E  V  H  N  A  
AAGACCAAGCCCAGAGAGGAACAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACAGTGCTG 
 K  T  K  P  R  E  E  Q  Y  N  S  T  Y  R  V  V  S  V  L  T  V  L  
CACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGCCCTGCCTGCCCCC 
 H  Q  D  W  L  N  G  K  E  Y  K  C  K  V  S  N  K  A  L  P  A  P  
ATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAACCCCAGGTGTACACACTGCCTCCC 
 I  E  K  T  I  S  K  A  K  G  Q  P  R  E  P  Q  V  Y  T  L  P  P  
AGCAGGGACGAGCTGACCAAGAACCAGGTGTCCCTGACCTGTCTCGTGAAAGGCTTCTACCCCTCC 
 S  R  D  E  L  T  K  N  Q  V  S  L  T  C  L  V  K  G  F  Y  P  S  
GATATCGCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTG 
 D  I  A  V  E  W  E  S  N  G  Q  P  E  N  N  Y  K  T  T  P  P  V  
CTGGACAGCGACGGCTCATTCTTCCTGTACAGCAAGCTGACCGTGGACAAGTCCCGGTGGCAGCAG 
 L  D  S  D  G  S  F  F  L  Y  S  K  L  T  V  D  K  S  R  W  Q  Q  
GGCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTG 
 G  N  V  F  S  C  S  V  M  H  E  A  L  H  N  H  Y  T  Q  K  S  L  
AGCCTGAGCCCCGGCAAGCTCGAGATTCGCAATCAGGGTTACAGCACGGTCACCTTCGACGGGACG 
 S  L  S  P  G  K  L  E  I  R  N  Q  G  Y  S  T  V  T  F  D  G  T  
CCCAGCTACGGTCACACGCCCTCGCACCATGCGGCGCAGTTCCCCAACCACTCATTCAAGCATGAG 
 P  S  Y  G  H  T  P  S  H  H  A  A  Q  F  P  N  H  S  F  K  H  E  
GATCCCATGGGCCAGCAGGGCTCGCTGGGTGAGCAGCAGTACTCGGTGCCGCCCCCGGTCTATGGC 
 D  P  M  G  Q  Q  G  S  L  G  E  Q  Q  Y  S  V  P  P  P  V  Y  G  
TGCCACACCCCCACCGACAGCTGCACCGGCAGCCAGGCTTTGCTGCTGAGGACGCCCTACAGCAGT 
 C  H  T  P  T  D  S  C  T  G  S  Q  A  L  L  L  R  T  P  Y  S  S  
GACAATTTATACCAAATGACATCCCAGCTTGAATGCATGACCTGGAATCAGATGAACTTAGGAGCC 
 D  N  L  Y  Q  M  T  S  Q  L  E  C  M  T  W  N  Q  M  N  L  G  A  
ACCTTAAAGGGAGTTGCTGCTGGGAGCTCCAGCTCAGTGAAATGGACAGAAGGGCAGAGCAACCAC 
 T  L  K  G  V  A  A  G  S  S  S  S  V  K  W  T  E  G  Q  S  N  H  
AGCACAGGGTACGAGAGCTAA 
 S  T  G  Y  E  S  *  
 
 Nucleotide Amino acid 
Leader 1-78 1-26 
Flag tag 85-109 29-36 
Heavy chain variable domain 116-468 139-156 
Heavy chain constant domain of IgG1 472-1471 156-490 







 M  N  F  G  F  S  L  I  F  L  V  L  V  L  K  G  V  Q  C  E  V  K  
CTGGTGCCCCGGCAATTGGACTACAAGGACGACGACGACAAAGAATTCGAGGTGCAGCTGCAGCAG 





























































 L  V  P  R  Q  L  D  Y  K  D  D  D  D  K  E  F  E  V  Q  L  Q  Q  
TCTGGCCCCGTGCTCGTGAAACCTGGCGCCTCCGTGAAGATGAGCTGCAAGGCCAGCGGCAACACC 
 S  G  P  V  L  V  K  P  G  A  S  V  K  M  S  C  K  A  S  G  N  T  
TTCACCGACAGCTTCATGCACTGGATGAAGCAGAGCCACGGCAAGAGCCTGGAATGGATCGGCATC 
 F  T  D  S  F  M  H  W  M  K  Q  S  H  G  K  S  L  E  W  I  G  I  
ATCAACCCCTACAACGGCGGCACCTCCTACAACCAGAAGTTCAAGGGCAAGGCCACCCTGACCGTG 
 I  N  P  Y  N  G  G  T  S  Y  N  Q  K  F  K  G  K  A  T  L  T  V  
GACAAGAGCAGCAGCACCGCCTACATGGAACTGAACAGCCTGACCAGCGAGGACAGCGCCGTGTAC 
 D  K  S  S  S  T  A  Y  M  E  L  N  S  L  T  S  E  D  S  A  V  Y  
TACTGCGCCAGAAACGGCGTGCGGTACTACTTCGACTACTGGGGCCAGGGCACAACCCTGACAGTG 
 Y  C  A  R  N  G  V  R  Y  Y  F  D  Y  W  G  Q  G  T  T  L  T  V  
TCTAGCAGATCCTCTAGCGCCAGCACAAAGGGCCCCAGCGTGTTCCCTCTGGCCCCTAGCAGCAAG 
 S  S  R  S  S  S  A  S  T  K  G  P  S  V  F  P  L  A  P  S  S  K  
AGCACATCTGGCGGAACAGCCGCCCTGGGCTGCCTCGTGAAGGACTACTTTCCCGAGCCCGTGACA 
 S  T  S  G  G  T  A  A  L  G  C  L  V  K  D  Y  F  P  E  P  V  T  
GTGTCCTGGAACTCTGGCGCCCTGACAAGCGGCGTGCACACCTTTCCAGCCGTGCTGCAGAGCAGC 
 V  S  W  N  S  G  A  L  T  S  G  V  H  T  F  P  A  V  L  Q  S  S  
GGCCTGTACTCTCTGAGCAGCGTCGTGACTGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATC 
 G  L  Y  S  L  S  S  V  V  T  V  P  S  S  S  L  G  T  Q  T  Y  I  
TGCAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAACCCAAGAGCTGCGAC 
 C  N  V  N  H  K  P  S  N  T  K  V  D  K  K  V  E  P  K  S  C  D  
AAGACCCACACCTGTCCCCCTTGTCCTGCCCCTGAACTGCTGGGCGGACCTTCCGTGTTCCTGTTC 
 K  T  H  T  C  P  P  C  P  A  P  E  L  L  G  G  P  S  V  F  L  F  
CCCCCAAAGCCCAAGGACACCCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGAT 
 P  P  K  P  K  D  T  L  M  I  S  R  T  P  E  V  T  C  V  V  V  D  
GTGTCCCACGAGGACCCTGAAGTGAAGTTTAATTGGTACGTGGACGGCGTGGAAGTGCACAACGCC 
 V  S  H  E  D  P  E  V  K  F  N  W  Y  V  D  G  V  E  V  H  N  A  
AAGACCAAGCCCAGAGAGGAACAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACAGTGCTG 
 K  T  K  P  R  E  E  Q  Y  N  S  T  Y  R  V  V  S  V  L  T  V  L  
CACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGCCCTGCCTGCCCCC 
 H  Q  D  W  L  N  G  K  E  Y  K  C  K  V  S  N  K  A  L  P  A  P  
ATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAACCCCAGGTGTACACACTGCCTCCC 
 I  E  K  T  I  S  K  A  K  G  Q  P  R  E  P  Q  V  Y  T  L  P  P  
AGCAGGGACGAGCTGACCAAGAACCAGGTGTCCCTGACCTGTCTCGTGAAAGGCTTCTACCCCTCC 
 S  R  D  E  L  T  K  N  Q  V  S  L  T  C  L  V  K  G  F  Y  P  S  
GATATCGCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTG 
 D  I  A  V  E  W  E  S  N  G  Q  P  E  N  N  Y  K  T  T  P  P  V  
CTGGACAGCGACGGCTCATTCTTCCTGTACAGCAAGCTGACCGTGGACAAGTCCCGGTGGCAGCAG 
 L  D  S  D  G  S  F  F  L  Y  S  K  L  T  V  D  K  S  R  W  Q  Q  
GGCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTG 
 G  N  V  F  S  C  S  V  M  H  E  A  L  H  N  H  Y  T  Q  K  S  L  
AGCCTGAGCCCCGGCAAGCTCGAGGCTAGTACAGCTAGTGACAATTTATACCAAATGACATCCCAG 
 S  L  S  P  G  K  L  E  A  S  T  A  S  D  N  L  Y  Q  M  T  S  Q  
CTTGAATGCATGACCTGGAATCAGATGAACTTAGGAGCCACCTTAAAGGGAGTTGCTGCTGGGAGC 
 L  E  C  M  T  W  N  Q  M  N  L  G  A  T  L  K  G  V  A  A  G  S  
TCCAGCTCAGTGAAATGGACAGAAGGGCAGAGCAACCACAGCACAGGGTACGAGAGCGATAACCAC 
 S  S  S  V  K  W  T  E  G  Q  S  N  H  S  T  G  Y  E  S  D  N  H  
ACAACGCCCATCCTCTGCGGAGCCCAATACAGAATACACACGCACGGTGTCTTCAGAGGCATTCAG 
 T  T  P  I  L  C  G  A  Q  Y  R  I  H  T  H  G  V  F  R  G  I  Q  
GATGTGCGACGTGTGCCTGGAGTAGCCCCGACTCTTGTACGGTCGGCATCTGAGACCAGTGAGAAA 
 D  V  R  R  V  P  G  V  A  P  T  L  V  R  S  A  S  E  T  S  E  K  
CGCCCCTTCATGTGTGCTTACCCAGGCTGCAATAAGAGATATTTTAAGCTGTCCCACTTACAGATG 
 R  P  F  M  C  A  Y  P  G  C  N  K  R  Y  F  K  L  S  H  L  Q  M  
CACAGCAGGAAGCACACTGGTGAGAAACCATACCAGTGTGACTTCAAGGACTGTGAACGAAGGTTT 
 H  S  R  K  H  T  G  E  K  P  Y  Q  C  D  F  K  D  C  E  R  R  F  
TCTCGTTCAGACCAGCTCAAATAA 
 S  R  S  D  Q  L  K  *  
 
 




 Nucleotide Amino acid 
Leader 1-78 1-26 
Flag tag 85-109 29-36 
Heavy chain variable domain 116-468 139-156 
Heavy chain constant domain of IgG1 472-1471 156-490 






















































 M  N  F  G  F  S  L  I  F  L  V  L  V  L  K  G  V  Q  C  E  V  K  
CTGGTGCCCCGGCAATTGGACTACAAGGACGACGACGACAAAGAATTCGAGGTGCAGCTGCAGCAG 
 L  V  P  R  Q  L  D  Y  K  D  D  D  D  K  E  F  E  V  Q  L  Q  Q  
TCTGGCCCCGTGCTCGTGAAACCTGGCGCCTCCGTGAAGATGAGCTGCAAGGCCAGCGGCAACACC 
 S  G  P  V  L  V  K  P  G  A  S  V  K  M  S  C  K  A  S  G  N  T  
TTCACCGACAGCTTCATGCACTGGATGAAGCAGAGCCACGGCAAGAGCCTGGAATGGATCGGCATC 
 F  T  D  S  F  M  H  W  M  K  Q  S  H  G  K  S  L  E  W  I  G  I  
ATCAACCCCTACAACGGCGGCACCTCCTACAACCAGAAGTTCAAGGGCAAGGCCACCCTGACCGTG 
 I  N  P  Y  N  G  G  T  S  Y  N  Q  K  F  K  G  K  A  T  L  T  V  
GACAAGAGCAGCAGCACCGCCTACATGGAACTGAACAGCCTGACCAGCGAGGACAGCGCCGTGTAC 
 D  K  S  S  S  T  A  Y  M  E  L  N  S  L  T  S  E  D  S  A  V  Y  
TACTGCGCCAGAAACGGCGTGCGGTACTACTTCGACTACTGGGGCCAGGGCACAACCCTGACAGTG 
 Y  C  A  R  N  G  V  R  Y  Y  F  D  Y  W  G  Q  G  T  T  L  T  V  
TCTAGCAGATCCTCTAGCGCCAGCACAAAGGGCCCCAGCGTGTTCCCTCTGGCCCCTAGCAGCAAG 
 S  S  R  S  S  S  A  S  T  K  G  P  S  V  F  P  L  A  P  S  S  K  
AGCACATCTGGCGGAACAGCCGCCCTGGGCTGCCTCGTGAAGGACTACTTTCCCGAGCCCGTGACA 
 S  T  S  G  G  T  A  A  L  G  C  L  V  K  D  Y  F  P  E  P  V  T  
GTGTCCTGGAACTCTGGCGCCCTGACAAGCGGCGTGCACACCTTTCCAGCCGTGCTGCAGAGCAGC 
 V  S  W  N  S  G  A  L  T  S  G  V  H  T  F  P  A  V  L  Q  S  S  
GGCCTGTACTCTCTGAGCAGCGTCGTGACTGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATC 
 G  L  Y  S  L  S  S  V  V  T  V  P  S  S  S  L  G  T  Q  T  Y  I  
TGCAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAACCCAAGAGCTGCGAC 
 C  N  V  N  H  K  P  S  N  T  K  V  D  K  K  V  E  P  K  S  C  D  
AAGACCCACACCTGTCCCCCTTGTCCTGCCCCTGAACTGCTGGGCGGACCTTCCGTGTTCCTGTTC 
 K  T  H  T  C  P  P  C  P  A  P  E  L  L  G  G  P  S  V  F  L  F  
CCCCCAAAGCCCAAGGACACCCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGAT 
 P  P  K  P  K  D  T  L  M  I  S  R  T  P  E  V  T  C  V  V  V  D  
GTGTCCCACGAGGACCCTGAAGTGAAGTTTAATTGGTACGTGGACGGCGTGGAAGTGCACAACGCC 
 V  S  H  E  D  P  E  V  K  F  N  W  Y  V  D  G  V  E  V  H  N  A  
AAGACCAAGCCCAGAGAGGAACAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACAGTGCTG 
 K  T  K  P  R  E  E  Q  Y  N  S  T  Y  R  V  V  S  V  L  T  V  L  
CACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGCCCTGCCTGCCCCC 
 H  Q  D  W  L  N  G  K  E  Y  K  C  K  V  S  N  K  A  L  P  A  P  
ATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAACCCCAGGTGTACACACTGCCTCCC 
 I  E  K  T  I  S  K  A  K  G  Q  P  R  E  P  Q  V  Y  T  L  P  P  
AGCAGGGACGAGCTGACCAAGAACCAGGTGTCCCTGACCTGTCTCGTGAAAGGCTTCTACCCCTCC 
 S  R  D  E  L  T  K  N  Q  V  S  L  T  C  L  V  K  G  F  Y  P  S  
GATATCGCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTG 
 D  I  A  V  E  W  E  S  N  G  Q  P  E  N  N  Y  K  T  T  P  P  V  
CTGGACAGCGACGGCTCATTCTTCCTGTACAGCAAGCTGACCGTGGACAAGTCCCGGTGGCAGCAG 
 L  D  S  D  G  S  F  F  L  Y  S  K  L  T  V  D  K  S  R  W  Q  Q  
GGCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTG 
 G  N  V  F  S  C  S  V  M  H  E  A  L  H  N  H  Y  T  Q  K  S  L  
AGCCTGAGCCCCGGCAAGCTCGAGGCTAGTACAGCTGCGCTGCTGCCCGCCGTCCCCTCCCTGGGT 
 S  L  S  P  G  K  L  E  A  S  T  A  A  L  L  P  A  V  P  S  L  G  
GGCGGCGGCGGCTGTGCCCTGCCTGTGAGCGGCGCGGCGCAGTGGGCGCCGGTGCTGGACTTTGCG 
 G  G  G  G  C  A  L  P  V  S  G  A  A  Q  W  A  P  V  L  D  F  A  
CCTCCGGGCGCTTCGGCTTACGGGTCGTTGGGCGGCTAA 
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